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Abbreviations
ACN  acetonitrile
ADAM  a disintegrin and metalloproteinase
AD  Alzheimer’s disease
APP  b-amyloid precursor protein
AQUA  Absolute quantification
BACE  b-site APP cleaving enzyme
BLAST  Basic local alignment search tool
Ca2+   calcium-ion
cDNA  complementary DNA 
CID  collision-induced dissociation
CSF  cerebrospinal fluid 
CNS  central nervous system
2DE  2 dimensional gel electrophoresis
EGFP  enhanced green fluorescent protein
ESI  electrospray ionization
FT ICR  Fourier transform ion cyclotron resonance
FWHM  Ful with half maximum
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HPLC  High performance liquid chromatography
ICAT  isotope-coded affinity tag
IgA, (G, M) immunoglobulin A, (G, M)
iTRAQ  isobaric tags for relative and absolute quantification
K+   potassium-ion 
Kb  kilo-base pairs 
kDa  kilodalton
KO  knock-out
LC  Liquid chromatography
LC-MS/MS Liquid chromatography tandem mass spectrometry
LG   laminin-globular domain 
LG-3  laminin-globular domain 3 of agrin
LRP-1  low-density lipoprotein receptor-related protein 1
LTD  long-term depression 
LTP  long-term potentiation
MALDI  Matrix Assisted Laser Ionization Desorption
Mr  molecular mass
MS  Mass spectrometry
MS/MS  Tandem mass spectrometry
mRNA  messenger RNA 
MuSK,  muscle-specific kinase 
m/z  mass-to-charge-ratio
Na+  sodium-ion 
NMDA  N-methyl-D-aspartate 
NMDAR NMDA-type glutamate receptor 
NMJ  neuromuscular junction
PBS  phosphate-buffered saline
PBS-T  PBS with Tween-20
PEI  polyethylenimin
PCR  polymerase chain reaction
PFR  picrotoxin, forskolin, and rolipharm
PTP  Proteotypic peptide
PVDF  polyvinylidene fluoride
ppm  parts per million
RF  radio frequency
RNA  ribonucleic acid 
RP  reversed phase
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SILAC  stable isotope labeling by amino acids in cell culture
SRM  selected ion monitoring
TEA  tetraethylammonium chloride
TFA  triflouracetic acid
TIC  total ion chromatogram
TOF  time of flight
tPA  tissue-type plasminogen activator
uPA  urokinase-type plasminogen activator 
wt  wild-type
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Summary
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The neuronal serine protease neurotrypsin is predominantly expressed in the central nervous 
system. Its expression level peaks in the first postnatal week followed by a decrease until 
adulthood. There is evidence that neurotrypsin is involved in neuronal plasticity during 
development and adulthood. This hypothesis is mainly supported by the finding that a 4 base-
pair deletion in the human gene leads to a nonsyndromic form of mental retardation. Recently, 
the proteoglycan agrin was found to be the unique substrate for neurotrypsin. Neurotrypsin 
cleaves agrin at two homologous positions which results in the release of the intermediate 
90 kDa fragment and the C-terminal 22 kDa fragment (agrin-22) from the N-terminal moiety. 
To analyze whether agrin is a substrate of neurotrypsin in vivo and to quantify the proteolytic 
activity of neurotrypsin in non-neuronal tissue, a study of serum from neurotrypsin-deficient 
and neurotrypsin-overexpressing mice was performed. The results confirmed that the catalytic 
activity of neurotrypsin on agrin was increased in neurotrypsin-overexpressing mice and 
completely absent in neurotrypsin-deficient mice. Additionally, an age-associated regulation 
of the neurotrypsin-dependent cleavage product agrin-22 was observed in murine serum. The 
motoneuron-derived transcripts of the four z splice variants of agrin were characterized as pro-
synaptic molecules at the neuromuscular junction. There is strong evidence for a regulatory 
function of agrin in the central nervous system as well, but until now the differential role of 
the z-transcripts has not been worked out. In order to identify and quantify the distribution of 
the four z-transcripts in vivo, targeted mass spectrometric analyses were performed. Specific 
parameter settings were evaluated in order to optimize the elution, fragmentation, and 
recovery of the specific tryptic peptides of the four agrin-22 z-transcripts. The results showed 
that synaptic recruitment and externalization of neurotrypsin are regulated by neuronal 
activity. In addition, the generation of synaptic precursors, namely filopodia, could be rescued 
in hippocampal slices from neurotrypsin-deficient mice by the application of the neurotrypsin-
dependent 22 kDa fragment.  Neurotrypsin-dependent cleavage of agrin at the synapse 
is thought to influence the synaptic function of agrin. Therefore, the processing of agrin by 
neurotrypsin is suggested as a potential pathway for activity-dependent reorganization and 
remodeling of synaptic circuits in the brain. To further evaluate the potential functional effects 
of the neurotrypsin-agrin interaction in vivo, human cerebrospinal fluid (CSF) samples were 
analyzed in relation to age and in the context of neurological disorders such as Alzheimer`s 
disease and epilepsy. The quantitative analysis of immunoblots confirmed that the proteolytic 
activity is modulated throughout development and showed a moderate increase in epilepsy 
patients. In contrast, the amount of agrin-22 was slightly decreased in Alzheimer`s disease. 
Furthermore, the proteolytic processing of the transmembrane protein calsyntenin-1 was 
identified and quantified. Calsyntenin-1 and APP undergo a similar coordinated proteolytic 
processing. After proteolysis, the transmembrane stump of calsyntenin-1 is internalized and 
accumulated in an endosomal compartment of the synapse. Thus, proteolysis-dependent 
translocation is suggested to illustrate an independent downstream event in protease-mediated 
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synaptic plasticity. To shed light on the processing of calsyntenin-1, the presence of proteolytic 
fragments was analyzed in human CSF by mass spectrometry. Exclusively calsyntenin-1 
ectodomain was found to be accumulated in human CSF. Additionally, it has been recently 
shown that calsyntenin-1 ectodomain-shedding is increased by induction of synaptic activity. 
In order to define the functional aspects of calsyntenin-1 processing, human CSF samples were 
analyzed in association to age and in the relation to neurological disorders such as Alzheimer`s 
disease and epilepsy. Quantitative immunoblot analysis showed that the proteolytic processing 
of calsyntenin-1 is consistent throughout aging. In addition, ectodomain shedding is unaltered 
in Alzheimer`s disease and epilepsy patients. 
Zusammenfassung
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Die neuronale Serinprotease Neurotrypsin wird vorwiegend im Zentralnervensystem exprimiert. 
Seine Expression erreicht ihren Höhepunkt in der ersten postnatalen Woche, woraufhin eine 
Abnahme bis zum Erwachsenenalter folgt. Es gibt Hinweise darauf, dass Neurotrypsin in die 
neuronaler Plastizität des sich entwickelnden und auch des adulten Nervensystems involviert 
ist. Diese Hypothese wird vor allen Dingen durch die Feststellung bekräftigt, dass eine Deletion 
von vier Basenpaaren im menschlichen Gen zu einer schweren Form von geistiger Behinderung 
führt. Kürzlich wurde herausgefunden, dass das Proteoglykan Agrin das bisher einzige 
Substrat für Neurotrypsin ist. Neurotrypsin spaltet Agrin an zwei homologen Stellen, was die 
Freisetzung des intermediären 90-kDa-Fragments und des C-terminalen 22-kDa-Fragments 
(Agrin-22) vom N-terminalen Teil bewirkt. Um zu analysieren, ob Agrin in vivo ein Substrat 
von Neurotrypsin ist und um die proteolytische Aktivität Neurotrypsins in nicht neuronalem 
Gewebe zu quantifizieren, wurde eine Studie des Serums von Neurotrypsin knock-out und 
Neurotrypsin überexprimierenden Mäusen durchgeführt. Die Resultate bestätigen, dass 
die katalytische Aktivität  von Neurotrypsin auf Agrin in Neurotrypsin überexprimierenden 
Mäusen erhöht ist und in Neurotrypsin knock-out Mäusen durchweg abwesend ist. Zusätzlich 
konnte in Mausserum eine altersabhängige Regulation des von Neurotrypsin abhängigen 
Spaltproduktes Agrin-22 festgestellt werden. Die aus den Motoneuronen stammenden 
Transkripte der vier z-Splice-Varianten von Agrin wurden als ein pro-synaptische Moleküle 
an der neuromuskulären Kontaktstelle charakterisiert. Es gibt überzeugende Hinweise dafür, 
dass Agrin auch im Zentralen Nervensystem eine solche regulatorische Funktion zugesprochen 
werden kann, jedoch ist die differentielle Rolle der z-Transkripte bisher nicht ausgearbeitet 
worden. Um die in vivo-Verteilung der vier z-Transkripte zu identifizieren und quantifizieren, 
wurden gezielte massenspektrometrische Analysen durchgeführt. Es wurden spezielle 
Einstellungen der Parameter zur optimierten Elution, Fragmentierung und Rückgewinnung 
der Agrin-22 z-Transkripten evaluiert. Neueste Ergebnisse zeigten, dass die synaptische 
Rekrutierung und Ausschüttung von Neurotrypsin durch neuronale Aktivität reguliert werden. 
Darüber hinaus konnte nachgewiesen werden, dass die Generierung von Vorläufersynapsen, so 
genannte Filopodien, in Neurotrypsin knock-out Mäusen durch die Zugabe des von Neurotrypsin 
abhängigen Agrin-22 Fragments wiederhergestellt werden konnte. Es wird vermutet, dass 
die von Neurotrypsin abhängige Spaltung Agrins an der Synapse seine synaptische Funktion 
beeinflusst. Folglich wird angenommen, dass die Spaltung von Agrin durch Neurotrypsin einen 
potenziellen Pfad in der aktivitätsabhängigen Umorganisation und Umgestaltung synaptischer 
Schaltkreise im Gehirn darstellt. Um den potenziellen funktionalen Effekt der Interaktion von 
Neurotrypsin und Agrin in vivo weiter aufzuklären, wurde humane cerebrospinale Flüssigkeit 
(CSF) in Bezug auf das Alter und im Kontext neurologischer Störungen wie Alzheimer und 
Epilepsie analysiert. Die quantitative Analyse der Immunoblots ergab, dass die proteolytische 
Aktivität während der Entwicklung durchwegs reguliert wird und zeigte zudem einen 
schwachen Anstieg in Epilepsie Patienten. Im Gegensatz dazu, war die Menge an Agrin-22 in 
Alzheimer leicht vermindert. 
Zusammenfassung12
Desweiteren wurde der proteolytische Abbau des transmembranen Proteins Calsyntenin-1 
identifiziert und quantifiziert. Calsyntenin-1 und APP werden einem gleichermaßen 
koordinierten proteolytischen Abbau unterzogen. Nach der Proteolyse wird der transmembrane 
Stumpf von Calsyntenin-1 internalisiert und in einem endosomalen Kompartiment der Synapse 
akkumuliert. Die proteolyseabhängige Translokalisierung wird daher als eigenständiger 
Abbauschritt in der proteasevermittelten synaptischen Plastizität angesehen. Um den Abbau 
von Calsyntenin-1 weiter aufzuklären, wurde das Vorkommen proteolytischer Fragmente in 
humanem CSF mit Massenspektrometrie analysiert. Es wurde gezeigt, dass ausschließlich 
eine Anreicherung der Ectodomäne von Calsyntenin-1 im CSF vorliegt. Es wurde zudem 
kürzlich gezeigt, dass die Ausschüttung der Ectodomäne von Calsyntenin-1 bei der Induktion 
synaptischer Aktivität erhöht ist. Um die funktionalen Aspekte des Abbaus von Calsyntenin-1 
zu definieren, wurden humane CSF Proben im Zusammenhang mit dem Alter und in Verbindung 
mit neurologischen Störungen wie Alzheimer und Epilepsie analysiert. Die quantitative Analyse 
der Immunoblots ergab, dass der Abbau von Calsyntenin-1 beim Altern durchwegs konstant 
ist. Zusätzlich scheint die Freisetzung der Ectodomäne von Calsytnenin-1 in Alzheimer und 
Epilepsie unverändert zu sein. 
1 Introduction
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In this chapter, the conceptual background will be given for the following more detailed 
approaches in this thesis. I will start with the classification of proteases followed by a 
detailed introduction about serine proteases in the brain. Then the three proteins of interest 
in this study will be presented: (1) the neuronal serine protease neurotrypsin, (2) its unique 
substrate agrin, and (3) the transmembrane protein calsyntenin-1 which is as well a substrate 
of extracellular proteolysis. Detailed information will be provided about mass spectrometry 
and possible workflows for quantification will be discussed, followed by a closer look on the 
discovery of biomarkers.
1.1 Proteases
Proteases (also known as peptidases, proteinases or proteolytic enzymes) catalytically cleave 
the peptide bonds linking adjacent amino acids in proteins or peptides. They represent 
approximately 2% of human genes, which makes them the largest enzyme family in man. Due 
to their ubiquitous presence in virtually any pathophysiological process, proteases are one of 
the primary targets in drug and biomarker discovery. They are classified into six clans within 
each clan ranked into families of related proteases based on similarities in their amino acid 
sequence (Barrett & Rawlings, 2003). The clans show a more distant relation in sequence 
and are primarily characterized by structural comparison Further criteria for classification 
are either peptidase specificity or domain architectures. To date, 39 different groups and 183 
families are registered:14 aspartic peptidase families (A), 60 cysteine peptidase families (C), 1 
glutamic peptidase family (G), 53 families of metallo peptidases (M), 42 serine peptidase families 
(S), 4 threonine peptidase families (T) and 9 families of unknown catalytic type (U). They are 
organized in the MEROPS database (http://merops.sanger.ac.uk) which is an integrated source 
of information about peptidases, substrates and inhibitors (Rawlings et al, 2010). The database 
covers about 39.000 known cleavage sites in proteins, peptides, and synthetic substrates. 
Protease specificity and alignments of their substrates offers the information about conserved 
cleavage sites, and thus the probable physiological relevance. One important class of proetases 
are the serine proteases which cover about one-third of the protease families. 
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1.1.1 Serine Proteases
Serine proteases are named according to their nucleophilic serine residue in the active site. 
They represent about one-third of all peptidases and are divided into four clans: chymotrypsin 
(S1), subtilisin (S8), carboxypeptidase Y (S10), and Clp protease (S14) (Hedstrom, 2002). The 
difference among them is based on the structure of their catalytical triad Asp-His-Ser, which 
forms the catalytic machinery in these molecules (Dodson & Wlodawr, 1998). They are present 
in eukaryotes, prokaryotes, archae, and virus and are synthesized as inactive precursors 
(“zymogens”) containing N-terminal extensions. Proteolytic processing activates the zymogen, 
releasing the N-terminus. Protease specificity of chymotrypsin-like serine proteases is based 
on the P1/S1 interaction (based on the nomenclature of Schechter & Berger, 1967), where 
P1-P1’ denotes peptide residues on the acyl and leaving group side of the scissile bond. The 
adjacent peptide residues are numbered S1-S1’ and denote corresponding enzyme binding 
sites. Chymotrypsin-like proteases are implemented in many essential physiological functions 
including digestion, hemostasis, apoptosis, signal transduction, reproduction, and immune 
response (Neurath, 1984; Johnson, 2000; Joseph et al, 2001; Coughlin, 2000; Barros et al, 1996). 
In the central nervous system (CNS), they have been as well implicated in physiological and 
pathophysiological pathways and are involved in a huge number of processes during neuronal 
development. 
In the following section some general information about proteases in the CNS will be provided 
and their importance will be described by means of the tissue-plasminogen activator (tPA) 
which is the  predominant expressed plasminogen activator (PA) in the brain. 
1.1.2 Proteases in the brain
Biosynthesis of active neuropeptides or peptide hormones is usually based on the generation 
of a precursor protein. Proteolytic processing as well as other molecular modifications increase 
the number of potential products and lead to a wide range of mature products from the basic 
transcript. Extracellular serine proteases are expressed in the developing and adult nervous 
system (Davies et al, 1998). They are implemented in the regulation of neurogenesis, cell 
migration, axonal growth, and synapse elimination. Extracellular proteolysis leads to structural 
and functional changes at synapses in the brain. This mechanism allows reorganization 
and elimination of established synaptic circuits, as well as generation of new synapses. It is 
described to be important for adaptive changes in signal transmission which are the base 
of learning and memory. In addition, they contribute to neuronal death, tumor growth and 
invasion. They are as well suggested to be involved in several forms of neuropathologies, 
including neurodegenerative diseases (e.g. Alzheimer’s disease (AD), Parkinsons’s disease), 
demyelination diseases (e.g. multiple sclerosis), and epileptic seizures.
Tissue-type plasminogen activator
In the central nervous system the well-known extracellular serine protease tPA has received 
great attention. tPA is localized in the intravascular space between the blood and the brain 
(i.e. neurovascular unit), as well as in the parenchyma consisting of neurons, astrocytes and 
microglia (Siao et al, 2003; Nicole et al, 2001). Thus, tPA serves different roles which depend on 
the compartment. The inactive zymogen plasminogen is the main substrate of tPA in the 
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intravascular space. It is primarily a thrombolytic enzyme, as plasmin`s main substrate is 
fibrin. Hence, recombinant tPA is used for treatment in acute stroke due to its thrombolytic 
activity (The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study group, 
2005). It remains the only FDA-approved treatment of ischemic stroke. Nonetheless, there are 
reports about enhanced excitotoxic neuronal cell death and it is known that tPA also has a 
deleterious effect on the ischemic brain including cytotoxicity and increased permeability of 
the neurovascular unit with the development of cerebral edema (Armstead et al, 2010).
In the brain parenchyma, the function of tPA is multifaceted and associated with synaptic 
plasticity and cell death (Benchenane et al, 2004; Samson & Medcalf, 2006). There is growing 
evidence, that the tPA function is controlled either by plasminogen-dependent or –independent 
pathways (Tsirka et al, 1995; Chen & Strikland, 1997; Yepes et al, 2000). A major number of 
reports demonstrate tPA as a direct modulator of glutamatergic transmission. Currently, there 
are three models how tPA mediates neuromodulatory effects via the NMDA receptor (NMDAR). 
(1) tPA cleaves the NR1 subunit of NMDAR which could modify the Ca2+ signaling leading to 
changes in long term potentiation (LTP) (Liot et al, 2004; Kvajo et al, 2004). The direct function 
of this process is so far unknown. (2) Non-proteolytic interaction and upregulation of the NR2B 
subunit of NMDAR induces phosphorylation of extracellular signal-regulated kinase 1/2 (ERK 
1/2) mediating LTP and long term depression (LTD) (Pawlak et al, 2005; Medina et al, 2005; Ito-
Ishida et al, 2006). (3) Binding of tPA to the low-density lipoprotein receptor-related protein 
(LRP-1) increases the level of cyclic adenosine monophosphate (cAMP) and protein kinase A 
(PKA) activity which results in synaptic potentiation (Huang et al, 1996; Wang et al, 2003).
Expression of tPA is relatively low in the central nervous system (CNS) (Sappino et al, 1993). 
However, it was shown to be increased due to events such as LTP, seizures and motor learning 
(Carroll et al, 1994; Kian et al, 1993; Seeds et al 1995). tPA is rapidly released into the synaptic 
cleft in response to stimuli followed by neuronal depolarization (Yepes et al, 2002). In addition, 
a relation between tPA and dopaminergic transmission was hypothesized for the CA1 and CA3 
region of the hippocampus during induction of LTP (Baranes et al, 1998). It could be assessed 
that overexpression of tPA in the murine CNS enhances LTP in both, hippocampal LTP and 
special learning and memory performance (Madani et al, 1999). The activity of extracellular 
tPA is modulated by inhibitors like neuroserpin, a serine protease inhibitor (serpin) and 
plasminogen activator inhibitor-1 (PAI-1) (Yepes & Lawrence, 2004). Neuroserpin`s inhibitory 
effect is suggested to play a neuroprotective role (Galliciotti & Sonderegger, 2006). 
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1.2 Neurotrypsin
Neurotrypsin is a trypsin-like serine protease with a unique domain composition (Gschwend et 
al, 1997). The presence of a putative signal sequence and the lack of a transmembrane domain 
characterize neurotrypsin as a secreted protein. Human neurotrypsin has a molecular mass 
of about 97 kD and consists of a proline-rich basic domain, a kringle domain, four scavenger 
receptor cysteine-rich (SRCR) domains and the C-terminal protease domain (Figure 1-1 (A); 
Proba et al, 1998). In contrast, the molecular mass of murine neurotrypsin is of approximately 
85 kDa, due to the expression of only three SRCR domains (Figure 1-x1(B); Gschwend et al, 
1997).
PB KR SRCR SRCR SRCR SRCR PROT
PB KR SRCR SRCR SRCR PROT
PB KR SRCR SRCR
Figure 1-1. Schematic representation of the neurotrypsin domain structure. (A) human neurotrypsin 
(Proba et al, 1998). (B) mouse neurotrypsin (Gschwend et al, 1997). (C) truncated neurotrypsin 
(Molinari et al, 2002). SP, putative signal peptide (aa 1 – 20); PB, proline-rich basic segment (aa 21 – 91); 
KR, kringle domain (aa 92 – 166); SRCR1 through SRCR4, SRCR domains 1 – 4(aa 170 – 271, aa 280 – 381, 
aa 387 – 487, and aa 500 – 601); ZA, segment with homology to zymogen activation region of tPA (aa 
671 – 630); PROT, serine protease domain (aa 631 – 875). 
The typical S1 type serine protease domain of human and murine neurotrypsin is located in the 
C-terminal part of the molecule. The zymogen activation site is located proximal to this domain 
and includes the conserved catalytic triad of serine peptidases. Neurotrypsin is proteolytically 
activated by cleavage at the zymogen activation site followed by separation of the protein into 
two chains which are still connected via a disulfide bond. The cascade of catalytic activation of 
neurotrypsin is so far not known. The non-catalytic domains are thought to mediate binding of 
neurotrypsin to cell surfaces or extracellular matrix molecules (ECM), navigating the peptidase 
to its site of action or to arrange it in the proximity of its substrates.
1.2.1 Neurotrypsin expression in the CNS
Human neurotrypsin was isolated from a human fetal brain cDNA library using a PCR-amplified 
probe (Proba et al, 1998). In-situ hybridization in adult murine nervous system suggested a 
highly intriguing expression pattern of neurotrypsin mRNA in a distinct subset of neurons in 
the cerebral cortex, the hippocampus and the amygdala (Figure 1-2; Gschwend et al, 1997). 
These brain areas are implicated in processing and storing learned behavior and memories. 
A
C
B
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Figure 1-2. In situ hybridisation of sections from different CNS regions of adult mice using DIG-
labeled neurotrypsin antisense cRNA. A, Brain section cut in a dorsocaudal-rostroventral plane (angle: 
approximately 30° to the coronal plane). The section was hybridized with a neurotrypsin antisense 
riboprobe. Labeling is seen in distinct layers throughout the neocortex (Te, temporal cortex; Oc, occipital 
cortex) with a more widespread labeling in the transition zones between iso- and allocortex (Ic, insular 
cortex; RS, retrosplenial cortex). In the allocortex, labeling is detected in the piriform cortex (Pir), with 
a strong labeling in the endopiriform nucleus (arrow), and in the hippocampal formation (see also 
D). Neurotrypsin expression is also seen in the lateral amygdala (arrowhead). Scale bar: 1 mm. B, C, 
Consecutive coronal sections of the parietal cortex, either stained with cresyl violet B, or hybridized with 
neurotrypsin antisense riboprobe C. Cortical layers are marked in B. C, Large positive neurons are seen 
in the lower half of layer V. In layer VI, positive cells are found throughout the layer, but concentrated 
at the border to the white matter. Weak labeling is associated with cells scattered in layers II and III. 
No labeling is detected in layers I and IV. Scale bar in C represents 100 μm. D, Coronal section of the 
hippocampus. Labeling is detected in neurons of the subiculum (S), in pyramidal neurons of CA1 and 
CA3, and in granule neurons of the dentate gyrus (DG). Scale bar: 300 μm. E, Cross section of the cervical 
spinal cord. Large cells are labeled in the motor columns (arrowheads). Labeling is also detected in the 
DRG (arrow). Scale bar: 300 μm. Figure and text taken and modified from (Gschwend et al., 1997).
The spatio-temporal mRNA expression of neurotrypsin during pre- and postnatal development 
in mouse brain suggests a role of neurotrypsin in morphogenesis of non-neuronal tissues, 
as well as in crucial stages of neuronal development, in particular in axonal target invasion, 
synaptogenesis and Schwann cell differentiation (Wolfer et al, 2001). 
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Figure 1-3. Semi-quantitative time course of neurotrypsin mRNA expression in neural tissues during 
pre- and postnatal development. Columns represent developmental stages. Rows represent regions. The 
shading pattern of each box indicates the average signal intensity, assigned to one of the four staining 
levels listed on the right in the figure. E: embryonic, P: postnatal. Figure and text modified from (Wolfer 
et al, 2001).
The semi-quantitative time course confirms that neurotrypsin mRNA expression lasts until 
adulthood (Figure 1-3). The mRNA expression peaks at postnatal day 10 (P10), decreases by 
P16 and continues with low levels in the seven month old murine CNS. Thus, there is evidence 
that neurotrypsin is involved in neuronal plasticity during development and in the adult. 
Neurotrypsin was found to be important for cognitive brain functions, as a 4bp deletion in 
the coding region leads to the generation of a truncated protein lacking the catalytic domain 
(Figure 1-1 (C); Molinari et al, 2002). This inactive variant of neurotrypsin causes a severe 
form of nonsyndromic mental retardation in humans. The affected children exhibited severe 
deficits in cognitive development after normal psychomotor development during the first 
18 months. Beside this, neurotrypsin has been localized to presynaptic nerve terminals of 
excitatory synapses in human brain and in the hippocampus and cerebral cortex of the murine 
brain based on pre-embedding immunogold labeling (Figure 1-4; Molinari et al, 2002; Stephan 
et al, 2008). Besides, neurotrypsin seems to be secreted and activated under certain stimuli 
(Frischknecht et al, 2008). Its synaptic recruitment as well as its externalization is regulated 
by neuronal activity, and externalized neurotrypsin is accumulated at the synapse for minutes 
before disappearing due to diffusion or degradation. Taken together, these findings characterize 
neurotrypsin as regulator of adaptive synaptic functions during later stages of development 
and suggest an activity-dependent extracellular proteolytic function of neurotrypsin at the 
synapse.
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Figure 1-4. Subcellular localization of neurotrypsin in hippocampus and cerebral cortex of wild 
type mice. (A, B) Immuno-electron microscopy of the neuropil of the hippocampal CA1 area and the 
cerebral cortex localized neurotrypsin in presynaptic terminals, close to presynaptic membranes lining 
in the synaptic cleft. Silver-intensified gold particles reporting neurotrypsin immunoreactivity were 
accumulated at vesicles close to the presynaptic membrane opposite to postsynaptic density (arrows). 
Scale bars = 0.2 µm. 
1.3 Agrin
Agrin is an extracellular matrix (ECM) protein named assigned to its key role in the 
aggregation of acetylcholine receptors (AChRs) which takes place during synaptogenesis in the 
neuromuscular junction (NMJ) (Sanes & Lichtman, 2001). The amino acid sequence of agrin 
has a predicted mass of 210 kDa. Due to addition of O- and N-linked carbohydrates as well as 
glycosaminoglycans (GAGs) in the N-terminal part of the molecule, the molecular weight of 
native agrin is increased to 400-600 kDa (Figure 1-6; Tsen et al, 1995). The three O-linked GAGs 
serve as binding sites for heparan sulfate glycosaminoglycans (HS-GAG), which classify agrin 
as a member of the heparan sulfate proteoglycans (HSPGs). The lamini-globular domain (LG) 
at the C-terminus is required for AChR-clustering at the NMJ (Gesemann et al, 1995; Cornish et 
al, 1999). 
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Figure 1-5. Schematic representation of agrin. Structural domains, sites of alternative mRNA splicing, 
andbinding regions of some of the most important part ners for agrin are illustrated. Signal sequence 
(SS) and amino (N)-terminal agrin domain (NtA) are present in a secreted agrin isoform which is 
localized at the NMJ  and bind to laminin in the basal lamina (NtA). The alternatively spliced type II 
transmembrane segment (TM) of agrin anchors this isoform at places that are devoid of basal laminae 
such as the ECM of the brain. The N-terminal half of agrin is highly glycosylated at Ser/Thr (S/T) 
attachment sites. These regions are involved in binding to NCAM L1 and heparin-binding growth factors. 
The C-terminal 95 kDa part of agrin is fully active in AChR aggregation and contains binding sites for 
ɑ-dystroglycan, heparin some integrins and a as yet unidentified agrin receptor. The four amino acid-
long insert at the A/y site encodes a separate exon. Similarly, the different inserts at the B/z site of 8, 11, 
and 19 amino acids are encoded by separate exons. The most C-terminal 21-kDa LG3 domain is sufficient 
to induce AChR aggregation although at much lower potency. Its activity requires the eight amino acid 
insert. FS, follistatin-like domain; LE, laminin EGF-like domain; LG, laminin globular domain; SEA, sperm 
protein enterokinase and agrin domain. Figure and text were modified from (Bezakova & Ruegg, 2003). 
1.3.1 Alternative splicing of agrin
Agrin is encoded by a single gene but alternative RNA splicing gives rise to several isoforms 
with distinct tissue expression and functional characteristics. Different N-termini are either 
leading to a secreted form, which is mainly expressed in muscle and peripheral tissues, or to a 
shorter non-secreted type II transmembrane protein specifically expressed in neurons (Figure 
1-5; Neumann et al, 2001; Burgess et al, 2000). Both isoforms have at least two additional 
splicing sites in the C-terminal part of the molecule, designated as y and z in humans (Figure 
1-6). Splicing at the y-site is leading to a protein with the insertion of 0 or 4 (Lys-Ser-Arg-Lys) 
amino acids at the LG2 domain. The y4 variant is required for a-dystroglycan- and heparin-
binding (Gesemann et al, 1996; Hopf et al, 1996). Furthermore, splicing at the z-site in the LG3 
domain gives rise to proteins with 0, 8, 11, or 19 (8+11) amino acid insertions. Results from 
localization studies of the mRNA in adult rat brain show a broad expression of the z-transcripts 
throughout the CNS (O`Connor et al, 1994). While non-neuronal cells express only agrin z0, 
neurons express various combinations of one or more agrin transcript (Yang et al, 2001). The 
total mRNA expression is > 40% for agrin z0, whereas agrin z8 and z19 account for the majority 
of 60%. Agrin z11 constitutes a very small percentage (< 7%) of these transcripts (see Figure 
1-6 (B)).
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Figure 1-6. Alternatively spliced isoforms of agrin mRNA are expressed in the adult rat CNS. (A), Film 
autoradiogram from a typical experiment indicating each of the four agrin isoforms is expressed in the 
CNS. Note that one of these isoforms, agrin z11, can only be detected in RNA isolated from regions of 
the forebrain. The control lane represents a reaction in which RNA was omitted from first-strand cDNA 
synthesis. (B), Expression levels of each transcript was calculated using quantitative densitometry of 
film autoradiogram. They were expressed as a fraction of all four transcripts. Agrin z0 (stippled bars) 
comprises the largest percentage (> 40%) of these transcripts in all regions of the CNS while agrin z19 
(hatched bars) and agrin z8 (open bars) account for the majority of the remaining 60%. By comparison, 
when agrin z11 (solid bars) is expressed, it constitutes a very small percentage (~ 7%) of these 
transcripts. Figure and text modified from (O`Connor et al, 1994).
Agrin mRNA is present at high levels in hippocampal regions CA3 and CA1. The transcript z11 
is restricted to forebrain structures (see Figure 1-6. B). The characteristic pattern of alternative 
splicing is influenced by regionally specific cues and supports the idea of a physiological 
significant mechanism of agrin`s regulation in the adult CNS. In addition, the z+ variants are 
crucial for agrin`s ability to aggregate AChRs at the NMJ whereas the z0 variant is inactive 
(Burgess et al, 1999). AChRs are still aggregating in vitro when applying the 22 kDa LG3 domain 
(agrin-22) with z+ insertions, though with decreased potency compared to the agrin full-length 
form (Gesemann et al, 1995; Cornish et al, 1999).
1.3.2 Agrin and the neuromuscular junction
AChR clustering is an essential characteristic in the process of postsynaptic differentiation. At 
birth, AChRs are clustered underneath the nerve terminals and a single muscle fiber is innervated 
by several motor axons. In the adult conformation, a single axon innervates one muscle fiber. 
Therefore, nerve terminals are in competition and upon synapse elimination the postsynaptic 
apparatus is remodeled. At the end of this process of synapse maturation, AChR clusters have 
acquired a pretzel-like shape. Agrin was first purified from basal-lamina-containing extracts of 
the electric organ of the marine ray Torpedo california (Godfrey et al, 1984; Nitkin et al, 1987). 
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At the NMJ, agrin is synthesized in motor neurons in the spinal cord and transported along 
motor axons to the muscle (Magill-Solc, 1988; Magill-Solc, 1990). After secretion at the nerve 
terminal, agrin induces tyrosine phosphorylation of the muscle-specific receptor tyrosine 
kinase (MuSK) (De Chiara et al, 1996; Glass et al, 1996). As agrin and MuSK could not be shown 
to interact directly, the linkage between these molecules was missed for a decade. Recently, a 
member of the family of low-density lipoprotein receptors, namely LRP4, was demonstrated to 
be associated with MuSK and agrin (Zhang et al, 2008; Kim et al, 2008). Further, neuronal agrin 
induced tyrosine phosphorylation in non-muscle cells exclusively if LRP4 was co-expressed 
with MuSK. These results suggest that LRP4 is the functional receptor for agrin at the NMJ. 
The importance of agrin for the development of the NMJ is nicely illustrated by the fact that 
agrin-deficient mice die directly after birth due to insufficient innervation of the respiratory 
muscles (Gautam et al, 1996). The motoneuron-derived form of agrin is defined as pro-synaptic 
molecule at the neuromuscular junction (Sanes & Lichtman, 2001; Kummer et al, 2006). Recent 
studies have shown that there is strong evidence for a regulatory function of agrin in the CNS 
(Annies et al, 2006; Mc Croskery et al, 2006; Hilgenberg et al, 2006; Matsumoto-Miyai et al, 
2009). 
1.3.3 Synaptic functions of agrin in the brain
Besides its role at the NMJ, in situ hybridization demonstrate that agrin mRNA is also expressed 
in cells of the CNS. For example, agrin could be detected at interneuronal synapses and the 
course of expression coincides with synapse formation. But at present its role remains still 
unclear (O´Connor et al, 1994; Mann & Kröger, 1996; Cohen et al, 1997). All four agrin z-isoforms 
are expressed in the adult CNS. However, both the level of expression and the pattern of the 
alternative splice variants are differentially regulated in the brain (O’Connor et al., 1994). In 
contrast to the situation at the NMJ, all agrin-22 z-transcripts (0, 8, 11, and 19) are equally potent 
agonists of the neuronal receptor and agrin-22 z0 and 8 are sufficient for receptor activation 
(Hilgenberg et al, 1999; Hoover et al, 2003). Subcellular localization in the hippocampus 
and the cerecral cortex of wild-type mice showed a perisynaptic as well as an extrasynaptic 
localization of agrin (Figure 1-7, Stephan et al, 2008). Agrin`s expression pattern in the CNS 
and its function at the NMJ suggests a similar role in synaptogenesis and  has therefore been 
hypothized to be implicated in several brain functions. This hypothesis is mainly supported by 
the finding of abnormal synapse formation and generation of fewer synapses in hippocampal 
neuron cultures after suppression of agrin by antisense oligonucleotide treatment or the 
expression of non-functional agrin (Ferreira 1999; Böse et al, 2000). The perinatal death of 
agrin-deficient mice could be preventes by ectopic expression of agrin in motoneurons. Similar 
as for the experiments in neuron cultures, these mice showed reduced number of pre- and 
postsynaptic structures (Ksiazek, 2007). It has been biochemically shown that the a3 subunit 
of Na+/K+-ATPase (NKA) is a neuronal receptor for agrin (Hilgenber et al, 2006). Agrin binds to 
the a3NKA in CNS neurons and signaling is regulated by release of intracellular Ca2+. Increased 
cytoplasmic Ca2+ concentration activates CaMKII and other Ca2+ effectors which are known as 
regulators of various synaptic functions and neurotransmitter turnover (Hilgenberg and Smith, 
2004). 
Introduction 23
A B
Figure 1-7. Subcellular localization of agrin in hippocampus and cerebral cortex of wild type mice. 
(A, B) Silver-intensified gold particles indicate for agrin immunoreactivity at perisynaptic, as well as 
extrasynaptic locations in the neuropil of the hippocampal CA1 area and the cerebral cortex. Arrows 
point to postsynaptic densities. Scale bars = 0.2 µm. Figure and text was modified from (Stephan et al, 
2008).
1.3.4 Agrin in Alzheimer`s disease
Alzheimer`s disease (AD) is a neurodegenerative disorder characterized by the loss of neurons 
and synapses in the brain (Davies et al, 1987; Hamos et al, 1989; Martin et al, 1994). A pathologic 
feature of this disease is the occurrence of b-amyloid-containing senile plaques, neuro-fibrillary 
tangles within neurons, and cerebral amyloid angiopathy (Roses, 1996). Clinically, the disease 
is associated with progressive dementia and memory loss (Snow et al, 1988). Furthermore, 
the pathological properties of AD are associated with HSPG function (Snow & Wight, 1989, 
Fukiuchi et al, 1998) and HSPG levels are elevated in AD brains (Table 1-1; Horssen et al, 2003; 
Snow & Wight, 1989). 
Table 1-1. The distribution of HSPGs in various AD lesions. Table from (Horssen et al, 2003).
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Severely affected brain regions in AD show highest agrin expression e.g. in the hippocampus 
and amygdala (Boew & Fallon, 1995; Braak& Braak, 1991). Agrin binds b-amyloid peptide Ab 
(1-40) in its fibrillar state via a mechanism involving the heparan sulfate glycosaminoglycan 
chains of agrin (Cotman et al, 2000). Furthermore, agrin is able to accelerate Ab fibril formation 
and protects Ab (1-40) from proteolysis in vitro. Immunocytochemical studies demonstrate 
agrin`s presence within senile plaques and cerebrovascular amyloid deposits, and capillaries 
immunostained for agrin exhibit pathological alterations in AD brain (Figure 1-8; Donahue et 
al, 1999; Verbeek et al, 1999; van Horssen et al, 2002). Therefore it was suggested that agrin 
may be an important factor in the progression of Ab peptide aggregation and Ab persistence in 
the brain of AD patients.
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Figure 1-8. Localization of agrin in aged control and AD brain. Sections were immunohistochemically 
stained with either diaminobenzidine-labeled tertiary antibody (A–E). (A) Aged control brain 
section labeled with antiagrin antibody. Agrin immunoreactivity is prominent within the cerebral 
microvasculature (large arrows) and is also evident in selected neurons (small arrows). Prefrontal 
cortex, A10, 3200. (B) Prefrontal cortex (A10) of a patient with AD immunostained with anti-agrin 
antibody. Note the robust staining of neuritic and diffuse plaques (large arrows) and blood vessels. In 
contrast to aged control cases (e.g., A), blood vessels in AD had attenuated diameters and a more ragged 
profile (small arrows). No immunoreactivity was observed when the antisera were preabsorbed with 10 
M agrin protein (Inset). (3200.) (C) Normal infant skeletal muscle labeled with anti-agrin antibody. Note 
the uniform agrin immunoreactivity of the basement membranes surrounding individual muscle fibers 
(small arrows) and capillaries (large arrows). (Inset) The same skeletal muscle after the primary antibody 
was preabsorbed with 10M agrin protein. There is complete abolishment of agrin immunoreactivity. 
(Quadriceps muscle, 3200.). Figure and text modified from (Donahue et al, 1999).
1.3.5 Agrin is a unique substrate of neurotrypsin 
Co-transfection of wild type neurotrypsin and the transmembrane isoform of agrin in 
eukaryotic cells resulted in cleavage at two sites and the release of three fragments at 110, 90 
and 22 kDa into the culture supernatant that are detectable by Western blot (Figure 1-9). The 
cleavage sites are located in the sequence PIER ↓ ASCY (a-cleavage site) and in the sequence 
LVEK ↓ SVGD (b-cleavage site). Neurotrypsin-dependent cleavage has been observed in vivo 
and was absent in neurotrypsin-deficient mice. The agrin-22 fragment was identified in brain 
and kidney. Therefore, neurotrypsin is responsible for the cleavage of agrin.
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Figure 1-9. Neurotrypsin cleaves agrin in vitro and in vivo. (A) Western blot analysis of HeLa cells co-
transfected with combinations of membrane-bound agrin (+), wild type neurotrypsin (wt), inactive 
neurotrypsin (S/A), and empty pcDNA3.1 (-). Supernatants (S) and cell lysates (CL) were analyzed 
with anti-agrin (R132 and G92) antibodies, directed against the C-terminus of agrin. (Top) Transfection 
of agrin alone resulted in a signal above 250 kDa in cell lysate. Upon co-transfection with wild type 
neurotrypsin, full-length agrin was cleaved resulting in fragments running at 22, 90 and 110 kDa in 
supernatant. No cleavage was found after co-transfection with inactive neurotrypsin. (Bottom) Control 
for neurotrypsin expression with G93 antibody. (B) Western blot analysis of tissue from wild type (wt) 
and neurotrypsin-deficient (KO) mice. The 90 kDa agrin cleavage product was detected in brain, kidney, 
and lung of wild type mice but was absent in neurotrypsin-deficient. Similar results were obtained for 22 
kDa fragment except for lung. b-Actin was used as a loading control. Figure and text taken and modified 
from (Reif et al, 2007).
The heparan sulfate proteoglycan agrin is until today the exclusive substrate of neurotrypsin. 
Neurotrypsin cleaves agrin at two homologous sites which are highly conserved in evolution 
(Figure 1-10, Reif et al, 2007). It has been reported that neurotrypsin-dependent cleavage is 
sequence specific. Based on the terminology of Schechter and Berger (Schechter & Berger, 
1967), strong preference of neurotrypsin for substrate cleavage was observed for basic amino 
acids in the P1 position and a strictly conserved Glu at the P2 position which is important for 
recognition by the S2 subsite of neurotrypsin.
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Figure 1-10. Alignment of a- and b-cleavage sequences of agrin of different species. For comparison 
of amino acid residues surrounding scissile bond of a- and b-cleavage sites, terminology of Schechter 
and Berger was used. P1 denotes the N-terminal and P1’ the C-terminal residue engaged in scissile 
bond. Flanking residues in N-terminal direction are denoted P2, P3,…Pn, flanking residues in C-terminal 
direction are denoted P2’, P3’,…Pn’. Figure and text are taken and modified from (Reif et al, 2007).
The temporal expression pattern suggests that cleavage is active during the late phase of 
synaptogenesis and decreases in adult brain (Figure 1-11). The agrin-22 fragment is only 
detectable in murine brain tissue until age P60 whereas the persistence of agrin-90 indicates 
that neurotrypsin cleavage is active at both sites throughout life. Recent observations implicate 
a synapse-regulating function of agrin and its neurotrypsin-dependent fragments in the CNS. It 
has been reported that clustering of transmembrane agrin by polyclonal anti-agrin antibodies 
induce a dose- and time-dependent formation of numerous filopodia-like processes extending 
from axons and dendrites of the CNS and PNS neurons (Annies et al, 2006). Dendritic filopodia 
are thin and long membranous protrusions which have been characterized as precursors of 
spines (Matus, 2005; Knott et al, 2006). They are able to mature into a persistent synapse 
within days by establishing preliminary contacts with axonal boutons or shafts. The formation 
of dendritic filopodia was found to be reduced in hippocampal CA1 neurons of neurotrypsin-
deficient mice (Matsumoto-Miyai et al, 2009). Remarkably, exogenous application of agrin-22 
fully rescued the filopodial response in the observed slice culture. In addition, presynaptic 
activity was documented to trigger the release of neurotrypsin, whereas additional activation of 
postsynaptic NMDA-receptor was required for the neurotrypsin-dependent cleavage of agrin. 
Western blot analyses of synaptosomes confirmed that neurotrypsin-dependent cleavage of 
agrin occurs locally at the synapse (Stephan et al, 2008). In addition, higher increase of the 
agrin-90 fragment was observed compared to the amount of agrin-22. Hence, agrin-22 appears 
to be more diffusible and indicates mobility by passing the non-synaptic tissue into the 
cerebrospinal fluid (CSF). Neurotrypsin-dependent cleavage of agrin at the synapse is thought 
to influence the synaptic function of agrin. The release of biological active agrin fragments may 
modulate the interaction with receptors which are possibly abolished for full-length agrin. 
Together, these results suggest the neurotrypsin-dependent cleavage of agrin as a potential 
pathway for activity-dependent reorganization and remodeling of synaptic circuits in the brain.
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Figure 1-11. Developmental course of neurotrypsin-dependent agrin cleavage. Brain tissue from 
C57BL/6 mice from embryonic day E16 until postnatal day P730 were analyzed by Immunoblotting 
using anti-agrin (R132 and R139) and anti-neurotrypsin (G93) antibodies. Neurotrypsin expression and 
appearance of both 90 and 22 kDa fragments of agrin peaked during late fetal days and in first postnatal 
week. However, the 90 kDa fragment remained detectable at low level at all adult stages. Figure and Text 
taken from (Reif et al, 2007).
1.4 The Calsyntenin Family
Calsyntenin-1 was named for bindinding synaptic Ca2+ with its cytoplasmic domain (Vogt et al, 
2001). It was identified by in vitro screen for targeted proteins of extracellular proteases as a 
transmembrane protein of the postsynaptic membrane in excitatory and inhibitory synapses in 
the CNS. Calsyntenin-1 has two cadherin-like repeats in its N-terminal extracellular region and 
a highly acidic cytoplasmic C-terminal region. Northern blot analysis and in situ hybridization 
illustrated the expression of three different calsyntenin members: calsyntenin-1, -2, and 
-3 (Hintsch et al, 2002). They show a stringent homology of their extracellular sequences, 
but show high variability in their architecture of the cytoplasmic domains. The N-terminus 
of calsyntenin-1 is released into the extracellular space after x-cleavage by ADAM10 and 
ADAM17 (Marcello et al, 2007; Hata et al, 2010). Thus, it exhibits strikingly similar features 
as the prominent transmembrane, amyloid precursor protein (APP), whose misregulation in 
proteolytic processing is thought to contribute to Alzheimer`s disease (Figure 1-12). In the case 
of the calsyntenin members, the transmembrane stump is internalized and accumulated in the 
spine apparatus of the synapse and the Ca2+-binding domain is translocated from the cytoplasmic 
side. Hence, calsyntenin-1 is implicated in the dynamic modulation of postsynaptic Ca2+-
signaling. The proteolysis-dependent translocation is suggested to illustrate an independent 
downstream event in protease-mediated synaptic plasticity. 
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Figure 1-12. Schematic representation of the domain structure of the calsyntenin family members, of 
b-amyloid precursor protein and their proteolytic processing. A, Calsyntenins are type-I transmembrane 
proteins and possess two N-terminal cadherin domains (cad), a transmembrane domain (tm) and 
relatively short cytoplasmic domains (cyt). All three calsyntenins bear conserved WDDS motifs, either 
in two copies in calsyntenin-1 or in on copy in calsyntenin-3 and murine calsyntenin-2, respectively. 
All calsyntenins undergo ectodomain shedding (x) by ADAM10 and ADAM17, followed by g-secretase-
mediated regulated intramembrane proteolysis, at least in the case of calsyntenin-1 and -3. However, 
latter resulting proteolytic fragments were not yet identified in vivo. B, b-Amyloid precursor protein 
(APP) undergoes constitutive ectodomain shedding mediated by a-secretase (a) ADAMs 9, 10, and 17 
or alternatively by b-secretase (b) BACE, both resulting in the release of soluble APP and the retention 
of a C-terminal transmembrane stump. Subsequent g-secretase-mediated intramembrane proteolysis 
(g) of the transmembrane stump generates p3 (a-cleavage) or Ab (b-cleavage) peptides. Accumulation 
of latter peptides leads to its amyloidogenic aggregation, which is a hallmark of Alzheimer`s disease. 
The non-transition state inhibitor DAPT abolishes g-secretase-mediated proteolytic processing and 
thus results in an accumulation of the transmembrane stumps. Figure and text taken and modified from 
(Steuble M., Dissertation, 2008).
Furthermore, calsyntenin-1 is mainly expressed in all CNS neurons, whereas expression levels 
of Calsyntenin-2 and -3 vary between neuronal subpopulations (see Figure 1-13). Pyramidal 
neurons in the hippocampal CA1 region show high expression of only Calsyntenin-1. In contrast, 
part of the Purkinje cells in the cerebellum express calsyntenin-2 and -3, but lack calsyntenin-1. 
The distinct pattern for each of the members suggests specific functions in distinct neuronal 
areas. In addition, the putative Ca2+-binding region exhibits the highest degree of structural 
diversity between the calsyntenin members. Based on the characteristic clusters of acidic 
amino acids, calsyntenin-1 shows enhanced Ca2+-binding capacity compared to the other family 
members (Lucerno et al, 1994). 
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Figure 1-13. Differential expression pattern of calsyntenin members in the brain. (A-C) In situ 
hybridization of coronal (upper panels) and horizontal (lower panels) sections of adult mouse brain. 
Calsyntenin-1 and -3 are expressed in the neocortical regions (nc), hippocampus (hp), olfactory bulb 
(ob), and cerebellum (ce), whereas calsyntenin-2 is expressed only in the hippocampus and olfactory 
bulb. Figure and text taken and modified from (Hintsch et al, 2002).
Intracellular proteolysis of the type I transmembrane protein APP generates the amyloid-b-
protein (Ab) which, through aggregation and accumulation, is implemented in the pathogenesis 
of AD (Haass & Selkoe, 2007). The transmembrane protease is named b-site APP cleaving 
enzyme (BACE) and processes APP at the b-site generating a large extracellular N-terminal 
domain (sAPPb) and a cellular C-terminal fragment including the entire Ab domain. Subsequent 
intramembrane proteolysis of the transmembrane stump by g-secretase gives rise to Ab. 
Alternatively, a non-amyloidogenic a-secretase pathway by the metallo proteases ADAM9, 
ADAM10, and ADAM17 can take place (Sisodia, 1992). This process inhibits the production of 
Ab by cleavage of APP within the amyloid domain. 
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Figure 1-14. Schematic model of the interdependence between calsyntenin-1 and b-amyloid precursor 
protein. Calsynetnin-1 and APP associate with each other through their interaction with X11L, forming a 
tripartite complex, which stabilizes the metabolism of calsyntenin-1 and APP. Upon dissociation of X11L, 
calsyntenin-1 and APP are cleaved at their primary cleavage site (x and a or b, respectively) followed by 
cleavage at the secondary site (g/e). The generated intracellular fragment of APP (AICD) forms a complex 
with the nucleoshuttling protein Fe65 and the histone acetyltransferase Tip60, which exhibit the gene 
transactivation activity. The intracellular fragment of calsyntenin-1 (CICD) can as well associate with 
Fe65 and inhibit the Fe65-dependent gene transactivation activity of AICD (Araki et al, 2004). Figure and 
text taken and modified from (Steuble M. Dissertation, 2008). 
Calsyntenins and APP undergo a similar coordinated proteolytic processing (Figure 1-14). 
Hence, they are also termed Alzheimer-related cadherin-like proteins (alcadeins; Araki et al, 
2003). Recent findings demonstrate that APP and the cytoplasmic X11L/Mint2 protein form 
a tripartite complex with calsyntenin-1 (Araki et al, 2003). It was suggested that formation 
of this complex stabilizes intracellular APP metabolism and mediates suppression of the 
Ab generation. The dissociation of X11L from the tripartite complex enables cleavage of 
calsyntenin-1 and APP at their primary cleavage sites (x and a or b, respectively). Followed by 
secondary cleavage at the e/g-site, an intracellular fragment of APP (AICD) is generated. The 
cytosolic AICD cleavage product is thought to bind the nucleo-cytoplasmic shuttling protein 
Fe65 and the histone acetyltransferase Tip60 and forms a transcriptionally active complex 
(Araki et al, 2004). Similarly, the intracellular fragment of calsyntenin-1 (CICD), which is 
generated after g-cleavage, can associate with Fe65. It was suggested that CICD suppressed 
the Fe65-dependent gene transactivation activity of AICD, probably because CICD competes 
with the APP intracellular domain fragment for binding to Fe65. In addition, deficiencies in the 
X11L-mediated interaction and imbalance in the metabolism of calsyntenin-1 and APP may be 
related to neuronal disorders like AD.
Recently, it was shown in our group that proteolytic processing of calsyntenin-1 and APP is 
dependent on neuronal activity (Steuble M., unpublished results). The chemical LTP stimulation 
was performed in whole hippocampi of young mice. Both potassium-based TEA and non-
potassium-based PFR chemical LTP stimulation protocols increase ectodomain shedding of the 
two molecules, whereas TEA elicits a stronger LTP-inducing effect than PFR (Figure 1-15). 
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It might well be, that there is a connection of neuronal activity and proteolytic processing. 
Further studies on proteolytic processing could contribute to better understand pathological 
mechanisms leading to neuronal disorders.
time [min]
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Figure 1-15. Timecourse of the relative amount of full-length calsyntenin-1 (Cst1 full) (A and C) and 
the cleavage product calsyntenin-1 ectodomain (Cst CTF) (B and D) during chemical LTP stimulation in 
whole hippocampi. LTP induction was performed by potassium-based TEA (A and B) and non-potassium-
based PFR (C and D) stimulation. The hippocampi were taken from young mice (P10). Experiments were 
performed with in triplicates with n=5 hippocampi; normalized to b-actin; *p < 0.05; **p < 0.005; ***p < 
0.001; paired t-test (Steuble M., unpublished results).
1.5 Mass spectrometry
Mass spectrometry (MS) is a powerful analytical tool used in chemistry, biology, pharmacy and 
medicine and provides insights e.g. into possible interaction partners and signaling pathways. 
The measurement of the accurate molecular weight of a compount provides information about 
the sample purity and helps to determine post-translational modifications. Fragmentation of 
selected proteolytic precursor ions in so called tandem MS analyses offers the possibility to 
obtain inormation about the sequence of biomolecules and their identification by matching the 
MS fragment ion spectra to sequence databases. 
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Nomenclature of fragment ions
The nomenclature according to Roepstorff and Fohlmann (Roepstorff & Fohlmann, 1984) 
is based on the idea of the breaking peptide bond (Figure 1-16. The y-fragment is the piece 
representing the original C-terminus. Fragment ions representing the N-terminus are named 
b-ions. Amino acids with functional groups (Asp, Glu, Lys, Arg, Cys) and distinctive structural 
features (Pro) can influence the fragmentation process of a peptide. Thus, the process of 
fragmentation can change within the peptide.
Figure 1-16. Peptide fragmentation pattern according to Roepstorff
The mass spectrometer mainly consists of four important and very flexible parts: the HPLC-
interface, the ionization section, the mass analyzer, and the detector. A large variety of 
ionization methods and mass analyzers offers the identification of unknown compounds, 
the quantification of known compounds and the elucidation of the structure and chemical 
properties of molecules. The sections 1.5.1 and 1.5.2 will describe two predominant types of 
ionization and the commonly used mass analyzer in more detail. 
1.5.1 Ionization
For the ionization of large biomolecules such as peptides and proteins a soft ionization method 
is essential, since these molecules are a polar, nonvolatile, and thermally unstable species, 
therefore relatively fragile and fragment easily when using conventional ionization methods. 
The two important ionization methods with regard to soft ionization are electrospray ionization 
(ESI) and matrix assisted laser desorption ionization (MALDI).
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Electrospray ionization
Electrospray is a continuous ionization method coupled to the continuous analysis mass 
spectrometer. It uses the formation of charged liquid droplets that contain the analyte and 
from which the ions are desolvated or desorbed (Fenn et al, 1989). During ionization, single 
and multiply charged ions like [M+H]1+ and [M+nH]n+ are formed in solution. ESI allows the 
analysis of molecules with a high mass, such as proteins, because a high amount of charge 
i.e. protons, can be transferred to the molecule during the ionization process. Therefore large 
biomolecules can be detected as multiple charged ions in a moderate m/z range. As ESI is 
perfectly compatible with liquid separation techniques it has become one of the most widely 
used methods in biological analyses. The development of micro and nano ESI offers higher 
sensitivity, as they can be coupled to capillary reversed phase columns which run at low flow 
rates in the nano-liter per minute range (Griffin et al, 1991; Emmett et al, 1994; Shen et al, 
2003).
Matrix assisted laser desorption ionization
Unlike ESI, the MALDI source produces mainly [M+H]1+ ions from solid phase. The matrix in 
MALDI applications functions as the carrier of the charge (Karas and Hillenkamp, 1988). It 
absorbs the energy from the laser beam, gets ionized and transfers part of the charge to the 
biomolecules which have been co-crystallized with the matrix before. The absorption of the 
excessive energy by the matrix molecules prevents the degradation of the analyte. As matrix, 
low-molecular substances with high tendency for crystallization are used. Their absorption 
peak is in the range of the wavelength of the applied laser. 
1.5.2 Mass analyzer
After a long period of research for enhancing the performance of the ionization, MS 
instrumentation is now dominated by the improvements of the performance of the mass 
analyzer. This part of the instrument enables isolation and storage of ions and separates them 
based on the m/z ratio. The basis consists of three different mass analyzers: (i) the quadrupole 
(Q) which uses m/z stability; (ii) the time-of-flight (TOF) which uses flight time and (iii) the ion 
trap (IT), orbitrap (OT) and ion cyclotron resonance (ICR) which is based on m/z resonance 
frequency (Yates et al, 2009). Through the combination of several mass analyzers, advanced 
MS-MS capabilities can be created. The types of mass spectrometers which are commonly used 
in proteomic studies are summarized in Table 1-2.
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 Instrument Resolution    Mass  Sensitivity Dynamic
     accuracy      range
 LIT (LTQ)      2.000 100 ppm      fmol    1E4
 TQ       2.000 100 ppm     amol    1E6
 LTQ-OT 100.000      2 ppm      fmol    1E4
 LTQ-FTICR 500.000  < 2 ppm      fmol    1E4
 Q-TOF    10.000  2-5 ppm     amol    1E6
Table 1-2. Performane comparison of commonly used mass analyzers in proteomics. Linear ion trap 
(LIT/LTQ which is the Thremo Scientific version). Figure and text taken and modified from Yates et al, 
2009.
1.5.3 Separation and LC-MS coupling
On-line coupling of the nano-liquid chromatography system to the ESI source of the mass 
spectrometer offers a fast and powerful tool to effectively reduce the complexity of the sample 
mixtures (e.g. serum, urine, cerebrospinal fluid) and increase the sensitivity. It is the first step 
in method development and essential for analyzing molecules in the low abundant peptides 
(Yates et al, 2009). The reversed phase (RP) resins separate proteins and peptides according 
to their hydrophobicity. Development of narrow capillary RP columns showed an increase in 
sensitivity and dynamic range in peptide separation (Shen et al, 2002; Shen and Smith, 2002; 
Shen et al, 2005). Additionally, improvement of peak capacity, resolution and faster analysis 
was achieved by using small particle size (> 2µm) (Anspach et al, 2007). The Workflow of a 
typical proteomic experiment is illsutrated in Figure 1-17. Typically, proteins are digested to 
produce a complex mixture of peptides, which are separated by HPLC before analysis by MS. 
The overall process consists of a number of steps, specifically the ionization of the peptides, 
acquisition of a full spectrum (survey scan) and selection of specific precursor ions to be 
fragmented, fragmentation, and acquisition of MS/ MS spectra (product-ion spectra).  Two of 
the predominant mass analyzers used in Proteomics will be disscussed in the following section. 
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Figure 1-17. Workflow of a typical proteomic experiment. Proteins are digested to produce a complex 
mixture of peptides, which are separated by HPLC before analysis by MS. The overall process consists 
of a number of steps, specifically the ionization of the peptides, acquisition of a full spectrum (survey 
scan) and selection of specific precursor ions to be fragmented, fragmentation, and acquisition of MS/ 
MS spectra (product-ion spectra). The data are processed to either quantify the different species and/
or determine the peptide amino acid sequence through a database search. Figure and text taken and 
modified from (Domon and Aebersold, 2010).
1.5.4 Instrumentation and applications
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
Fourier transform mass spectrometry (FT MS) is based on the concept of ion cyclotron 
resonance (ICR). The ions are formed in an external source and trapped in the FTMS analyzer 
cell which is placed in a center of a strong magnetic field. The ions move in raid spirals around the 
magnetic field lines. The cyclotron frequency is dependent on the m/z ration of each ion as well 
as the magnetic field strength. When ions are passing the receiver plates, their image current 
signals are recorded. This results in high resolution and mass accuracy since frequencies can 
be recorded more precise than other physical parameters. Mass spectra are generated using 
Fourier transform analysis. The time-dependent transients of the ions are therefore converted 
into a frequency-dependent function.
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Quadrupole instruments
The quadrupole mass spectrometer consists of four precisely straight and parallel rods and 
functions as a mass filter. As a result of the high frequency electric field, ions are oscillating in 
x and y direction through the quadrupole. Only resonant ions with a specific m/z ratio pass the 
quadrupole filter on a stable flight path, whereas all others are non-resonant and get redirected 
on their path. During m/z analysis, the frequency and DC voltage of the poles is varied whereby 
the spectrum is generated.
Targeted mass spectrometry
In contrast to shotgun or directed MS, this technique uses previously established information 
to develop a detection and quantification method of previously evaluated analytes in complex 
protein mixtures. It allows the analysis of predetermined fragment ions which are anticipated, 
but not necessarily detected in a survey scan (Domon and Aebersold, 2010). The experiment is 
mainly performed on a triple quadrupole instrument which operates in selected reaction mode 
(SRM, often also called MRM). For SRM approaches using TQ instruments, the first quadrupole 
Q1 is set for a distinct precursor ion mass, which then enters the Q2 collision cell. The Q3 is 
additionally set for one or several distinct fragment ion masses. In this manner, the transition 
of Q1 to Q3 is monitored. The workflow of a targeted MS assay is demonstrated in Figure 1-18. 
Figure 1-18. Workflow of a targeted proteomic experiment. As the experiment is hypothesis-driven, it 
targets a very specific subset of peptides uniquely associated with the proteins of interest. An instrument 
method is built using existing proteomic resources (peptide spectral libraries) required for a target 
analysis and is typically performed using a triple-quadrupole instrument. For each peptide, a series of 
transitions (pairs of precursor and fragment ion m/z values) are monitored during a time that specifically 
corresponds with its predicted elution time. This enables hundreds of peptides to be analyzed in a single 
experiment. Figure and text taken and modified from (Domon and Aebersold, 2010).
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For each transition, the m/z of the precursor ion, its elution time and characteristic high-
intensity fragment ions need to be defined. An initial effort is required to evaluate ideal 
fragmentation parameters and to generate an optimized method for each peptide (Domon and 
Aebersold, 2010). The method is highly specific and the most sensitive mass spectrometric 
strategy and therefore used to screen complex sample mixtures for distinct target proteins.
Figure 1-19. Effect of biochemical background on quantification by the shotgun (discovery), directed 
and targeted proteomics strategies. Whereas dotted lines indicate a low-complexity background, full 
lines represent a complex background, such as a full cell lysate. LLOQ, lower limit of quantification; ULOQ, 
upper limit of quantification. Figure and text taken and modified from (Domon and Aebersold, 2010).
The limit of detection (LOD) is defined as three times the signal-to-noise ratio, while the limit 
of quantification (LOQ) is defined as nine times the signal-to-noise ratio. The complexity of 
the sample matrix is affecting the dynamic range as well as the LOD/LDQ of a certain method 
(Figure 1-19). The LOD of the same peptide can be shifted by several orders of magnitude if 
this peptide is surrounded by a complex sample matrix and decreased signal intensities of 
the analyte in complex samples are recorded when compared to pure analyte (Domon and 
Aebersold, 2010). The differences in limit of detection and dynamic range are shown in Figure 
1-20.
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Figure 1-20. Effect of background on the detection of a peptide mixture in various concentrations 
(arbitrary units). (A) low/moderate background; (B) high background; (C) In-beam, no background; 
(D) trapping instrument, no background; note the changes in the ordinate as ion counts decrease. c, 
concentration; u, arbitrary units; S/N, signal-to-noise; the x and y axes correspond to m/z values and 
signal intensities, respectively. Figure and text taken and modified from Domon & Aebersold, 2010.
1.5.5 Quantitative proteomics
Protein quantification via isotope labeling
The reliable quantification of proteins is essential for the understanding of biological 
processes and evaluation of protein biomarkers in order to shed light on disease processes. 
A quantification model needs to be independent of protein sequence, accurate over several 
orders of magnitude and should not be affected by the overall sample complexity. The first 
quantization strategy was the comparison of spot intensities after sample separation with 2 
Dimensional Electrophoresis (2DE) gels. The limitations of quantification via 2DE gels is due 
to a low resolution, low dynamic range and the difficulty of detecting proteins with extreme 
molecular mass or isoelectric point (pI) (Gygi et al, 2000). In addition, spots on a given 2DE-gel 
often contain more than one protein, making it difficult to quantify changes of the protein of 
interest since it is not clear which protein has changed in the spot. Beside the 2DE-gel approach, 
a various set of isotope labeling techniques have been developed: isotope-coded affinity tag 
(ICAT) (Gygi et al, 1999), isobaric tags for relative and absolute quantification (iTRAQ) (Ross 
P.L. et al, 2004), stable isotope labeling by amino acids in cell culture (SILAC) (Ong et al, 2002), 
absolute quantification (AQUA), metabolic 15N/14N labeling and enzymatic 16O/18O labeling. 
Therefore, samples are labeled separately, mixed together and analyzed by MS. The m/z 
ratio of the paired peptides can be distinguished by a few mass units. The first approach uses 
chemical modification by isotope-coded affinity tag (ICAT). Two proteomes can be analyzed 
and isolated proteins from experiment and control are denatured, reduced and modified with 
the heavy or light chemical reagent. ICAT involves cystein-directed tagging of intact proteins 
following tryptic digestion of the combined proteomes of labeled proteins and control. The 
labeled peptides are further enriched by avidine column via a biotin tag, leading to an overall 
reduction in sample complexity. Another MS-based approach for relative quantification of 
proteins is iTRAQ which relies on derivatization of primary amino groups in intact proteins. 
Therefore, proteins are labeled using isobaric tags that produce fragment ions 114, 115, 116 
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or 117 Da allowing analysis of four different proteomes in one single analysis. Differentially 
labeled proteins do not differ in their mass and their tryptic peptides appear as single peak 
in the MS spectrum. The quantitative information is provided by isotope-encoded reporter 
ions which are observed exclusively in the MS/MS spectra. For the absolute quantification 
(AQUA), samples are spiked with a synthesized set of peptides. The stable isotopes (13C, 15N) 
are incorporated in these peptides at the lysine or arginine position and result in a +8 Da or +10 
Da mass shift. As the standard peptides show identical physicochemical properties, they elute 
with the same retention and ionize in a similar manner as the unlabeled endogenous peptides 
of interest. This allows for absolute quantification of the analyte, but can only be applied after 
identification of the biomarker of interest (Kirkpatrick et al, 2005). The constriction in all 
isotope labeling methods is the need for a mass spectrometer with high mass resolution and 
the labeling of the samples has to be complete. Statistical analysis is not necessarily possible, 
since the labeling is basically designed for comparative analysis of two sample sets or upon 
eight when using iTRAQ. Additionally, one has to keep in mind, that the isotope labels are very 
cost intensive. The general approaches of quantitative proteomics are depicted in Figure 1-21.
Figure 1-21. General approaches of quantitative proteomics. (a) Shotgun isotope labeling method. After 
labeling by light and heavy stable isotope, the control and sample are combined and analyzed by LC-MS/
MS. The quantification is calculated based on the intensity ratio of isotope-labeled peptide pairs. (b) 
Label-free quantitative proteomics. Control and sample are subject to individual LC-MS/MS analysis. 
Quantification is based on the comparison of peak intensity of the same peptide or the spectral count of 
the same protein. Figure and text taken and modified from (Zuh et al, 2010).
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Label-free protein quantification
In contrast to labeling methods, this method is simple, no extra step for sample preparation is 
needed, and the inclusion of statistical analysis is possible, since a high sample number can be 
compared. Quantification is either based on ion-intensity changes such as peak area and peak 
height or on spectral counting of identified proteins after MS/MS analysis. 
Relative quantification by peak intensity
Early studies report relative quantification of peptides upon comparison of peptide ion peak 
intensities in several LC-MS runs (Chelius et al, 2002; Bondarenko et al, 2002). This method 
is based on the finding that peak areas linearly increase with increased concentration. It 
could be demonstrated that this method is reproducible even at the complexity of proteome 
samples when using a correlation of the peak area and retention time between replicate runs 
(Wang et al, 2006). The method is vulnerable to experimental variability and normalization 
is required. Additionally, highly reproducible LC performance is essential to accurately align 
chromatographic peaks. A shift in retention time and/or m/z will result in huge variability and 
inaccurate quantification. The TOP3protein quantification approach by Silva (Silva et al, 2006) 
uses precursor ion intensities of the three best performing PTPs in terms of ionization and 
identification of a certain protein.
Relative quantification by spectral count
The linear correlation between increasing protein abundance and resulting number of PTPs 
is the basis of relative quantification by comparing the number of identified MS/MS spectra 
(spectral count) from the same protein identified in multiple LC-MS/MS runs (Washburn et al, 
2001). To normalize the influence of protein lengths on spectral count, a normalized spectral 
abundance factor (NSAF) was calculated (Zybailov et al, 2006). 
Absolute quantification by spectral count
A modified spectral counting strategy is absolute expression (APEX) and enables for absolute 
protein quantification per cell (Lu et al, 2007). The fraction of expected number of peptides is 
proportional to the observed number of peptides when including correction factors in order to 
determine the APEX score.
Bioinformatics tools
There is enormous increase in developing bioinformatics tools for label-free quantitative data 
analysis and several computational methods like SuperHirn, APEX, Mascot-emPAI and T3PQ 
are available either commercially or as open-source programs (Müller et al, 2008; Grossmann 
et al 2010). All available software for label-free quantification enables data normalization, time 
alignment, peak detection, peak quantification, peak matching, identification, and statistical 
analysis. The workflow illustrated in Figure 1-22 depicts the steps for quantification of proteins 
in a complex mixture using T3PQ.
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Figure 1-22. Workflow of Top 3 Protein Quantification. The figure illustrates the different steps for 
achieving quantitative values for proteins in a complex mixture using Top 3 Protein Quantification 
(T3PQ). Figure and text taken and modified from (Grossmann et al, 2010).
1.6 Biomarker discovery from body fluids via mass spectrometry
The evaluation of biomarkers as reporters of the patho-physiological status of the human 
body is of exceeding interest. Especially those biomarkers that would allow diagnosis at the 
early-onset of a disease. Their identification may result in a fast treatment and thus, in a better 
prognosis of the disease.
The development of novel methods in mass spectrometry offered a new path in the analysis 
of peptides and proteins from serum samples as source for new diagnostic markers. 
Initiation was the analysis of serum samples by spot detection in 2DE gels (Anderson, 2002). 
The implementation of so called fingerprints, peak patterns of peptides, as parameter for 
identification started in 2002 and shed light on the pathological processes in prostate cancer 
(Adam et al, 2002; Qu et al, 2002) and breast cancer (Li et al, 2002). Followed by the first 
SELDI-TOF experiments, where serum samples are incubated on chips providing specific 
surfaces (C18, immunoglobulins, ion exchange) to fractionate and enrich the proteins. Unbound 
molecules are removed in a wash step and subsequent application of a matrix on top of the 
sample spots enables the collection of mass spectra by laser ionization TOF mass spectrometry 
(Simpkins et al, 2006). By using the peak intensities, protein concentrations were correlated 
for the blood samples. Additional, first MALDI-TOF studies were based on statistical analysis of 
peak intensities between a set of cases with a specific disease and control subjects to designate 
differences in protein concentration (Villanueva et al 2004; Villanueva et al, 2006; Baumann 
et al, 2005; Callesen et al, 2005). These methods do not necessitate a biological knowledge 
of the pathological or physiological cause of the disease. Possible biomarkers do not have to 
be selected before the experiment. Alongside, there are critical comments on the use of mass 
spectrometric peptide patterns in the process of declaration of novel biomarkers. The pitfalls 
of the mass spectrometric workflow are threefold:
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(i) High variability in experimental design and data mining
As a high number of these studies are based on the comparative analysis of two sample 
sets, individuals with a specific disease and healthy control subjects. In many cases, a slope 
in expression of proteins was due to non-specific reactions of the organism, for example the 
increase of acute-phase response proteins (Diamandis, 2004; Koomen et al, 2005). Another 
major mistake was the use of faulty algorithms for the classification of diagnostic markers. 
The result was over-fitting of peak patterns and generation of artifacts. The use of a larger 
sample number and the careful evaluation of the obtained biological model can help overcome 
these mistakes (Diamandis, 2004; Wagner et al, 2004; Hilario et al, 2006). Another effect was, 
that resulting data was not reproducible, neither in other groups nor in the same laboratory 
(Diamandis, 2003; Feng et al, 2004; Coombes, 2005).
(ii) Technical limitations of the instrumentation
The parameters influencing signal intensity are yet not well understood. Quantification of 
a certain protein in two samples with distinct compositions may lead to false alterations in 
protein concentration (Gillette et al, 2005; Aebersold & Mann, 2003).
(iii) The biological relevance of the data
Protein concentrations in the blood cover about 10 orders of magnitude, ranging from albumin 
(35-50 mg/ml in serum) to IL6 (0-5 pg/ml in serum) Figure 1-23; Anderson & Anderson, 2002). 
The major group of high abundant plasma proteins comprises albumin, immunoglobulins, 
fibrinogen, a-1 antitrypsin, a-2 macroglobulin, transferrin and lipoproteins (Schulte et al, 
2005). The residual 3% are middle- to low-abundant proteins and are considered to provide 
information about the patho-physiological condition of the body. As the dynamic range of 
detection in mass spectrometry is about 2-3 orders of magnitude, it is insufficient to target 
the overall range of proteins in blood samples. Another effect of high-abundant proteins 
is suppression of signals of low-abundant proteins (Diamandis, 2004; Gillette et al, 2005; 
Koomen et al, 2005). Therefore, observed spectral patterns have to be carefully investigated, 
as they may be caused by artifacts from the analytical process or the natural fluctuations of 
the blood. A common way to eliminate these disadvantages is the selective depletion of most 
abundant proteins or the fractionation of the sample. One current depletion technique is the 
use of resins with efficient binders or antibodies against the high-abundant proteins (Omenn 
et al, 2005; Echan et al, 2005; Zolotarjova et al, 2005; Huang et al, 2005). Other procedures 
are ultrafiltration (Rezaee et al, 2006) or adding organic solvents like ACN to enrich globular 
proteins and albumin in a pellet (Mitchell et al, 2005). Until today, all these methods applied 
for the depletion of high-abundant proteins remove as well some middle- and low-abundant 
proteins from the sample (Shen et al, 2005; Granger et al, 2005; Moritz et al, 2005).
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Figure 1-23. Depicted are the plasma protein concentrations as described by Anderson and Anderson 
(2002). The proteins can be grouped in three main categories (classical plasma proteins, tissue leakage 
products, interleukins/cytokines). Red dots indicate proteins that were identified by the HUPO plasma 
proteome initiative (States et al, 2006) and yellow dots represent currently utilized biomarkers (Polanski 
and Anderson, 2006). Figure and text taken and modified from (Schiess et al, 2009).
1.6.1 Diagnostic markers in serum
Serum is a very interesting source for such diagnostic markers since its proteome carries 
information about the physiological and pathophysiological state of the human body. It is 
influenced by the status of various organs and disease-dependent changes. Thus, it delivers 
biomarkers to monitor the clinical status of the patient. The various proteins cover a wide 
range of concentrations, for example the amount of serum albumin is in the mg/ml range 
compared to the pg/ml range of cytokines (Bishop, 2000). Serum albumin covers about 50-
70% of the total serum proteins and immunoglobulin heavy and light chains take additional 
25%. Whereas sample supply is relatively easy, it is among the most difficult samples to analyze 
when using LC-MS instrumentation (Anderson and Anderson, 2002). The presence of high-
abundant proteins can mask others and results in a loss of resolution in LC-MS approaches. 
Removal of highly abundant proteins is essential prior to LC-MS analysis (Colantonio, 2005).
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1.6.2 Cerebrospinal fluid - a source for biomarkers
The human cerebrospinal fluid (CSF) is one important source for diagnostic markers of 
neurological diseases. It is produced in the choroid plexus and gets its inputs from extracellular 
space of the spinal cord and the brain (Mc Comb, 1983). CSF is accumulated in the four ventricles 
and is an important determinant of the extracellular fluid (ECF) surrounding neurons and 
glia in the CNS. The CSF has a low protein concentration (150–450 mg/ml) and a high salt 
concentration (4150 mmol/l). Despite the low total protein concentration, the concentration 
of albumin (60% of the total CSF protein) and immunoglobulin is extremely high in the CSF 
(Hammack et al., 2003). The changes of proteins which are involved in biochemical pathways 
may be reflected in CSF. For example the level of total-tau protein and the light subtype of the 
neurofilament proteins (NF-L) after acute ischemic stroke (Hesse et al., 2001). The collection 
of CSF is predominantly performed by lumbar puncture ( Figure 1-24). A spinal needle is 
inserted between the lumbar vertebrae L3/L4 or L4/L5 through the dura and the arachnoid 
mater into the subarachnoid space. CSF is a multifunctional body fluid and it for example 
physically protects the CNS and actively regulates CNS activity via circulating hormones and 
neuropeptides (Stopa et al, 2001; Chodobski, 1998). The physiological and pathological status 
of the CNS can be monitored (Carrette et al, 2003; Davidsson et al, 2005). Thus, CSF serves as 
ideal biological source for identification of neurological biomarkers to describe the status of 
the brain. For several years, various groups used the CSF proteome to characterize diagnostic 
markers in the context of brain diseases (Abdi et al, 2006; Zhang et al, 2005).
Figure 1-24. CSF collection by lumbar punture. Figure taken from (Olson & Pawlina, 2008)
As there is a high variability between results of several laboratories studying the CSF proteome, 
there are some factors which have to be carefully discussed when working with CSF. The main 
influences on heterogeneity between results are: variability of patients, experimental design, 
sample processing and the proteomics technology. 
Introduction 45
Variability of patients
The total CSF volume in an adult is about 150 ml. As CSF is renewed every 6-8 hours, the overall 
daily production is about 500 ml. In addition, there is a bulk flow of molecules, regardless of 
the molecular size, from extracellular fluid of the spinal cord and the brain to CSF (Cserr et al, 
1981). Besides, plasma proteins enter the CSF upon diffusion with respect on their molecular 
size (Thompson, 1995). In the lumbar cisterna, highest protein concentrations of about 2.5 
times compared to the ventricular zone are found (Huhmer et al, 2006). Therefore, it is of high 
importance for the quantification assay, that CSF is collected always in the same way. In our case 
we included only human CSF collected by lumbar puncture, which is a conventional method. In 
some biomarker studies, only later fractions (15-25th ml) were used, because concentrations 
of brain-derived proteins should be highest with regard to the caudorostral gradient (Abi et 
al, 2006; Zhang et al, 005; Pan et al, 2006). Other factors on protein concentrations in CSF 
are age and circadian rhythm. The CSF turnover decreases with age (Preston, 2001) and the 
secretion rate is reported to be about doubled at night when compared to the afternoon in 
healthy subjects (Nilsson et al, 1992). Timing of the lumbar puncture and the age of a subject 
thus affect quantitative proteomics. Hence, we included the correlation of agrin-22 levels to age 
for each subject. Agrin and neurotrypsin expression shows age-dependency. 
Sample storage
It has been reported, that protein degradation occurs when they have undergone multiple 
freezing/thawing and when stored at -20°C (Carrette et al, 2005). CSF samples should be 
stored at -80°C in aliquot samples to avoid freeze/thaw cycles. Since there is no information 
about suitable protease inhibitors, addition of inhibitor cocktails is not recommended.
Sample processing
Relatively high salt concentrations in CSF require a desalting step in the beginning of sample 
preparation. According to the documentation of Zhang (Zhang, 2007), desalting of CSF is 
achieved best with dialysis in terms of protein recovery. The dynamic range of CSF proteins 
is comparable to blood (Blennow et al, 1993). Therefore, depletion of high-abundant proteins 
and enrichment of low abundant proteins is required.

2 Aim
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The approach towards developing a biomarker for monitoring activity of the drug target 
neurotrypsin was based on identifying and quantifying the product of neurotrypsin`s 
proteolytic activity in bodyfluids, i.e. the 22 kDa fragment of its unique substrate agrin. This 
was supposed to be achieved by quantitative mass spectrometry as well as Western blot 
analysis. The cleavage of agrin by neurotrypsin releases its C-terminal domain agrin-22 into 
the serum and CSF. Hence, the level of this fragment in these bodyfluids gives rise on the 
proteolytic activity of neurotrypsin in the brain as well as in the periphery. The following work 
is aimed in detecting and quantifying the agrin-22 fragment in murine serum of neurotrypsin 
overexpressing as well as neurotrypsin deficient mice and human CSF at different ages and 
various neurological diseases. The level of this fragment could report about the activity of 
neurotrypsin at the synapse. Its concentration might have a diagnostic value or serve for the 
monitoring of therapeutically interventions. Since it was shown that the release and activation 
of neurotrypsin follows an activity dependent mechanism, the focus was set on diseases with 
uncommon neuronal activity e.g. epilepsy and Alzheimer’s disease. The activity of neurotrypsin 
and therefore the level of the cleavage fragment agrin-22 in CNS could serve as diagnostic 
biomarker for neurological diseases. Besides, neurotrypsin’s unique substrate agrin has been 
extensively studied at the neuromuscular junction, where a synapse promoting effect could 
be observed. As the role of agrin in the CNS is not well understood, it is conceivable to have a 
synapse stabilizing effect in the brain as well. Hence, the work was as well aimed to improve the 
understanding of the functional role of agrin-22 in the CNS. 
Furthermore,  proteolytic ectodomain shedding of the transmembrane protein calsyntenin-1 
was identified and quantified. Calsyntenins and APP undergo a similar coordinated proteolytic 
processing. After ectodomain shedding (x) by ADAM10 and ADAM17, cleavage by g-secretase 
regulateds intramembrane proteolysis. The transmembrane stump of calsyntenin-1 is 
internalized and accumulated in the spine apparatus of the synapse. Thus, proteolysis-dependent 
translocation is suggested to illustrate an independent downstream event in protease-
mediated synaptic plasticity. Furthermore, the similar metabolism of calsyntenin-1 and APP 
may be related to neuronal disorders like AD and it was recently shown that calsyntenin-1 
ectodomain-shedding is increased by induction of synapse activity. Further studies on the 
proteolytic processing could contribute to better understand pathological pathways leading to 
neurological diseases.

3 Results
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The generation, reorganization and elimination of synaptic circuits is an essential mechanism 
during learning and memory tasks in the central nervous system (CNS). It is known that 
extracellular proteases are involved in these structural changes in neurons. The neuronal serine 
protease neurotrypsin is expressed in many brain areas during neuronal development. A four 
base pairs deletion in the coding region leads to an inactive form of neurotrypsin and causes 
severe mental retardation in humans. Therefore, neurotrypsin was linked to adaptive synaptic 
functions. Neurotrypsin cleaves agrin at two well-defined sites and one released fragment, 
agrin-22, shows a promoting effect on filopodia generation. To address the cleavage activity 
of neurotrypsin, agrin-22 was quantified by Western blots of murine serum from mice either 
overexpressing or lacking neurotrypsin. To investigate the role of agrin-22 in the CNS, human 
cerebrospinal fluid (CSF) from patients of different ages, with Alzheimer’s disease (AD) and 
epilepsy compared to healthy control subjects, was analyzed by Western blot. The main focus 
of this project was the development of a targeted mass spectrometry assay to quantify the four 
agrin-22 isoforms z0, 8, 11, and 19, since they are not distinguishable in Western blot analysis. 
Additionally, quantification of calsyntenin-1 ectodomain was included in the studies of human 
CSF samples. There was supporting evidence that ectodomain shedding of calsyntenin-1 is 
dependent on neuronal activity and thus could provide a diagnostic marker for AD as well as 
epilepsy.
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3.1 Isolation and identification of agrin-22
In this paragraph, I am going to identify and describe the presence of the neurotrypsin-
dependent agrin-22 fragment in murine serum and rat cerebrospinal fluid (CSF). I will start 
with the identification of agrin-22 using data-dependent LC-MS/MS measurements and give 
an overview about the activity of neurotrypsin in association with the age and the genotype of 
different mouse groups. So far, neither murine serum nor rat CSF were subjected to detailed 
analysis, therefore nothing was known about the distribution of agrin-22 isoforms in these 
body fluids. 
3.1.1 Neurotrypsin-dependent processing in murine serum and rat cerebrospinal fluid
As a result of the relatively low agrin and neurotrypsin expression, enrichment of agrin-22 was 
essential. Immuno-affinity isolation was performed, pooled elution fractions were trypsinized 
and analyzed by mass spectrometry. Analysis was achieved using an inclusion list for agrin-22 
z0, 8, 11, and 19, which enabled selection of peptide ions with particular mass-to-charge (m/z) 
ratio for collision-induced dissiociation (CID) in the LTQ mass spectrometer. The mapped tryptic 
peptides from LC-MS/MS are shown below and confirmed the presence of the neurotrypsin-
dependent cleavage fragment agrin-22 in murine serum (Figure 3-1) and rat CSF (Figure 3-2). 
All tryptic peptides match the very C-terminal part in the LG3 domain of agrin.  
SVGDLETLAF	DGRTYIEYLN	AVIESEKALQ	SNHFELSLRT	EATQGLVLWI	GKVGERADYM	
ALAIVDGHLQ	LSYDLGSQPV	VLRSTVKVNT	NRWLRVRAHR	EHREGSLQVG	NEAPVTGSSP	
LGATQLDTDG	ALWLGGLQKL	PVGQALPKAY	GTGFVGCLRD	VVVGHRQLHL	LEDAVTKPEL	
RPCPTL
Mascot search results: 
Database: UniRef100 20020206
Agrn protein [Mus musculus] Q99KT4, Mass: 28364, Score: 276, Queries matched: 9
Figure 3.1. Identification of the neurotrypsin-dependent cleavage fragment agrin-22 in murine serum 
samples. The identified tryptic peptides from LC-MS/MS analysis are highlighted in colors.
Results 51
SVGDLETLAF	 DGRTYIEYLN	 AVIESEKALQ	 SNHFELSLRT	 EATQGLVLWI	 GKAAERADYM	
ALAIVDGHLQ	 LSYDLGSQPV	 VLRSTVKVNT	 NRWLRIRAHR	 EHREGSLQVG	 NEAPVTGSSP	
LGATQLDTDG	 ALWLGGLQKL	 PVGQALPKAY	 GTGFVGCLRD	 VVVGHRQLHL	 LEDAVTKPEL	
RPCPTP
Mascot search results: 
Database: UniRef100 20051018
Agrin precursor [Rattus norvegicus] UPI00005038EA, Mass: 206096, Score: 251, Queries 
matched: 6
Figure 3-2. Identification of the neurotrypsin-dependent cleavage fragment agrin-22 in murine serum 
samples. The identified tryptic peptides from LC-MS/MS analysis followed by Mascot database search 
are highlighted in colors.
The absence of N-terminal parts of agrin in serum and CSF was confirmed by Western blot 
analysis using the antibodies R139 against the C-terminal LG3 domain of agrin and the antibody 
R132 against the N-terminal part of agrin (not shown). The identified tryptic peptides are not 
proteotypic for one specific z-isoform of agrin-22. Hence, no suggestion can be given for the 
distribution pattern or neurotrypsin`s favorable substrate in case of agrin-22 splice variants. 
Neither full-length agrin (smear at 250-200 kDa) nor one of the other neurotrypsin-dependent 
cleavage products agrin-90 or agrin-110 could be detected. Therefore it was concluded, that 
agrin-22 is released into the blood and CSF and can serve as reporter on neurotrypsin`s 
proteolytic activity.
3.1.2 Neurotrypsin-dependent cleavage of agrin is linked to the genotype
To confirm the neurotrypsin-dependent processing of agrin, mouse serum was compared by 
Western blot. Serum of transgenic mice overexpressing neurotrypsin (tg/+, Muslik 533) and of 
homozygous neurotrypsin-deficient mice (KO/KO, NT-KO) of different ages (P4 and P10) was 
analyzed. As reference, sera of wild type littermates from each mouse group were included. The 
control sera used for signal normalization were from wild type mice (+/+, NMRI) of the age E18 
(Figure 3-3). 
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Figure 3-3. Evaluation of agrin-22 in homozygous neurotrypsin-deficient mice (KO/KO), transgenic 
neurotrypsin-overexpressing mice (tg/+) and wild type littermates (+/+). (A) Agrin-22 levels at P4. (B) 
Agrin-22 levels at P10. Murine serum was separated by 4-12% NuPAGE gels and quantitative Western 
Blot was performed from the same sample in triplicates. Error bars represent STDEV. The small insert in 
(A) shows the result of the t-test for five independent samples of (tg/+, open bars) and (+/+, black bars). 
** p < 0.005. Western Blot was performed in triplicates. Error bars represent STDEV.
The neurotrypsin-dependent processing of agrin is particularly active during neuronal 
development. Additionally, neurotrypsin-overexpressing animals show significantly increased 
amounts of agrin-22 at P4 compared to wild type animals (p < 0.005). The increase in signal 
intensity in serum of neurotrypsin-overexpressing animals displays a higher accumulation of 
agrin-22 which is likely due to higher expression of neurotrypsin and thus due to increased 
proteolytic processing of agrin. At P10, signal intensity was clearly reduced in both neurotrypsin-
overexpressing mice as well as their wild type littermates. There is no difference in agrin-22 
levels compared to P4. This might be explained by a decreased expression of neurotrypsin and 
particularly of endogenous agrin with increased age of the animals (see also next chapter). In 
contrast, the agrin-22 signal was clearly absent in homozygous neurotrypsin-deficient animals 
at both ages. This reflects most likely the lack of neurotrypsin-dependent cleavage. Furthermore, 
it supports the finding that the presence of agrin-22 is exclusively dependent on cleavage of 
agrin by neurotrypsin. The full length form of agrin was not present in murine serum neither 
in neurotrypsin overexpressing animals nor in serum from their wild type littermates (data 
not shown). The unprocessed full-length agrin variants are therefore thought to accumulate in 
the tissues. Distribution into the blood stream is abolished as a result of agrin`s high molecular 
weight or agrin remains N-terminally linked to the tissue. On 4-12% NuPAGE gels followed 
by Western blots the four isoforms of agrin-22 were not resolved, but appeared as one band 
at the molecular weight level of 22 kDa. The differentiation of agrin-22 splice variants is not 
possible when using Western blot, because the antibody R139 against the C-terminal part of 
agrin, which is used in this study, does not distinguish between the splice inserts.
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3.1.3 The appearance of agrin-22 is linked with aging and neuronal development in mice
The amount of neurotrypsin and agrin at the mRNA and protein level is particularly high from 
the late embryonic phase throughout the first postnatal week (Wolfer et al, 2001, Stephan 
et al, 2008) and therefore it is linked to early neuronal development. Thus, neurotrypsin`s 
cleavage activity in relation to age was examined and the presence of the agrin-22 fragment 
in murine serum of increasing age was analyzed. For this purpose, murine serum samples 
ranging from P1 until P30 were collected. Again, the concentration of agrin-22 was monitored 
using heterozygous littermates from neurotrypsin-overexpressing transgenic mice, knock-out 
littermates from neurotrypsin-deficient mice and wild type siblings. The data shown in figure 
3-4 are based on quantification of Western blots with antibody R139 to detect the neurotrypsin-
dependent cleavage fragment agrin-22.
The agrin-22 values in murine serum of transgenic neurotrypsin-overexpressing mice as well as 
the wild-type animals show a decrease following a similar age-dependent course as previously 
described for endogenous neurotrypsin and full-length agrin. The expression and cleavage 
activity of neurotrypsin and its substrate agrin is similarly and developmentally regulated (Reif 
et al, 2007). Highest expression of neurotrypsin was reported to take place around E18 and 
P10. The results from murine serum samples are in accordance with these previously reported 
findings on mRNA as well as on protein level.
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Figure 3-4. Age-dependent agrin-22 levels. (A) Western blot of sera from transgenic neurotrypsin-
overexpressing mice (tg/+) and their wild type littermates (+/+) from P4 to P30. (B) Western blot of 
sera from homozygous neurotrypsin-deficient mice (KO/KO) and their heterozygous littermates  (+/-) at 
P1. Serum from E18 aged wild type mice (K) is loaded as reference for quantification. All serum samples 
were diluted 1:10 in PBS and 10 µl of this dilution were seperated with 4-12% NuPAGE gels and analyzed 
by Western blot with antibody R139. (C) Quantitative analysis of Western blots from wild-type sera from 
P4 to P30. Western blots were perfromed in triplicates using the same sample. Error bars represent 
STDEV.
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3.2 Evaluation of sample preparation for mass spectrometry
Blood, serum, CSF as well as other body fluids can be obtained relatively easily and thus serve 
as a useful source for the detection and quantification of novel biomarkers. To quantify the four 
splice variants of agrin-22 in murine serum with mass spectrometry, depletion of the complex 
protein matrix was necessary. Various high-abundant proteins suppress the signals of low-
abundant proteins when using chromatography for protein separation and mas spectrometry 
(MS) for protein identification. In general, low sample volumes (10-300 ml) are used in liquid 
chromatography-MS (LC-MS) analysis. Thus most expressed proteins are not present in 
sufficient quantities and remain undetectable (Fountoulakis, 2001). However, less abundant 
proteins are often of great interest as they are most likely drug targets and diagnostic markers. 
Therefore, the removal of highly abundant proteins is essential (Colantonio, 2005). 
I am going to describe the advantages and disadvantages in conjunction with depletion. Four 
depletion columns and three fractionation techniques were tested to deplete murine serum 
prior to  LC-MS analysis (Table 3-1).
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 Depletion device        Loading capacity      Method          Performance/
             (supplier)             (in µl serum)        Agrin-22 Recovery
 ProteomeLab IgY-12          10       Affinity          -
 (Beckman Coulter)         column
 ProteoPrep Immunoaffinity         25      Affinity       -
 Albumin/IgG Depletion Kit                 spin column
 ProteoSpin Abundant Serum         10  Ion-exchange       -
 Protein Depletion Kit     spin column
 (Norgen)
 ProteoExtract Albumin/IgG         15     Affinity       -
 Removal Kit                 gravity column 
 (Calbiochem)
 Microcon YM-30       200    MWCO filter       -
 Microcon YM-50 
 (Millipore)
 Ammonium Sulfate            5    Precipitation       +
 Gelfiltration        100   Size-exclusion       +
 Superose 12 (10/30)         column
Table 3-1. Depletion columns and fractionation techniques used for serum depletion prior to analysis 
with LC-MS.
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3.2.1 ProteomeLab IgY-12
The depletion column was tested with 10 ml murine serum (wild-type, E18). Protein 
concentrations were monitored with the Bradford protein assay. The fractions of depleted 
serum, wash and bound proteins were TCA-precipitated, separated by 12,5% SDS-PAGE for 
silver staining or loaded on a 4-12% NuPAGE gel for Ponceau staining followed by Western blot 
analysis with antibody R139 (Figure 3-5).
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Figure 3-5. Murine serum proteins (wild-type, E18) after depletion of high-abundant proteins using 
ProteomeLab IgY-12 column. Protein amounts after TCA precipitation were separated by 12,5% gels for 
(A) silver staining and by 4-12% NuPAGE Bis-Tris gels for (B) Ponceau staining and (C) Western blot with 
antibody R139. Agrin-22 is marked by an arrowhead. Asterisks on the right indicate the relative position 
of albumin. 
The protein bands in the silver gel show an accumulation of low-molecular weight proteins in 
the depleted serum fractions. Additionally, high-molecular weight proteins like albumin and 
immunoglobulins are enriched in the elution fraction of bound proteins. This suggests that 
depletion of high-abundant serum proteins and enrichment of low molecular weight molecules 
is possible with the depletion column. The Western blot in panel (C) Figure 3-5 shows a signal 
for agrin-22 in the load but, the signal was absent in the depleted serum as well as in all other 
fractions (bound proteins and wash fractions). Thus, agrin-22 could not be eluted from the 
column neither in the depleted serum nor in the bound protein fractions or wash. This result 
may indicate that agrin-22 is lost through unspecific binding to the column material.
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3.2.2 ProteoPrep Immunoaffinity Albumin and IgG Depletion Column
To monitor the protein recovery with a well-defined input, recombinant agrin-22 z19 was 
included into the column test. Depletion was performed with 25 µl murine serum (wt, E18) and 
25 µl murine serum with addition of recombinant agrin-22 z19 (275 ng, protein concentration 
measured by UV-absorbance). The samples were previously diluted in 75 µl equilibration 
buffer before their concentration was determined. Depleted serum fractions are obtained 
as flow-through after 10 minutes of incubation followed by centrifugation. Elution of bound 
proteins was performed with the same volume as the load. Samples were precipitated with 
chloroform-methanol (Wessel & Flügge, 1984), followed by separation using 4-12% NuPAGE 
gels and analyzed by Western blot (Figure 3-6).
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Figure 3-6. Murine serum proteins after depletion of high-abundant proteins using ProteoPrep 
Immunoaffinity Albumin and IgG depletion kit. Proteins after chloroform-methanol precipitation were 
separated by 4-12% NuPAGE Bis-Tris gels and Western blot using antibody R139 was performed. Lanes: 
1-2, depleted serum; 3, bound proteins eluted from depletion column; 4, control (recombinant agrin-22 
z19); 5, empty; 6-7, bound proteins eluted from depletion column; 8, depleted serum; 9, control murine 
serum (wt, E18).
The signal for agrin-22 was visible as a faint band in all fractions, the depleted serum, wash 
fractions and elution fractions of bound proteins. This indicates that isolation of agrin-22 in 
the fraction of the depleted serum failed. Addition of recombinant agrin-22 z19 in the second 
experiment results in a high signal for agrin-22, which was detected in all fractions. Additionally, 
the signal for endogenous agrin-22 was detected in all fractions and is highest in the fraction 
of the bound proteins. The signal intensity was much higher in all fractions compared to the 
previous experiment where recombinant agrin-22 z19 was absent. It is therefore believed, 
that the presence of recombinant agrin-22 z19 prevents unspecific binding of the endogenous 
agrin-22 to the resin of the column. Due to the unspecific binding of agrin-22, the depletion kit 
is found to be not suitable for the purposes.
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3.2.3 ProteoSpin Abundant Serum Protein Depletion Column
This depletion column provides a fast and simple procedure for the effective depletion of 
major serum proteins. It is based on an ion-exchange mechanism and not on the use of 
specific antibodies. The complexity of the sample is reduced, allowing for the detection of less-
abundant proteins. The eluted samples are ready for use in downstream applications including 
LC-MS. The depletion column was tested with 10 µl murine serum (wt, P5), which was diluted 
in activation buffer. Binding takes place during centrifugation, whereby high-molecular weight 
proteins are not retained to the flow-through. Elution of depleted serum is performed in two 
portions of 100 µl elution buffer after neutralization. The efficiency of depletion was controlled 
by a silver-stained 4-12% NuPAGE Bis-Tris gel as well as by Western blot using antibody R139 
(see Figure 3-11 in the paragraph “Sample preparation for murine serum”). Taken together, 
the kit shows a high efficiency in depletion, as high-molecular weight proteins were clearly 
accumulated in the flow-through fraction as shown in the silver gel. Nevertheless, the elution 
fraction of depleted serum appears as a smear which is distributed throughout all molecular 
weight regions in the gel. Besides, the signal intensity for agrin-22 in the Western blot was poor, 
indicating a low recovery for the protein of interest when compared to the same murine serum 
sample (non-depleted, wt, P5). The depletion column is therefore another unsuited method for 
the isolation of agrin-22. 
3.2.4 ProteoExtract Albumin/IgG Removal Kit
The gravity column is based on a novel albumin affinity resin and a unique immobilized 
protein-A polymeric resin. Depletion was achieved using 15 µl murine serum (wt, P5) which 
was diluted to a volume of 350 µl with binding buffer before being applied on the column. The 
depleted serum is obtained by washing the resin two times with 600 µl binding buffer, while 
bound proteins remain trapped in the column after elution. The depleted serum was loaded 
on 4-12% NuPAGE Bis-Tris gel and analyzed via silver staining and Western blot with antibody 
R139 as shown in Figure 3-11 in the paragraph “Sample preparation for murine serum”. The kit 
shows satisfying performance in the depletion. High-molecular weight proteins were clearly 
reduced in the wash fraction. Nonetheless, overall signal intensity for endogenous agrin-22 
in the depleted serum is very poor when compared to the column input and the control 
sample (non-depleted, wt, P5). In conclusion, this finding reveales that this depletion kit is not 
convenient for sample preparation.
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3.2.5 Microcon YM-30, 50
In order to separate serum protein mixture by their size, Microcon centrifugal filter devices 
were tested. The idea was to enrich albumin and immunoglobulins in the supernatant to 
obtain a low-molecular protein mixture in the flow-through fraction. First experiments were 
performed with recombinant agrin-22 splice variant z19. Protein concentration was measured 
by UV-absorbance on a nano-Drop spectrophotometer. Measurements were performed for the 
load, flow-through and the supernatant of the recombinant protein solution. The results are 
shown in Figure 3-7. 
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Figure 3-7. Protein recovery for depletion with Microcon centrifugal filter devices: (A) YM-30 (30 kDa 
MWCO) and (B) YM-50 (50 kDa MWCO). Each bar represents protein concentration measured by UV-
absorbance for the load, flow-through and supernatant.
The low protein concentration after centrifugation indicates the absence of the agrin-22 z19 
in the depleted flow-through fraction as well as in the supernatant. Protein recovery was not 
possible as indicated by the drop in concentration. To monitor the performance on endogenous 
agrin-22, microcon YM-50 device was additionally tested with 200 ml rat CSF Figure 3-7, B).
Analysis with Western blot confirms that the isolation of endogenous agrin-22 in the depleted 
serum (flow-through fraction, Figure 3-8.) was not possible with the filter devices. Moreover, 
agrin-22 can be found in the supernatant which contains high-abundant proteins as well. In 
conlusion, the depletion of murine serum and the parallel isolation of agrin-22 is not possible 
with this method. 
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Figure 3-8. Rat CSF proteins after depletion according to the molecular mass using YM-50 centrifugal 
filter devices with MWCO 50kDa. Proteins were separated with 12,5% SDS-PAGE and Western blot was 
performed using antibody R139. Lanes: 1, load; 2, depleted CSF; 3, supernatant.
3.2.6 Gel filtration
Besides the commercial depletion columns, gel filtration was considered as an alternative 
method for serum depletion. This chromatographic method is based on size-exclusion and 
molecules are mainly separated according to their stokes`s radius. Larger molecules elute 
faster as they are less or not retained at all in the pores of the column material. In contrast, 
small molecules have a high ability to diffuse into higher number of pores, thus elute after 
the high-molecular weight fraction. The column used was a Superose 12 (10/30) and 100 ml 
murine serum (wt, P10) was applied without any previous dilution. The elution fractions were 
analyzed with silver-stained 4-12% NuPAGE Bis-Tris gel and Western blot using antibody R139 
(Figure 3-9).
250
150
100
75
50
35
25
25
15
1    2     3    4    5     6    7    8    9     1    2   3   4   5   6    7   8   9
A B
*
Figure 3-9. Murine serum proteins (P10) after separation by gel filtration. Elution fractions were loaded 
volume-adjusted (20ml) and separated by 4-12% NuPAGE Bis Tris gels. (A) Silver stain; (B) Western blot 
with antibody R139. Lanes: 1, Load (P10); 2-9, elution fractions. Agrin-22 is found in fraction 7. The 
Astersik on the left  indicates the relative postion of albumin. 
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Silver staining clearly indicated the accumulation of high-molecular weight proteins in earlier 
elution fractions. Size-exclusion chromatography lead to very good depletion of the murine 
serum sample compared to the column input. Agrin-22 could be isolated and eluted in fraction 
7, which additionally shows a high degree of depletion of serum proteins. These data support 
that gel filtration is a possible method to deplete serum samples and to isolate endogenous 
agrin-22 in one fraction of depleted serum.
3.2.7 Ammonium sulfate precipitation
The solubility of a protein in a solvent is defined by its interaction of the charged functional 
groups with the molecules of the solvent. This interaction can be manipulated and proteins 
will precipitate by the following additives: inorganic salts, organic solvent, basic proteins, 
pH variation and temperature change. The common method to achieve protein isolation, 
enrichment and purification is the fractionated precipitation by addition of inorganic salts 
like (NH
4
)
2
SO
4
. The ability of a protein to precipitate is a result of the number and special 
distribution of hydrophobic groups at the surface (functional groups of Phe, Tyr, Trp, Leu, Ile, 
Met and Val). For proteins like very nonpolar functional groups, small amounts of inorganic 
salts are sufficient to precipitate them. To deplete the murine serum samples, I tested the 
protein fractionation according to polarity by precipitation using ammonium sulfate. Here, 5 
ml murine serum (wt, E18) was diluted 1:2 in PBS. The ammonium sulfate solution (4 M) was 
added stepwise starting at 10% (v/v) saturation with increasing the amount until 100% (v/v) 
saturation. In order to avoid high local concentrations of ammonium sulfate, addition of the 
stock solution was performed with continuous shaking. The precipitate and the supernatant 
were analyzed in parallel with 4-12% NuPAGE Bis-Tris gels and Western blot using antibody 
R139 (Figure 3-10).
The signal for agrin-22 was exclusively detected in the supernatant containing 10% (NH
4
)
2
SO
4
. 
Thus, isolation of agrin-22 is possible with ammonium sulfate precipitation. Additionally, it 
can be claimed that the fraction comprising agrin-22 should not contain big amounts of high-
molecular weight proteins. This can be suggested by the Ponceau staining of the respective 
pellet after precipitation since it shows a higher accumulation of high-molecular weight 
proteins compared to the supernatant (Figure 3-10, B). Taken together, the data supports that 
serum depletion and isolation of agrin-22 in one of the depleted fractions is possible. 
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Figure 3-10. Murine serum samples (5µl) after precipitation with ammonium sulfate. Samples were 
separated on 4-12% NuPAGE gels and immunoblot was performed with antibody R139. Upper panels 
show Ponceau red-stained blotting membrane, lower pannels the corresponding immunoblots using 
antibody R139. (A) Supernatant and (B) Pellet after precipitation with the indicated ammonium sulfate 
concentration. Murine serum (wild-type, E18) is used as reference sample (K). 
3.2.8 Direct comparison of the three best enrichment methods 
The removal of high-abundant proteins in murine serum samples was expected to improve the 
signal intensity of agrin-22 by SDS-PAGE and Western blot as well as the quantification by LC-
MS analysis. The results display that all seven depletion techniques tested removed albumin 
and IgG with high efficiency. Based on reproducibility and binding specificity, size-exclusion 
separation via gel filtration offered the best depletion. The depleted sera of the three best 
depletion techniques, (i) Proteo-spin Abundant Serum Protein Depletion Kit, (ii) ProteoExtract 
Albumin/IgG Removal Kit, and (iii) gel filtration were further evaluated with silver-stained 
SDS-PAGE, Western blot and LC-MS analysis (Figure 3-11). The analysis was carried out on 
all fractions (load, depleted serum, wash and elution of bound proteins) to study the binding 
efficiency, recovery and possible unspecific interactions.
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Figure 3-11. Murine serum proteins after depletion of high-abundant proteins using different depletion 
columns. Proteins after chloroform-methanol precipitation were separated by 4-12% NuPAGE Bis-Tris 
gels. (A) Silver stain; (B) Western blot with antibody R139. Lanes: 1, control (E18); 2-5, Proteo-spin 
Abundant Serum Protein Depletion Kit; 2, depleted serum; 3-4, wash; 5, bound proteins eluted from 
depletion column; 6, empty; 7, ProteoExtract Albumin/IgG Removal Kit, depleted serum; 8, empty; 9, Gel 
filtration, elution pool. The asterisk on the left indicates the relative position of albumin. 
Based on the recovery and signal intensity of agrin-22, the ProteoExtract Albumin/IgG Removal 
Kit displayed promising results. It shows high protein recovery and specificity. Nevertheless, I 
chose the separation via size exclusion by gelfiltration for sample preparation before LC-MS 
analysis. Gel filtration allows the preparation of high amounts of serum (100 ml). The high 
sample volume is essential for the identification of agrin-22 due to its low concentration in 
serum and it shows the best performance in the removal of hig-abundant serum proteins, 
which is a crucial prerequisite for a successful analysis with LC-MS. Additionally, the recovery 
of agrin-22 after depletion with gel filtration was very good and highly reproducible.
After this comparative study, I wanted to test the depletion for human cerebrospinal fluid 
samples as well. Due to the low sample volume, the previous tested depletion kits were 
not compatible. The CSF has a low protein concentration (150–450 mg/ml) and a high salt 
concentration (4150 mmol/l). The high salt concentrations in CSF require a desalting step at 
the beginning of sample preparation. Desalting of CSF is achieved best with dialysis in terms 
of protein recovery (Zhang, 2007). The dynamic range of CSF proteins is comparable to blood 
(Blennow et al, 1993). Therefore, depletion of high-abundant proteins and enrichment of 
low abundant proteins is indeed needed. I choose a fractionation method via graduated ACN 
addition because of the low sample volumes available and the extensive dilution which would 
result after gel filtration. No significant variations were found in protein concentration in terms 
of precipitation when using this approach (Zhang et al, 2005). In order to evaluate differences 
between serum and CSF, I similarly performed dialysis followed by ACN fractionation of 100ml 
murine serum (wt, E18) and 100ml human CSF. Pellet P1 and supernatant S1 were collected 
after addition of 1.5 volumes (v/v) ACN. Pellet P2 and supernatant S2 were obtained after 
addition of 3 volumes (v/v) ACN to supernatant S1. Supernatant S2 was dried in a speed-vac. 
The resulting pellets (P1 and P2) and supernatant (S2) were loaded on a 4-12% NuPAGE gel 
followed by Western blot analysis. The Western blot was stained with Ponceau red to visualize 
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the quality of protein separation and depletion before incubation with antibody R139 for the 
detection of agrin-22. 
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Figure 3-12. Fractionation of human CSF in comparison to murine serum with ACN precipitation. 
Samples (30 µl) were separated on 4-12% NuPAGE gels. (A) Ponceau red staining of the blotting 
membrane corresponding to the Western blot in the lower panel of figure (B). (B) Western blots after 
incubation with antibody R139. Upper panel shows the signals of agrin-22 in the supernatant (S2) of 
human CSF and murine serum and reference samples for human CSF (K). Lower panel displays the 
signals of agrin-22 in the pellets (P1 and P2) for human CSF and murine serum.  The asterisk on the right 
indicates the relative position of albumin. 
Ponceau red staining indicates a clearly higher protein amount for pellets P1 and P2 of murine 
serum in comparison to relatively low protein amounts for the same fractions of human CSF 
(Figure 3-12). The signals for agrin-22 in murine serum were found in precipitated protein 
fractions P1. This fraction contains additionally accumulated high-abundant proteins like 
albumin and immunoglobulins. In contrast, agrin-22 was enriched in the supernatant S2 in 
human CSF. The S2 fraction represents a depleted CSF portion and includes low-abundant 
proteins (data not shown). The depletion upon fractionation and simultaneous isolation of 
agrin-22 was achieved for human CSF. Depletion and isolation of agrin-22 in murine serum 
was not possible by ACN.
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3.2.9 Data-dependent LC-ICR-FT-MS analysis of depleted murine serum 
For examining the improved signal intensity after depletion, murine serum was prepared 
according to the two most suited depletion strategies, gel filtration and protein precipitation by 
ACN. Sera were divided into two parts. One part was depleted by gel filtration, another one by 
protein precipitation with ACN. For the experiments murine serum obtained from E18 wild type 
mice (wt, E18) was chosen, because the level of agrin-22 was shown by Western blot to be the 
highest at this age compared to P1-P30. As previously shown for the identification of agrin-22 
in murine serum samples by LC-MS (see section 3.1), SDS-PAGE followed by in-gel digestion 
was a suitable sample preparation. After gel filtration, samples were thus further separated 
by SDS-PAGE. The gels were Coomassie blue stained and eight protein bands in the molecular 
weight region from 15-25 kDa were cut out and in-gel digestion was performed separately for 
each piece. In parallel, depleted samples using precipitation were digested in-solution. Both 
sample sets were subjected to sample clean-up with ZipTipC18 columns followed by LC-MS 
analysis for tryptic peptides with a standard gradient from 5-80% ACN. The designed steps of 
sample preparation are shown in Figure 3-13.
Gel filtration
SDS-PAGE
In-gel digestion
Precipitation
In-solution digestion
ZipTipC18 sample clean-up
LC-MS/MS
Data analysis
Figure 3-13. LC-MS workflow for evaluation of sample preparation.
LC-MS analysis was performed with LTQ-ICR-FT instrumentation followed by protein 
identification with Mascot. Peptide sequence information was generated by using an inclusion 
list for agrin-22 z0, 8, 11, and 19, which enables selection of peptide ions with particular mass-
to-charge (m/z) ratio tandem MS. Using sthe Mascot search engine (Perkins et al, 1999), the 
resulting CID spectra were automatically correlated with a sequence database to identify the 
protein from which the peptide originated. In order to enable identification of all four agrin-22 
z-isoforms, the database was extended by the sequence entry for agrin-22 z8, 11, and 19 splice 
variants because only the sequence of agrin-22 z0 was included in the original database. 
Comparison of multiple sample preparations was achieved by statistical data analysis of all MS/
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MS spectra with the software Scaffold (Proteome Software, Inc., USA). This software enables 
graphic comparison of protein expression between samples and displays correct protein 
identifications in a probability score. It uses results from the Mascot and Sequest searches and 
established statistical algorithms in order to calculate the protein abundance in the biological 
sample. Results from statistical analysis using Scaffold are shown in Figure 3-14.
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Figure 3-14.  LC-MS workflow for sample preparation evaluation. Samples were depleted with 
gelfiltration. (A) SDS PAGE and Coomassie blue staining of the elution fraction (L) of agrin-22 in murine 
serum after gel filtration. Selected protein bands for in-gel digestion are enlarged. (B) Scaffold statistical 
analysis of sample preparation. The diagram shows the normalized spectrum count for all analyzed 
samples. Lanes 1-8 , normalized spectrum count according to gel bands 1-8 shown in (A). Lanes 9-11, 
normalized spectrum counts for precipitated samples; 9, supernatant; 10, pellet 1; 11, pellet 2.  
Agrin-22 z0 was identified with 42% sequence coverage, but no specific peptides to differentiate 
between the other splice variants were detected in murine serum or below the detection limit 
for the LC-MS instrumentation. Highest amounts of agrin-22 z0, with regard to normalized 
spectrum counts of each LC-MS run, were found in the gel pieces 2-4. Piece 2 of SDS-PAGE gel 
showed the best accumulation of agrin-22 z0. Better detection of agrin-22 was achieved using 
in-gel digestion when compared to in-solution digestion.
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3.3 Quantification of agrin-22 via targeted mass spectrometry
The basic method and the “gold standard” used for targeted protein quantification to date is 
enzyme-linked immunosorbent assay (ELISA). However, its limiting step is the availability of 
highly specific antibodies. Most of the novel discovered biomarkers in recent proteomics studies 
are lacking these antibodies. Therefore, the concept of targeted quantitative proteomics has 
been implemented into the field of mass spectrometry (Haab et al, 2006). Mass spectrometry 
became the alternative approach to precisely detect peptides and proteins with high mass 
accuracy, selectivity and specificity (Pan et al, 2009). The most popular platform used is the triple 
quadrupole instrument with multiple (or selected) reaction monitoring (MRM, SRM) technique 
(Bower et al, 1993; Anderson et al, 2004; Janecki et al 2007). This method is so far the only 
selective and specific tool that allows for isoform-specific identification of low-abundant proteins 
without a specific antibody. As the four agrin-22 isoforms differ only in the insertion of 8, 11, and 
19 amino acids, analysis and differentiation is not easy. For the distinction and quantification 
of these isoforms, SDS-PAGE and subsequent Western blot analysis was not viable due to the 
lack of antibodies or even peptibodies, enabling differentiation of the four splice variants. In 
addition to the implementation of a less complex source for the biomarker, improvement of 
the detection of specific tryptic peptides for quantification of the four isoforms of agrin-22 
was the aim. To this end, a triple quadrupole mass spectrometer with higher sensitivity than 
the FT-ICR and the possibility to perform selected reaction monitoring (SRM) was considered.
In the SRM approach, only peptides of interest are isolated in the first quadrupol of the 
instrument, fragmented and resulting spectra consist exclusively of the specific selected 
fragments. Each agrin-22 isoform has one unique tryptic peptide (proteotypic peptide, PTP) 
and corresponding CID fragments can be selected to monitor the protein of interest and to 
quantify the amount based on the area under the eluting chromatographic peak of the selected 
fragment ions. I wanted to study neurotrypsin-activity in association with age and neuronal 
diseases. Only small amounts of CSF (100-200 µl/subject) could be obtained from the clinics 
for age-related studies, patients with epilepsy and Alzheimer`s diesease as well as healthy 
control subjects for each disease group. As the main interest was based on inter-subject 
variabilities,  the CSF samples could not be pooled and I wanted to test whether it is possible 
to detect agrin-22 isoforms in a small sample volume. Using targeted mass spectrometry, I 
measured different sample sets. Comparison of the obtained SRM spectra indicated that the 
measurements were not reproducible and the probability to detect and quantify the four 
agrin-22 isoforms remained difficult (data not shown). Hence, I wanted to experimentally 
determine the optimally suited parameter settings to get reproducible data and enhance 
PTP recovery for the quantification assay. In this paragraph, I will report about experimental 
investigations to identify and describe the impact of PTP selection, resolution of the first mass 
analyzer (Q1), LC parameters and matrix effects.
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3.3.1 Selection of unique proteotypic peptides for agrin-22 isoforms
For the quantification of neurotrypsin-dependent agrin-22 via SRM I wanted to target 
the unique PTPs of the four isoforms of agrin-22. To this end, the amino acid sequences of 
all four agrin-22 isoforms were in-silico digested using trypsin (/K/R-\P), Asn-C (/N) and 
GluC (/E) specificity to identify PTPs which are unique for each splice variant. Only trypsin 
results in one unique PTP for each variant at acceptable molecular mass values which can 
be used for identification of the protein of interest. The sequence information was further 
evaluated with Pinpoint software (Thermo) which can be used as a method builder and for 
data analysis of the SRM spectra. It enables in-silico identification of estimated CID fragments 
of the PTPs via a peptide library or by direct input of FASTA files. Software settings used for 
peptide fragmentation are based on theoretical and empirical rules, e.g. the predicted break 
of a peptide bond at proline. Therefore, transitions with proline as the first amino acid are 
preferably selected by the software. The charge state 2+ is as well preferred for the precursor 
selection and resulting fragments cover automatically the z-ion series. The generated list of 
all predicted transitions and fragmentation parameters was directly transferred into the 
instrument method using Xcalibur software. PTPs for each protein were selected based on the 
criteria to be unique for each isoform of agrin-22. Therefore, reasonable ionization efficiency 
and fragmentation based on empirical MS/MS data was not considered as main element in 
the selection of the PTPs. The proteins and their respective peptides are shown in Table 3-2.
Splice site z (0)
								10									20									30									40									50									60	
ARVNHHHHHH	HHSAGDVDTL	AFDGRTFVEY	LNAVTESEKA	LQSNHFELSL	RTEATQGLVL	
								70									80									90								100								110								120	
WSGKATERAD	YVALAIVDGH	LQLSYNLGSQ	PVVLRSTVPV	NTNRWLRVVA	HREQREGSLQ	
							130								140								150								160								170								180	
VGNEAPVTGS	SPLGATQLDT	DGALWLGGLP	ELPVGPALPK	AYGTGFVGCL	RDVVVGRHPL	
							190							
HLLEDAVTKP	ELRPCPTP	
Splice site z (8)
								10									20									30									40									50									60	
ARVNHHHHHH	HHSAGDVDTL	AFDGRTFVEY	LNAVTESELA	NEIPVEKALQ	SNHFELSLRT	
								70									80									90								100								110								120	
EATQGLVLWS	GKATERADYV	ALAIVDGHLQ	LSYNLGSQPV	VLRSTVPVNT	NRWLRVVAHR	
							130								140								150								160								170								180	
EQREGSLQVG	NEAPVTGSSP	LGATQLDTDG	ALWLGGLPEL	PVGPALPKAY	GTGFVGCLRD	
							190								200	
VVVGRHPLHL	LEDAVTKPEL	RPCPTP	
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Splice site z (11)
								10									20									30									40									50									60	
ARVNHHHHHH	HHSAGDVDTL	AFDGRTFVEY	LNAVTESPET	LDSGALHSEK	ALQSNHFELS	
								70									80									90								100								110								120	
LRTEATQGLV	LWSGKATERA	DYVALAIVDG	HLQLSYNLGS	QPVVLRSTVP	VNTNRWLRVV	
							130								140								150								160								170								180	
AHREQREGSL	QVGNEAPVTG	SSPLGATQLD	TDGALWLGGL	PELPVGPALP	KAYGTGFVGC	
							190								200	
LRDVVVGRHP	LHLLEDAVTK	PELRPCPTP
Splice site z (19)
							10									20									30									40									50									60	
ARVNHHHHHH	HHSAGDVDTL	AFDGRTFVEY	LNAVTESELA	NEIPVPETLD	SGALHSEKAL	
								70									80									90								100								110								120	
QSNHFELSLR	TEATQGLVLW	SGKATERADY	VALAIVDGHL	QLSYNLGSQP	VVLRSTVPVN	
							130								140								150								160								170								180	
TNRWLRVVAH	REQREGSLQV	GNEAPVTGSS	PLGATQLDTD	GALWLGGLPE	LPVGPALPKA	
							190								200								210	
YGTGFVGCLR	DVVVGRHPLH	LLEDAVTKPE	LRPCPTP 
Table 3-2. Amino acid sequences of the four z-isoforms of agrin-22. The unique PTP for each variant is 
highlighted in red. The splice insert is underlined.
The four proteins were expressed in HEK-Ebna cells as recombinant N-terminally His-tagged 
fusion proteins and affinity-purified by Ni2+-select column. All four proteins were separately 
digested according to the in-solution tryptic digestion protocol. The resulting mixture of PTPs 
for each agrin-22 isoform was used to further optimize MS parameters for SRM experiments 
of the specific PTPs. In addition, the four synthetic PTPs were purchased to allow the specific 
analysis of their performance in the SRM assay and to use them as internal standards for the 
quantification. The proteotypic peptides and their selected fragments and respective collision 
energy (CE) are shown in the chapter Materials and Methods in Table 5.2.
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3.3.2 Influence of resolution on PTP detection
The first SRM experiments for the identification of the most intense fragments for each PTP 
were performed using the listed set of transitions (Table 3-3). Two concentrations of 10fmol/
µl and 100fmol/µl were injected (8 µl) for each agrin-22 isoform. The mass peak width for the 
first quadrupole (Q1) full width half maximum (FWHM) was tested for two settings: the unit 
resolution where Q1 is set to 0.7 and the enhanced resolution were Q1 is set to 0.1. The thrid 
quadrupole (Q3) FWHM was in all cases set to 0.7, scan width to 0.002 m/z and scan time to 
0.05 sec (16 transitions = 0.8 sec/cycle). The enhanced resolution method with Q1 FWHM at 
0.1 requires a critical review of precursor mass settings. In figure 3-15, the resulting spectra 
for these transitions are shown.
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Figure 3-15. Change in response as a function of Q1 mass peak with of (A) recombinant agrin-22 z0 and 
(B) recombinant agrin-22 z19. Open bars: Q1 = 0.1 FWHM; black bars: Q1 = 0.7 FWHM.
In general, spectra obtained with unit resolution for Q1 (0.7 FWHM) show much higher signal 
intensities for all transitions of all isoforms. The enhanced resolution (0.1 FWHM) was leading 
to the loss of  detection for two transitions of agrin-22 z19. The results are described in more 
detail in Figures 3-16 and 3-17. 
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Figure 3-16. Q1 resolution agrin-22 z19. (A) Q1=0.1. (B) Q1=0.7. Mass spectrometric measurements 
were recorded in the targeted mode for selected reaction monitoring (SRM). The upper pannels show 
the total ion count (TIC) in black. In the lower pannel the extracted ion chromatograms (XIC) for all four 
transitions of the agrin-22 z19 isoform are shown in colour. 
The spectra show that parameter setting in the enhanced resoltuion mode (Q1=0.1) makes 
it impossible to isolate all transitions for the agrin-22 z19 isoform (Figure 3-16, A). Only two 
transitions (1382 m/z and 1578 m/z) have been isolated and detected. These transitions are, 
with regard to the relative abundance in the unit resolution (Q1=0.7) experiment, the most 
intense transitions (Figure 3-16, B). In contrast, unit resolution enables the isolation and 
detection of all transitions for agrin-22 z19. Therefore, unit resolution is considered to serve as 
better resolution mode. 
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Figure 3-17. Q1 resolution agrin-22 z0. (A) Q1=0.1. (B) Q1=0.7. Spectra were measured in the targeted 
mode for selected reaction monitoring (SRM). The upper pannels show the total ion count (TIC) in black. 
In the lower pannel the extracted ion chromatograms (XIC) for all four transitions of the agrin-22 z0 
isoform are shown in colour. 
Comparison of the measurements of the agrin-22 z0 transitions in the enhanced and unit 
resolution mode represented less differences as observed for the transitions of agrin-22 z19. All 
four transitions of the z0 variant were detected in both modi with satisfiable abundance (Figure 
3-17). The loss of intensity as sustained for the z19 isoform was not observed. The enhanced 
resolution of Q1 (0.1 FWHM) is suggested to increase the mass accuracy for the precursor 
isolation.  Therefore, background signals decreased and in parallel the signal-to-noise (S/N) 
rate raises. However, enhanced resolution was selected and the decrease in sensitivity has to be 
taken as a matter of fact. As agrin-22 belongs to the low-abundant protein fraction, unit mass 
resolution is suggested to be the more prosperous modus for the detection.
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3.3.3 Evaluation of PTP recovery in the context of ionization
ESI ionization: Performance characteristics of PTPs via selected ion monitoring
I wanted to further confirm whether discrepancies in peptide recovery are due to different 
accessibilities of the four splice variants for in-solution digestion or due to distinctive abilities 
to be ionized by ESI. Thus, we decided to measure PTPs with selected ion monitoring (SIM) on 
the triple quadrupole instrument. The SIM offers the possibility to selectively record spectra 
for the ion of interest. The S/N rate is markedly reduced. It provides an alternative to quantify 
the PTPs for each isoform in separate experiments. To ensure that PTPs are not lost, dilutions 
for each tryptic peptide mixture of the recombinant agrin-22 isoforms were introduced into 
the MS via direct infusion using 50% ACN without installing a chromatographic column.
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Figure 3-18. Selected ion monitoring (SIM) spectra were manually recorded via direct injection of 
agrin-22 z0 (A), z8 (B) and z19 (C) on the TSQ mass spectrometer. Spectra show the relative abundance, 
isotope pattern and the corresponding charge state for each variant. 
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The selected ion monitoring (SIM) spectra confirm that all isoforms are present at the same 
concentration and show similar ionization behavior (Figure 3-18). All PTPs show comparable 
signal intensities. Main differences between agrin-22 isoforms are found in the distribution of 
the most intense ion species resulting from the ionization process with regard on their charge 
state. While the dominant species for agrin-22 z0 was the [M+2H]2+, for agrin-22 z8 it was 
[M+3H]3+ and for agrin-22 z19 [M+4H]4+. This charge distribution depends on the amino acid 
sequence and previous measurements on the LTQ did show a different distribution. The 2+ 
charge state is automatically selected by the Pinpoint software for the precursor setting. In 
conclusion, the SIM spectra provided a good basis in the selection of the most abundant PTPs. 
 
Fragmentation of the PTPs
Besides quantization of PTPs via SIM and definition of the dominant charge states, the pattern 
of fragmentation was concomitantly analyzed. Isolation of the precursor was performed with a 
collision energy (CE) set to 10 V followed by the stepwise icrease in the CE until the precursor 
was fragmented to 100%. In this experiment, significant differences could be detected in the 
fragmentation characteristics between the agrin-22 splice variants, using the CE which are 
automatically selected by the software. Thus, I decided to manually define the CE for all PTPs to 
tune fragmentation to a point at which 10% of the precursor ion is still observed. Fragmentation 
of agrin-22 z0, z8, and z11 showed ideal performance whereas the isoform agrin-22 z19 showed 
almost no ability for fragmentation (Figure 3-19).
The efficiency of fragmentation is directly related to the quality of the product ion spectra. The 
experiments present a possible explanation for the poor signal intensity and PTP recovery. As 
fragmentation ability is likely a matter of the amino acid composition of the peptide, signal 
intensity and peptide recovery have to be improved in this particular case using other methods.
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Figure 3-19. Fragmentation ability of (A) recombinant agrin-22 z19 and (B) recombinant agrin-22 z0. 
Spectra were recorded via direct injection without using a chromatographic system. All fragment ions 
are labeld with their m/z values and precursor ions are additionally marked with an asterisk.
MALDI-ionization
To exclude the possibility that the ionization method highly influences signal intensity MALDI-
TOF/TOF mass spectrometry was perdormed. Furthermore, I wanted to ensure that the 
digestion is sufficient and adress the question whether ZipTipC18 sample clean up leads to an 
enhancement of the spectra quality. Samples were prepared according to standard proteomics 
digest (1) (see in Materials and Methods) and separated into two parts. One portion was 
directly spotted on the MALDI target plate without further sample clean up. For the second 
portion, ZipTipC18 sample clean up was performed to desalt the sample. The results indicate 
that the recombinant agrin-22 isoforms z0, 8, and 11 undergo efficient digestion and detection 
of the PTPs of these isoforms was possible. Overall, a number of 2 to 4 tryptic peptides for the 
identification of agrin-22 can be detected in all digestion solutions. For agrin-22 z0, 8, and 11, 
the specific PTPs for each splice variant can be detected in both sample sets, with and without 
ZipTipC18 clean-up. However, the PTP for the isoform agrin-22 z19 could not be identified with 
either method (Table 3-4) . The direct comparison of spectra from both sample sets showed a 
strong reduction of signal intensity for all tryptic peptides in case of ZipTipC18 sample clean up 
indicating significant sample loss on the ZipTipC18 resin (data not shown). 
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The resulting spectra did not show any improvement in quality when samples were processed 
with ZipTipC18. Taken together, tryptic peptides can be ionized with MALDI as well and the 
quality of digestion could be shown to be adequate.  
  Agrin-22     MH+  Sequence     
  Isoform        Total mass (Mo)                
  z0  1414.757 ALQSNHFELSLR            
        1629.805 TFVEYLNAVTESEK               
    2911.579 ADYVALAIVDGHLQLSYNLGSQPVVLR         
  z8  1389.736 TEATQGLVLWSGK          
    1414.757 ALQSNHFELSLR                
    2495.257 TFVEYLNAVTESELANEIPVEK         
    2911.579 ADYVALAIVDGHLQLSYNLGSQPVVLR        
  z11  1389.736 TEATQGLVLWSGK               
    1414.757 ALQSNHFELSLR               
    2737.335 TFVEYLNAVTESPETLDSGALHSEK        
    2911.579 ADYVALAIVDGHLQLSYNLGSQPVVLR        
  z19  1389.736 TEATQGLVLWSGK               
    1414.757 ALQSNHFELSLR              
Table 3-4. Tryptic peptides of agrin-22 isoforms identified with MALDI-TOF/TOF. The unique PTP 
for each agrin-22 isoform is highlighted in bold. Tryptic peptides which could not be detected after 
ZipTipC18 sample clean up are highlighted in red.
3.3.4 Estimation of peptide recovery in the context of their elution ability
The ability to ionize was identical in the SIM measurements for all agrin-22 isoforms. No 
differences with regard to amino acid sequence composition could be observed. Therefore, poor 
peptide recovery might be caused by other physico-chemical properties. It is well known that 
peptides with high hydrophobicity have a high surface interaction with some materials used 
for tubings and fittings in the chromatographic  systems. I therefore wanted to test the affinity 
of the peptides to the material of the LC equipment by bypassing the chromatographic column. 
The setup without analytical column allowed for the detection of objectionable interactions 
and retentions of the analyte in the system. The experiments were carried out on the LTQ 
using flow injection analyses (FIA). To test the affinity of the analyte with tubing, I used a low 
concentration of 5% ACN, which is a basic condition at the beginning of a standard gradient 
in liquid chromatography of peptides and proteins, and raised the ACN concentration to 20% 
and 50% in separate experiments. In order to quantify the signal intensities of the analyte in 
each run, the solvent peak 444.6948 m/z, which can serve as internal standard, was used as 
reference. The resulting spectra are displayed in Figure 3-20.
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The study clearly indicated highly unspecific interaction of agrin-22 isoforms z8, z11, and z19 
with the surface at low ACN concentrations when compared to z0. Even at concentrations 
of 20% ACN, these isoforms displayed massive retention in the chromatographic system. 
Usually, a concentration of 10 - 30% is sufficient for the elution of peptides from reversed 
phase C18 materials. The high affinity of agrin-22 z8, z11 and z19 could only be prevented 
using high ACN concentration of 50%. These findings could be further supported by in-
silico calculations using prospector. This program calculates a theoretical C18 retention 
index at given ACN concentrations (%) based on predicted elutions (Browne, 1982). 
Additionally, Bull-Breese indices for the hydrophobicity (%) of the peptides were calculated 
based on surface tension of amino acid solutions (Bull, 1974) using the same program.
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Figure 3-20. Full scan spectra of the flow injection experiments. (A) Agrin-22 z-isofroms measured in 5% 
ACN and (B) agrin-22 z0 and z19 with 50% ACN. The spectra were recorded on a LTQ mass spectrometer 
bypassing the chromatographic system. The ion with m/z value 444.6848 was chosen as reference to 
calculate the relative intensity for the agrin-22 isoforms in each spectrum.
Results 79
PTP-sequence    Bull-Breese index  RT-index
                Hydrophobicity (%)   ACN (%)
 
TFVEYLNAVTESEK       41.4     26.2
TFVEYLNAVTESELANEIPVEK    42.4     48.8
TFVEYLNAVTESPETLDSGALHSEK     38.1     57.9
TFVEYLNAVTESELANEIPVPETLDSGALHSEK  39.6     80.5
Table 3-5.  Bull-Breese and retention time (RT) indices of the four agrin-22 z-isoforms. Hydrophobicity is 
given in (%) based on surface tension of amino acid solutions. The RT-index is based on the theoretically 
predicted elution at given ACN concentration (%).
The retention index of  26.2% ACN for the PTP of agrin-22 z0 represents normal elution behavior. 
However, retention indices for other agrin-22 isoforms indicate very poor elution probabilities 
from C18 materials. Especially agrin-22 z19 requires extremely high concentration of eluent 
predicted with 80.5% ACN. The bull breese indices for hydrophobicity are in the same range for 
all PTPs and indicate medium hydrophobicity.
3.3.5 Validation and refinement of LC conditions and sample delivery for PTPs
After experimental and theoretical evaluation of the increased retardation of agrin-22 PTPs, the 
influence of different elution gradients used for LC separation was tested in order to enhance 
peptide elution from C18 material. Therefore, the ACN concentration for starting conditions 
of the LC-gradient was increased from 5% to 10%, 20% and 40% ACN (see Materials and 
Methods). To further enhance the elution efficiency, 10% isopropanol was added to each eluent 
solution. Samples of synthetic PTPs (amount on column: z0, 8 and 11 = 100 fmol; z19 = 800 
fmol) were prepared with similar solvent composition for each new starting condition. After 
each analysis stringent wash with injection of 10% isopropanol was applied to prevent carry-
over of PTPs. Mass spectra were recorded using the triple quadrupole mass spectrometer (TSQ, 
Thermo) in SRM mode. The spectrum for each transition was analyzed with pinpoint software 
(Figure 3-21). For each run, signal intensities with regard to peak areas of transitions were 
quantified.
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Figure 3-21. Pinpoint data analysis. The synthetic PTPs of all four agrin-22 isoforms (amount on column: 
z0, 8 and 11 = 100 fmol; z19 = 800 fmol) were measured with targeted mass spectrometry at different 
starting conditions of the LC-gradient. Transitions are given in different colours and ACN concentration 
for the measure is highlighted above the relative intensity pattern of the transisions. The calculated 
maximum of the relative intesity is given for each isoform. 
The standard gradient (detailed information on the gradient composition can be found in the 
Chater Materials and Methods) which starts at 5% ACN results in poor signal intensities for 
agrin-22 z0 and z11 and is insufficient for elution of isoforms z8 and z19. A strong increase in 
relative signal intensity is achieved for agrin22 z0 when using the 10% gradient. This effect is 
only slightly enforced with the 20% gradient. Agrin-22 z8 can be eluted using the 10% gradient 
and shows massive enhancement when using the 20% gradient. The same is true for agrin-22 
z11. The isoform z19 is detectable with the 20% gradient and elution improves by applying the 
40% gradient. However, the analysis of agrin-22 z19 was not reproducible in three replicates. 
In parallel, all other agrin-22 transcripts did not show any retardation when the 40% gradient 
was tested. They eluted directly when the gradient developed. Taken together, the 20% gradient 
is suggested as ideal condition for the optimized elution of all PTPs.
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3.3.6 Implementation of elevated temperature to enhance the elution of PTPs
Retardation is a sophisticated process when working with peptides and proteins because they 
are multifunctional molecules. The interaction of these large molecules is basically driven by 
the adsorption of their hydrophobical foot. But this mechanism can be as well influenced by 
additional, non-specific interactions with functional sites on the stationary phase like silanols 
and alkyl groups. The molecular shape and ion-pairing equilibrium contribute as well (Hancock 
et al, 1994). Elevated temperature leads to a reduction in viscosity and bigger solute diffusion 
and therefore results in more narrow and symmetrical peaks (Boyes, et al, 1993). However, a 
sufficient flow rate must be presented to overcome less effective diffusion (Zhu et al, 2004). 
Using a digested solution of fetuin (10fmol/ml) as a standard (see Figure 3-22) and a mixture of 
synthetic PTPs (10fmol/ml) of agrin-22 z0, 8, 11, and 19 (see Figure 3-23), I tested the influence 
of elevated temperature on the elution efficiency and retention time shift. Samples were 
analyzed using an Thermo Fisher LTQ ion trap mass spectrometer with standard LC-gradient 
from 5 to 80% ACN. The effects on retention time and recovery of hydrophobic peptides were 
tested at three temperatures: 40, 50, and 60°C.
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Figure 3-22. Base peak chromatograms for the comparison of retention times on RP-C18 material for a 
fetuin digest (stock 10fmol/ml) at RT, 40, 50, and 60°C using standard LC-gradient from 5-80% ACN. The 
full scan spectra were measured on an LTQ mass spectrometer. The base peak chromatograms show the 
retention time and m/z values for the most intense ions detected in the run.
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The increased temperature of 40 and 50°C resulted in a shift towards shorter retention time of 
about two minutes for typical most abundant tryptic peptides of fetuin (40fmol on column). No 
specific signals of the tryptic peptides of fetuin were detected at 60°C. This is a possible result 
of the spray instability at this elevated temperature.
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Figure 3-23. Base peak chromatograms for comparison of retention times on RP-C18 material for 
agrin-22 digest (stock 10fmol/ml) at room temperature (RT), 40, 50, and 60°C using standard LC-
gradient from 5-80% ACN. The full scan spectra were recorded on an LTQ mass spectrometer. The base 
peak chromatogramms show retention time and m/z falues for the most intense ions detected in the run. 
The synthetic PTPs of the four agrin-22 isoforms were exclusively detected in the full scan 
measurement at 40°C, but no specific signals for the tryptic peptides of interest were obtained 
using room temperature or higher temperatures of 50 and 60°C. For comparison of the 
retention times bewteen the runs, the flow rate was kept constant throughout all temperatures. 
This resulted in a decreased back pressure with higher temperature. Furthermore, instability 
in the spray performance was recognized at 50 and 60°C. A high number of unspecific signals 
with a high relative abundance was observed by applying a column temperature of 60°C. 
However, peptide recovery and retention time were not significantly improved with heated 
chromatography. 
3.3.7 Linear range and limit of quantification of agrin-22 z0
To ensure accuracy in quantification of agrin-22 z0, the linear concentration ranges and limits 
of quantification of the instrument were determined for pure, synthetic proteotypic peptide of 
agrin-22 z0 in 20% ACN. The response for agrin-22 z0 was found to be linear (R2 = 0,9984) over 4 
orders of magnitude. The limit of quantification was approximately 80 amol ( ~1 pg) of peptide 
injected on-column. The linear concentration range and limit of quantification are affected 
by matrix complexity as well as instrument sensitivity. For example, if the ion suppression in 
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the matrix is significant, the limit of quantification of the given target in the complex matrix 
will differ from the limit of quantification of the pure peptide. Hence, the linear concentration 
range and limit of quantification were also determined for agrin-22 z0 spiked into human CSF. 
As expected, the linear concentration range was greater and the limits of quantification were 
generally lower using pure peptide compared to the spiked peptide, since matrix complexity 
causes some degree of ion suppression. Three replicate measurements were performed and 
agrin-22 z0 was not detected (data not shown). 
3.3.8 Analysis of poor recovery of PTPs in the context of matrix effects
A comparative study of diluted human CSF was performed to elucidate the effect of the peptide 
matrix in fractionated human CSF samples on PTP recovery. In the first experiment, CSF samples 
were prepared according to the digestion protocol with 50% methanol followed by incubation 
of three hours at room temperature (see digest 2 in Materials and Methods). The digested CSF 
was further spiked with the synthetic PTP for agrin-22 z0 (25 fmol/ml) and dilutions of CSF 
(1:10, 1:100) with 20% ACN were prepared. Targeted mass spectrometry of agrin-22 z0 was 
performed and the resulting spectra are displayed in Figure 3-x. Targeted mass spectra show a 
shift to shorter retention time of ten minutes in case of the  1:100 diluted CSF sample. Based on 
this result the presence of a strong matix effect was claimed in human CSF samples. 
In a second experiment, a comparative study of a set of three samples was performed to 
elucidate the effect of the peptide matrix in fractionated human CSF samples on PTP recovery. 
Therefore the CSF digest from the previous experiment was split into two parts: (i) digested 
CSF as it is and (ii) digested CSF spiked with digested recombinant agrin-22 z0 (10fmol/ml). 
The digest of recombinant agrin-22 z0 was in parallel used as standard in order to visualize 
the matrix effect induced by the CSF peptide matrix. The PTP with the amino acid sequence 
TEATQGLVLWSGK from agrin-22 was included, which is not unique for one isoform and could 
later provide information about the entire agrin-22 level. From previous shotgun LC-MS/MS 
experiments with the ICR-FT-MS, it was known that this tryptic peptide is highly abundant. 
Concluding from this, additional interferences in LC-MS analysis, like extensive retention on the 
C18 column, were absent for this peptide. Thus, it was a perfect candidate for evaluating the 
matrix effect by itself. The three samples were used to test whether different dilutions of CSF 
(1:10, 1:20, 1:30 and 1:40) with 20% ACN have an effect on retention time and PTP recovery.
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Figure 3-24. Targeted mass spectrometry of agrin-22 z0 in human CSF spiked with the synthetic PTP of 
the z0 variant to document the matrix effect on the retention time. In the upper part, the total ion count 
(TIC) is shown in black. The lower panels show the four extracted ion chromatograms (XIC) for each 
fragment ion in colour. (A) 1:10 and (B) 1:100 dilution in 20% ACN.
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Figure 3-25. Targeted mass spectrometry of  transitions for agrin-22 z0  and the peptide TEATQGLVLWSGK 
which is identical for all agrin-22 isoforms. The measured sample was digested human CSF spiked with a 
digest of recombinant agrin-22 z0 to document the matrix effect on the retention time. All chromatograms 
show the total ion count (TIC). (A) 1:10 dilution. TEATQGLVLWSGK elutes at 41.26 minutes, agrin-22 
z0 at 41.50 minutes. (B) 1:20 dilution. TEATQGLVLWSGK elutes at 40.00 minutes, agrin-22 z0 at 40.10 
minutes(C) 1:30 dilution. TEATQGLVLWSGK elutes at 33.19 minutes, agrin-22 z0 at 35.01 minutes 
(D) 1:40 dilution TEATQGLVLWSGK elutes from 6.00-25.24 minutes, agrin-22 z0 at 28.46 minutes. All 
dilutions are prepared with 20% ACN.
The experiments clearly show that there is an effect on signal intensity and retention of the 
two PTPs induced by the complex peptide matrix (Figure 3-25). The signal suppression for 
the agrin-22 z0 PTP was about 95% comparing signal intensities between the most abundant 
transition in the pure digestion of recombinant agrin-22 z0 (10 fmol/ml; intensity for the most 
abundant transition: 4.05E3) and the 1:10 dilution of CSF spiked with the same digestion 
(10 fmol/ml; intensity for the most abundant transition: 2.37E2). This effect could not be 
eliminated by diluting the CSF matrix. The 1:40 dilution of CSF still displays strong signal 
suppression for the most abundant transition (intensity for the most abundant transition: 
1.00E1). Comparison of the retention time for all samples as well indicates a dramatic impact 
between digestion alone and spiked CSF samples. All four transitions for agrin-22 z0 elute at 
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27.41 minutes using pure digestion solution. Addition of 1:10 diluted CSF increases retention 
to 41.50 minutes. Dilution of CSF to 1:20 is without any improvement on retention time (40.10 
minutes) whereas dilution to 1:30 shows a slight decrease in agrin-22 z0 retardation  (35.05 
minutes). The 1:40 dilution recovers retention (28.46 minutes) and a shift back to the value 
observed for the pure digestion solutions was demonstrated. A similar situation is indicated 
for the tryptic peptide TEATQGLVLWSGK. The shift of retention time in the 1:10 diluted CSF to 
41.26 minutes accentuates the high impact of matrix effects on the elution behavior of tryptic 
peptides in complex samples. This effect cannot be rescued when diluting CSF to 1:20 (40.00 
minutes). A slight decrease in retardation is indicated for the 1:30 dilution (33.09 minutes). 
In the 1:40 dilution peak fronting is observed for this tryptic peptide. The elution starts at 6 
minutes, thus clearly indicating that no retardation of the peptide on the C18 material takes 
place. Additionally, this PTP showed poor interaction with the C18 column when analyzing 
the agrin-22 z0 digestion mixture without CSF, which clearly shows its low hydrophobic 
nature. This tendency is expected for tryptic peptides when using higher proportions of ACN 
as starting conditions for the LC-gradient. The experiments suggest evidence of strong matrix 
effects in addition to the high affinity of the agrin-22 z0 isoform to the C18 in comparison to the 
TEATQGLVLWSGK peptide. 
To further examine the positive impact on the PTP recovery using diluted CSF, the 1:30 diluted 
CSF was analyzed with LC-ICR-FT-MS. As shown in the previous experiment, the 1:30 dilution 
was measured with and without agrin-22 z0 digest (10 fmol/ml). The resulting spectra are 
shown in Figure 3-26. The elution time for the agrin-22 z0 PTP is shifted to 42.57 minutes. 
Additionally, identification of agrin-22 was not possible in the unspiked 1:30 CSF dilution using 
Mascot database search algorithm. Taken together, very strong matrix effects were observed 
which cannot be circumvented.
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Figure 3-x26. FT-ICR spectra were recorded in the data dependent mode using an inclusion list for 
agrin-22 z0. (A) human CSF (1:30) spiked with agrin-22 z0 digest (10 fmol/µl) and (B) human CSF  (1:30) 
alone. In the upper part the base peak chromatograms are shown in black, extracted ion chromatograms 
(XICs) are shown in dark red. The lower parts show the mass spectra at the specific retention times 
concluded from the XIC for the m/z value 815.3500-815.4500.
3.4 Identification of neurotrypsin-dependent cleavage of agrin 
      in human cerebrospinal fluid
The former studies on agrin-22 in the previous paragraphs documented the difficulties in 
agrin-22 isolation and recovery. CSF has a less complex protein composition, hence it can be 
directly used for analysis by Western Blot, whereas serum has first to be depleted or diluted. 
In addition, previous studies showed that the concentration of agrin-22 is lower in serum 
compared to CSF (unpublished observation). Physiologically, agrin-22 values in the CSF can 
give useful informations about neurotrypsin activity in the brain. Considering these criteria, 
I decided to chose CSF as sample system, which offers the possibility to quantify the agrin-22 
level without additional manipulations. 
I am going to identify and describe the activity of neurotrypsin in human CSF samples using 
quantitative Western blot analyses. I will start with the identification of agrin-22 in the context 
of aging and present the data in association with Alzheimer`s disease (AD)and epilepsy. 
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3.4.1 Age-related agrin cleavage can be monitored in human cerebrospinal fluid
As shown in paragraph 3.1, murine serum samples reflect an age-dependent appearance of the 
neurotrypsin-dependent agrin-22 fragment. Concerning this finding, it is likely that agrin-22 
amounts in the brain follow as well physiologically and age-associated properties. To obtain 
a detailed view on neurotrypsin`s activity in the human brain, a large set of 84 human CSF 
samples of different age (2 months – 35 years old, samples were ontained from from Prof. 
Blau, Children`s Hospital, Zurich) was analyzed without considering any status of disease. 
Equal amounts of CSF were resolved by 4-12% NuPAGE gels and analyzed by Western blot 
using antibody R139 against the C-terminal part of agrin. Normalization of signal intensities of 
agrin-22 was in all cases achieved by comparing agrin-22 CSF levels with a reference sample 
(murine serum, wt, E18).
The analysis demonstrates an age-dependent regulation of neurotrypsin-dependent processing 
of agrin (Figure 3-27). The agrin-22 level was strongest in the samples from 2 months old 
subjects and its intensity declined with aging and ongoing development. Amounts of cleavage 
product notably decrease at the age of 6 months. The decrease of signal intensity correlates 
well with neurotrypsin and agrin expression and the pattern of cleavage products in murine 
brain (Reif et al, 2007). Only a slight difference was obtained between subjects of the age 10 
to 35 years. The proteolytic activity is likely to persist at a basal level throughout adulthood. 
However, several CSF samples show relatively high levels of agrin-22 independent of age. This 
variability in agrin-22 values is likely to represent a specific or unspecific elevation of either 
neurotrypsin`s activity or the expression of both proteins due to individual changes in the 
brain. These changes can be due to physiological- or diseased-based mechanisms. Nonetheless, 
variances in agrin-22 levels underlying the particularly high activity of neurotrypsin are 
currently not understood. To provide evidence that neurotrypsin activity and cleavage of 
agrin-22 could give useful information on the course of neuronal diseases, I analyzed human 
CSF samples from epilepsy patients and patients with Alzheimer`s disease (AD).
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Figure 3-27: Age-dependent agrin-22 level in human CSF. Months: M, years: Y.
3.4.2 Quantification of neurotrypsin-dependent cleavage in Epilepsy
Experiments with green-fluorescent-protein tagged neurotrypsin in cultured hippocampal 
neurons indicated an activity-dependent release of neurotrypsin into the synaptic extracellular 
space (Frischknecht et al, 2008). Hence, I wanted to address the question whether the agrin-22 
level is significantly different in CSF of patients with epilepsy. To analyze neurotrypsin activity 
in the context of the diseases and to further shed light on the phenomenon of variances 
observed in the previous age-dependent study, quantitative Western blot analyzes of human 
CSF samples from epilepsy patients were performed compared to healthy controls as well 
as correlation to the levels in the age-dependent samples set. Comparative Western blot 
analyses of CSF samples from 17 epilepsy patients and 19 controls as well as an age-matched 
comparison with the 84 CSF samples were accomplished. CSF samples (30 µl) were separated 
by 4-12% NuPAGE gels and Western blot performed with antibody R139. The results obtained 
by Western blot analysis were normalized to the corresponding agrin-22 signal in a murine 
serum reference sample (wt, E18). One big disadvantage in the study was that CSF samples 
from healthy controls were grouped towards higher age. Therefore the direct comparison of 
agrin-22 levels was deceptive, since the previous study showed the decline of neurotrypsin-
dependent cleavage. Nevertheless, comparison to the set of 84 age-associated samples revealed 
relatively high correlation of agrin-22 levels in epilepsy with the control samples of the same 
age with unknown status of diseases (Figure 3-27). Still, epilepsy patients show increased 
signal intensities in a higher number of cases. The direct identification of agrin-22 levels at 
four specific ages as well as comparison of the average level for these samples demonstrated 
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a tendency for enhanced neurotrypsin activity in epilepsy patients (Figure 3-28). However, 
due to the low sample number at matching ages, statistical analysis could not be performed. 
Differences in agrin-22 signal intensities were apparent but do not allow for a significant 
distinction between values in the CSF of epilepsy patients and controls.  
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Figure: 3-28. Quantitative analysis of neurotrypsin activity in human CSF from epilepsy patients (black 
bars) compared to samples from the age-dependent study (open bars) at corresponding age. Samples 
were separated with 4-12% NuPAGE gels and Western blots were performed of the same sample in 
triplicates for quantification. Error bars show STDEV. The small insert displays the total average signal 
intensity of the four samples analyzed for each group.
3.4.3 Agrin-22 as reporter for neurotrypsin activity in Alzheimer`s disease
There are various reports about the interaction of agrin and b-amyloid precursor protein (APP) 
(Boew & Fallon, 1995; Braak & Braak, 1991; Cozman et al, 2000; van Horssen et al, 2002).  It 
was shown that agrin is able to accelerate Ab fibril formation and to protect Ab (1-40) from 
proteolysis in vitro. Immunostainings suggested the presence of agrin within senile plaques. 
Thus, agrin may play an important role in the progression of Ab peptide aggregation and in 
its persistence in the brain of AD patients. In addition, several cases of memory impairment in 
epilepsy encourage the idea of epilepsy-derived Alzheimer`s disease (AD) (Ito et al, 2009). AD 
patients seem to have a high risk to develop unprovoked seizures. In a study of Hogh (Hogh et 
al, 2002), a set of three patients with progressive memory dysfunction linked to AD underwent 
neuroimaging analysis and no loss of brain regions could be assigned. However, therapy with 
anti-epileptic medication showed improvement in memory performance. This phenomenon 
indicates that seizures are not necessarily a result of AD and that the connection of dementia 
and epilepsy is not unidirectional. Hence, there is emerging evidence that dementia could be a 
result of epilepsy due to simultaneous onset of seizures and dementia (Abou-Khalil, 2010). The 
activity-dependent release of neurotrypsin into the synaptic extracellular space (Frischknecht 
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et al, 2008) and the controversial results for agrin-22 levels in the context of epilepsy led us to 
investigate neurotrypsin`s activity in the context of AD.
To test for differences in agrin-22 levels and whether they correlate with AD, quantitative 
Western blot analyses of CSF from 10 AD patients and 10 healthy controls were performed. 
Neurotrypsin`s and agrin`s strong age-dependent association, it could not be considered in 
this measurement because infomation on the patient`s age was not available due to legal 
regulations. The CSF samples (30 µl) were separated by 4-12% NuPAGE gels and Western blot 
was performed using antibody R139. 
The comparison of agrin-22 levels revealed a slight decrease of neurotrypsin-dependent 
processing of agrin in the context of AD patients (Figure 3-29). However, statistical analysis 
confirmed the absence of a significancy between AD and healthy controls for agrin-22 values. 
This finding rendered it impossible to clearly decide whether neurotrypsin activity in AD is 
reduced.
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Figure 3-29. Comparison of agrin-22 levels in human CSF samples from 10 healthy controls (open bars) 
versus 10 AD patients (black bars). Samples were separated on 4-12% NuPAGE gels and Western blots 
were performed of each sample in triplicates for quantification. Error bars show STDEV. The insert 
shows the average signal intensity of all samples analyzed for each group.
Results92
3.5 Quantification of calsyntenin-1 ectodomain in human CSF
Neuronal excitation either increases production or activates the matrix metalloproteases 
ADAM10 and ADAM17 reported to cleave calsyntenin-1 and to release its soluble ectodomain 
into the extracellular space (Marcello et al, 2007, Hata et al, 2010). After proteolytic processing, 
the resulting ectodomain is accumulated in cerebrospinal fluid (Vogt et al, 2001). At the same 
time, its transmembrane stump is internalized. In addition, it could be shown by chemical 
induction of long term potentiation (LTP) in acute whole hippocampi that ectodomain shedding 
of calsyntenin-1 is enhanced in comparison to non-stimulated hippocampal tissue (unpublished 
results). The synaptic activity was chemically enhanced by blockade of K+ channels with 
tetraethylammonium chloride (TEA) or a combination of picrotoxin, forskolin, and rolipharm 
(PEA) which induces LTP in the hippocampal CA1 region in an NMDA-R-dependent manner. 
Both, potassium-based TEA as well as non-potassium-based PFR stimulation protocols enhance 
calsyntenin-1 ectodomain shedding. Thereby, induction of LTP by TEA showed a stronger effect 
as compared to PFR stimulation (see introduction). 
In this paragraph, I am going to identify and describe the accumulation of calsyntenin-1 
ectodomain in human CSF using quantitative Western blot approach. I will start with the 
identification of specific antibodies for calsyntenin-1, discuss the identification of calsyntenin-1 
in human CSF using data-dependent and targeted LC-MS/MS measurements, give an age-
associated overview of the calsyntenin-1 ectodomain level, before presenting the data in the 
context of epilepsy and AD.
3.5.1 Antibody specificity
To examine the specificity of the polyclonal antibodies against calsyntenin-1 ectodomain, 
recombinant proteins of mouse calsyntenin-1, -2 and -3 were expressed either with myc-tag 
or fused to EGFP in adherent HeLa cells. The cell lysate was chloroform-methanol precipitated 
and 20 µg protein was loaded on a 4-12% NuPAGE gel and Western blot analysis was performed 
with four different antibodies. The tested antibodies were R130 (IgG) raised against the P3-
immunogen of calsyntenin-1, R131 (IgG) 2nd and 3rd boost raised against P3-immunogen and 
R85 (affinity purified) raised against the P1-immunogen of calsyntenin-1. The P1-immunogen 
lies in the N-terminal part of the extracellular domain of calsyntenin-1, whereas the P3-
immunogen is targeting the more C-terminal region in the extracellular space of calsyntenin-1 
which is located proximal to the membrane. Figure 3-30 displays representative Western blots 
with the antibodies R85 and R131 3rd.
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Figure 3-30. Western blot analysis of recombinant calsyntenin family members in order to test the 
specificity of antibody R131 3rd boost. Cell lysates were chloroform-methanol precipitated and each 20 
µg protein was analyzed with 4-12% NuPAGE gels. Recombinant calsyntenin-1 ectodomain was used as 
reference. 
The experiments indicated the specificity of the antibody R130 for calsyntenin-1. In contrast, 
no signal could be obtained for the calsyntenin-1 ectodomain. Antibody R85 shows a broad 
interaction with all three calsyntenin family members, whereas antibody R131 (2nd and 3rd 
boost) is highly specific for calsyntenin-1. As signal intensities of calsyntenin-1 were highest 
with R131 3rd boost, this antibody was chosen for evaluating calsyntenin-1 ectodomain levels 
in human CSF samples using quantitative Western blot analyses.
3.5.2 Identification of calsyntenin-1 in human CSF with mass spectrometry
The three members of the calsyntenin family are predominantly expressed in neuronal regions 
(Hintsch et al, 2002). Interestingly, they show a different distribution pattern in the brain 
which suggests specialized functions in distinct regions.  In order to identify the presence of 
the calsyntenin members in human CSF, 4ml CSF of three independent subjects were denatured 
and reduced (25mM ammonium bicarbonate, 1% SDS, 5mM DTT) followed by concentration 
(Vivaspin 5 kDa MWCO) and 40 µl were separated on 4-12% NuPAGE Bis-Tris gel. The gel was 
stained with Coomassie brilliant blue, protein bands at corresponding molecular masses were 
cut out and in-gel tryptic digestion 2 (see Materials and Methods) was performed. Extracted 
tryptic peptides were purified with ZipTip C18 prior to mass spectrometric analysis. Data-
dependent mass spectrometry was carried out on the FT-ICR using standard LC-gradient 
(see Materials and Methods) and an inclusion list of calsyntenin-1, -2 and -3 for all tryptic 
peptides [M+2H]2+covering the m/z-range 300 – 1600. Identification was achieved with 
Mascot database search using Swissprot-d. The presence of calsyntenin-1 could be confirmed 
in three independent CSF samples. The eleven identified tryptic peptides are restricted to 
the extracellular N-terminal part of calsyntenin-1, in detail to the ectodomain (Figure 3-31). 
This finding suggests the possibility to monitor calsyntenin-1 ectodomain shedding in human 
CSF samples. The variants calsyntenin-2 and -3 were not identified, presumably due to their 
reported low expression in the brain (Hintsch et al, 2002).
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Figure 3-31. Amino acid sequence of calsyntenin-1. The signal peptide is highlighted in green, identified 
tryptic peptides are highlighted in red. The transmembrane part is underlined.
To further confirm the presence of calsyntenin-1 in human CSF samples, targeted mass 
spectrometry was used. Here, the Mascot sequence information from the data-dependent MS/
MS spectra search was converted into a spectral library using the pinpoint software (Thermo). 
To define the proteotypic precursors and their most abundant fragments, Mascot library 
scores were taken as reference to target the mainly expected transitions. The SRM method was 
created using pinpoint software and implemented into the Xcalibur instrument method on the 
TSQ. The selected peptides for targeted analysis of calsyntenin-1 were: (i) IPDGVVSVSPK (549 
m/z) and (ii) EGLDLQVLEDSGRGVQIQ (715 m/z). For the peptide separation and elution of the 
two proteotypic peptides from RP-C18 column, a standard LC-gradient from 5-80% ACN was 
used (see Materials and Methods). The results from targeted mass spectrometric analysis are 
displayed in Figure 3-32.
Results 95
32 .58
35 .3926 .36
23 .62
32 .58
26 .36
  
32 .54
26 .38
 
32 .42
 
26 .36
32 .60
26 .35
Time [min]
R
el
at
iv
e 
A
bu
nd
an
ce
32 .58
35 .3926 .36
23.62 36 .63
35 .39
32 .18
35 .38
 
32 .33
35 .43
32 .30
35 .38
 
 32 .23
A B
244.16 m/z
616.36 m/z 
715.43 m/z 
984.53 m/z 
775.39 m/z
903.45 m/z
1016.53 m/z
1131.56 m/z
Figure 3-32. Targeted mass spectrometry of human CSF for two PTPs of calsyntenin-1. (A) IPDGVVSVSPK 
(549 m/z) (B) EGLDLQVLEDSGRGVQIQ (715 m/z). The upper panel shows the TIC in black. In the lower 
panels, the XIC spetra for the four transitions of each peptide are shown in colour.
All four selected transitions for the two highly abundant tryptic peptides of calsyntenin-1 have 
been detected using targeted mass spectrometry. The relative signal intensities of the transitions 
show enhanced response for the peptide IPDGVVSVSPK (549 m/z) at 32.58 minutes and the 
peptide EGLDLQVLEDSGRGVQIQ (715 m/z) at 35.39 minutes. The analysis was reproducible in 
a set of four independent samples proving the presence of calsyntenin-1 in human CSF. Given 
the high sensitivity of this measurement, the presence of calsyntenin-1 in human CSF was fully 
proven. 
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3.5.3 Age-related processing of calsyntenin-1
To investigate the proteolytic ectodomain shedding of calsyntenin-1 and to test whether there 
is an age-dependent regulation, human CSF samples from 84 subjects were loaded on a 4-12% 
NuPAGE gel and quantified by Western blot analysis using antibody R131 3rd boost.
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Figure 3-33. Age-dependent calsyntenin-1 ectodomain level in human CSF.
Altogether, the level of calsyntenin-1 ectodomain remains at a certain basal level from age 2 
months throughout adulthood. No specific changes in calsyntenin-1 expression or proteolytic 
processing could be assessed in the context of its accumulation in CSF. However, several CSF 
samples show strong accumulation of calsyntenin-1 irrespective of the subject`s age. 
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3.5.4 Quantification of calsyntenin-1 ectodomain in Alzheimer’s disease
Calsyntenins and amyloid precursor protein (APP) undergo a similar coordinated proteolytic 
processing (Araki et al, 2003). Recent findings suggest that the formation of a tripartite 
complex of APP and calsyntenin-1 with the X11-like (X11L) protein stabilizes intracellular 
APP metabolism and mediates suppression of the amyloid-b-protein (Ab) generation. The 
dissociation of X11L from the tripartite complex enables cleavage of calsyntenin-1 and APP 
at their primary cleavage sites (x and a or b, respectively). Followed by secondary cleavage 
at the e/g-site, the intracellular fragments of both, APP (AICD) and calsyntenin-1 (CICD) are 
generated. It was suggested that CICD suppressed the Fe65-dependent gene transactivation 
activity of AICD, probably because CICD competes with the APP intracellular domain fragment 
for binding to Fe65. In addition, deficiencies in the X11L-mediated interaction and imbalance 
in the metabolism of calsyntenin-1 and APP may be related to neuronal disorders like AD. 
As calsyntenin-1 was reported as a potential biomarker in the diagnosis of AD (Hata et al, 
2002), this prompted us to evaluate whether calsyntenin-1 ectodomain shedding is increased 
or decreased in the context of AD. To answer this question, CSF samples (30 µl) from 10 AD 
patients compared to 10 healthy control subjects were loaded on a 4-12% NuPAGE gel and 
Western blot was achieved with antibody R131 3rd boost. The signal intensities were normalized 
to a reference sample (pooled human CSF). The group of AD patients does not reflect a strong 
change in ectodomain shedding compared to healthy control subjects (Figure 3-34). 
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Figure 3-34. Comparison of calsyntenin-1 ectodomain levels in human CSF samples from 10 healthy 
controls (HCS, open bars) versus 10 AD patients (black bars). Samples were separated on 4-12% 
NuPAGE gels and Western blots were performed for the same sample in triplicates for densitometric 
quantification. Error bars show STDEV. The inset shows the average signal intensity of all samples 
analyzed for each group.
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3.5.5 Calsyntenin-1 ectodomain shedding in Epilepsy
Recently, it could be shown by chemical LTP induction in acute whole hippocampi that both 
potassium-based TEA as well as non-potassium-based PFR stimulation protocols enhance 
ectodomain shedding of calsyntenin-1 in comparison to non-stimulated hippocampal tissue. 
Thereby, induction of LTP by TEA showed stronger effect when compared to PFR stimulation 
(see introduction). 
As there is an imbalance between neuronal inhibition and excitation in epilepsy, a change 
in ectodomain shedding was assumed as a measure of epileptic activity. Thus, it was tested 
whether this change can be monitored in human CSF by Western blot analyses. I used the 
previous sample set as described in paragraph 3.8.2 was included and comparative analysis of 
17 epilepsy patients and 19 control subjects was performed. As shown in the same paragraph, 
the sample set from the age-associated study and compared a set of four samples from epilepsy 
patients and the age-matched individuals. I determined the calsyntenin-1 ectodomain levels by 
seperating 30 µl CSF on 4-12% NuPAGE gels followed by Western blot analyses using antibody 
R131 3rd boost.
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Figure: 3-35. Quantitative analysis of calsyntenin-1 ectodomain in human CSF from epilepsy patients 
(black bars) compared to samples from the age-dependent study (open bars) at corresponding age. 
Samples were separated with 4-12% NuPAGE gels and Western blots were performed from each sample 
in triplicates. Error bars show STDEV.  The insert shows the average of all four samples for each group.
The results from the experiments showed no clear differences in calsyntenin-1 ectodomain 
levels between epilepsy patients and healthy control subjects. Additionally, analyses with age-
matched sample pairs (Figure 3-35) confirm that there is no tendency whether calsyntenin-1 
ectodomain is increased or decreased in epilepsy.
4 Discussion
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The quantification of differences in protein amounts in the physiological states of a biological 
system is among the most important tasks to unravel novel and pathological pathways. In addition 
to the classical quantification methods, analyzing proteins by SDS PAGE gel or immunoblot 
staining, mass-spectrometry-based quantification methods have gained increasing popularity.
The neuronal serine protease neurotrypsin is predominantly expressed in the nervous system 
and has been located in non-neuronal tissues as well (Wolfer et al, 2001). Neurotrypsin cleaves 
agrin in vitro (Reif et al, 2007). This proteolytic processing was observed at the NMJ in vivo 
(Bolliger et al, 2010). To further analyze whether agrin is a substrate of neurotrypsin in vivo and 
to quantify the proteolytic activity of neurotrypsin in non-neuronal tissue as well as in the central 
nervous system (CNS), mass spectrometric measures and quantitative Western blot analyses 
of murine serum and human cerebrospinal fluid (CSF) were performed. I further analyzed 
the potential functional effects of the neurotrypsin-agrin interaction in vivo using human CSF 
samples in relation to age and in the context of neurological disorders such as Alzheimer`s 
disease and epilepsy. The catalytic activity of neurotrypsin on agrin in murine serum was 
increased in neurotrypsin-overexpressing mice and completely diminished in neurotrypsin-
deficient mice. In the CNS as well as in non-neuronal tissues, neurotrypsin certainly recognizes 
the proteoglycan agrin and proteolytically cleaves it at two positions termed a- and b-sites. The 
proteolytic activity on the b-site can be screened in human CSF samples, as this cleavage step 
leads to the release of the C-terminal 22 kDa fragment (agrin-22) into body fluids. 
Furthermore, I identified and quantified the transmembrane protein calsyntenin-1. 
Calsyntenin-1 and APP undergo a similar coordinated proteolytic processing. After 
ectodomain shedding (x-cleavage) by ADAM10 and ADAM17, cleavage by g-secretase regulates 
intramembrane proteolysis (Araki et al, 2003). The transmembrane stump is internalized and 
accumulated in the spine apparatus of the synapse. Thus, proteolysis-dependent translocation 
is suggested to illustrate an independent downstream event in protease-mediated synaptic 
plasticity. Furthermore, the metabolism of calsyntenin-1 and APP may be related to neuronal 
disorders like AD and it was recently shown that calsyntenin-1 ectodomain-shedding is 
increased by induction of synapse activity (unpublished results). To evaluate ectodomain 
shedding of calsyntenin-1, mass spectrometric identification of cleavage products in human 
CSF was performed. I further analyzed the potential functional effects of ectodomain shedding 
in vivo by quantitative Western blot using human CSF samples in association to age and in 
the relation to neurological disorders such as Alzheimer`s disease and epilepsy. Proteolytic 
ectodomain shedding of calsyntenin-1 can be screened in human CSF samples. The cleavage of 
calsyntenin-1 leads to the accumulation of calsyntenin-1 in the surrounding CSF. 
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4.1 Neurotrypsin-dependent agrin fragments
       are accumulated in body fluids
The spatio-temporal expression pattern of neurotrypsin has been verified on the mRNA level 
and showed a peak at the postnatal day 10 (P10) in murine brain and in non-neuronal tissues 
(Wolfer et al, 2001). Neurotrypsin`s substrate agrin is either expressed in neurons, mainly as 
type II transmembrane protein, or as a secreted isoform in the whole brain and peripheral tissues 
such as kidney and lung. The distribution of agrin`s z-transcripts in tissue can be differentiated 
as well. The z0 transcript is the predominant isoform in non-neuronal tissues whereas all 
isoforms (z0, 8, 11, and 19) have been detected in the CNS (O`Connor et al, 1994). Recently, 
the developmental course of neurotrypsin-dependent agrin cleavage in murine brain tissue of 
wild-type mice from embryonic age E16 until postnatal day P730 was documented by Western 
blot using anti-agrin and anti-neurotrypsin antibodies (Reif et al, 2007). The distinct cleavage 
at the a-site and thus the release of the intermediate 90 kDa cleavage product (agrin-90) was 
shown to be persistent throughout life, whereas agrin-22 was detectable only until P60. It was 
therefore assumed that agrin-22 is more diffusible compared to agrin-90 and thus may pass 
the non-synaptic tissue into the cerebrospinal fluid (CSF). From what is known in our group, 
neither agrin nor neurotrypsin could be isolated and identified by mass spectrometry from 
synaptosomal preparations in neurotrypsin-overexpressing mice (Walther, 2007). There is no 
clear explanation for this finding. Possibly, the traceable amounts of neurotrypsin even from 
overexpressing mice were already lost during sample preparation, since neurotrypsin is known 
to be an extremely sticky protein (unpublished observation). Taken together, it was argued that 
it might be possible to monitor neurotrypsin`s proteolytic activity in the CNS and non-neuronal 
tissues by quantifying the level of cleavage products of its unique substrate agrin, particularly 
of its 22 kDa variant, in body fluids such as serum and CSF. 
This study is the first analysis of proteolytic cleavage products of agrin in these body fluids. 
To test this concept, agrin was isolated by immuno-affinity chromatography from murine 
serum and rat CSF using affinity-purified antibody R139 which is raised against the C-terminal 
agrin-22 fragment. The elution fractions were analyzed by Western blot and mass spectrometric 
analysis to identify the enriched agrin components. The results confirmed that targeting of the 
neurotrypsin-dependent fragment agrin-22 was possible in both body fluids. Therefore, we 
compelling evidence can be provided that agrin-22 is present in traceable amounts. Four tryptic 
peptides matching the amino acid sequences of mouse and rat agrin-22 have been identified by 
mass spectrometric analysis for each body fluid. The mass spectrometric data further indicated 
that the full-length form of agrin as well as the agrin-90 fragment is absent in serum and CSF. 
In respect of CSF, this strengthens the finding that mainly transmembrane agrin, which is 
predominantly expressed in neurons, is locally cleaved at the synapse, releasing the agrin-90 
and agrin-22 fragments into the synaptic cleft (Stephan et al, 2008). It is hypothesized that the 
transmembrane N-terminal part of agrin is internalized after a- and b-cleavage. Both cleavage 
fragments might interact with respective receptors which are possibly not accessible for full-
length agrin. However, specific proteotypic tryptic peptides of the agrin-22 splice variants z0, 8, 
11, and 19 have not been identified. This could either show that for these specific peptides in-gel 
digestion and elution from the gel is hindered or that the sensitivity of the mass spectrometric 
methods used during these experiments is not sufficient.
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4.2 Neurotrypsin`s cleavage activity is age- and genotype-specific
Endogenous neurotrypsin as well as agrin show a particularly high expression during 
late embryonic development and the first postnatal week in the brain, peripheral nervous 
system, and non-neuronal tissues (Wolfer et al, 2001; Stephan et al, 2008). Semi-quantitative 
analyses during prenatal development in non-neuronal tissues revealed a strong expression 
of neurotrypsin at mesenchymal boundaries and indicated that it may have additional roles 
in tissue and organ morphogenesis. Neurotrypsin cleaves agrin at two distinct sites and an 
intermediate agrin-90 molecule and the C-terminal agrin-22 fragment are released (Reif et al, 
2007). The agrin-90 cleavage product was detected in brain, kidney, and lung of wild-type mice 
but was absent in neurotrypsin-deficient animals. Similar results were obtained for agrin-22 
except for lung.
In this work, the first quantitative profiling of agrin-22 in murine serum samples is presented. 
In order to confirm the neurotrypsin-dependent cleavage of agrin in non-neuronal tissues, 
I performed quantitative profiling by Western blot of murine sera from neurotrypsin-
overexpressing, neurotrypsin-deficient as well as wild-type animals. With serum samples from 
neurotrypsin-deficient mice I wanted to test whether agrin is proteolytically processed by 
other proteases than neurotrypsin.
First, I took a comparative view on sera at P4 and P10, where the agrin-22 signal is present in 
well detectable amounts. Sera were diluted (1:10) and analyzed by Western blot in triplicates 
using antibody R139 against the agrin-22 fragment. Consequently, analyzes were performed 
volume-adjusted in order to identify intermediate changes related to the different subjects. 
Interestingly, significantly higher agrin-22 amounts were observed for the neurotrypsin-
overexpressing mice at P4 compared to wild-type mice. This result clearly indicated a higher 
proteolytic activity due to the enhanced expression of neurotrypsin in transgenic mice. In fact, 
agrin-22 levels were much higher at P4 in neurotrypsin-overexpressing mice and in their wild-
type littermates compared to the levels at P10. The difference in the amount of agrin-22 between 
both mouse groups as shown for P4 could not be observed at P10. The signal for agrin-22 was 
clearly absent in sera of homozygous neurotrypsin-deficient animals at both ages, P4 and P10. 
Enhanced proteolytic cleavage can be monitored in neurotrypsin-overexpressing mice at early 
stages of development, whereas no cleavage was observed in mice lacking neurotrypsin. The 
combined data indicates that agrin is exclusively processed by neurotrypsin in peripheral body 
tissues. The antibody used in this study is raised against the C-terminal domain of agrin enabling 
the detection of full-length agrin. Since no other proteolytic products in addition to agrin-22 
have been detected, neurotrypsin`s cleavage of agrin at both sites (a- and b-) is suggested to 
be highly specific. Thus, the level of agrin-22 can serve as a direct reporter for neurotrypsin`s 
proteolytic activity in vivo.
In transgenic mice, the activity of the Thy-1.2 promoter cassette declines to baseline after 
postnatal day 15 (P15). Therefore, quantitative profiling by Western blot of murine serum 
from P1 to P30 mice was undertaken in order to identify long-term activity changes of 
neurotrypsin`s proteolysis in transgenic, neurotrypsin-deficient as well as wild-type animals. 
I wanted to shed light on the changes that are temporally related to neurotrypsin`s activity 
during development in non-neuronal tissues. The amount of agrin-22 in murine serum of 
transgenic neurotrypsin-overexpressing mice and their wild-type littermates showed both a 
decrease following a similar age-dependent course. The highest agrin-22 level was detected at 
P1 and consistently declines until P30, where a faint band is still visible. In addition, I compared 
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signal intensities of agrin-22 between homo- and heterozygous neurotrypsin-deficient mice 
as well as their wild-type littermates at different ages. The signal for agrin-22 was clearly 
absent in all sera of homozygous animals, whereas in sera of their heterozygous and wild-type 
littermates signals for agrin-22 could be observed. The amount of cleavage product followed 
the same age-dependent pattern as already shown for the transgenic mouse line and their 
wild-type littermates. Together, the results are in perfect accordance with previously published 
data for mRNA expression and endogenous protein analyses for both, neurotrypsin and agrin, 
in non-neuronal tissues. In fact, it reinforces the concept that agrin-22 is more diffusible 
compared to agrin-90 and may pass tissues more easily to be accumulated in surrounding body 
fluids. In conclusion, the data supports the hypothesis that neurotrypsin and agrin may play an 
important role in the morphogenesis of connective tissues during development.
4.3 Quantification of agrin-22 z-transcripts by LC-MS/MS analysis
       – drawbacks and opportunities
Agrin-22 can serve as a marker for neurotrypsin`s proteolytic activity in vivo as shown in 
the previous section. The previously discussed, Western blot analyses were performed with 
4-12% NuPAGE Bis-Tris gradient gels. Nonetheless, the four isoforms of agrin-22 appeared 
as one band at the molecular level of 22 kDa. Thus, differentiation of the four splice variants 
(z0, 8, 11, and 19) was not possible by Western blot. In addition, the antibody R139 used for 
immunoblot is raised against a common epitope in the C-terminal part of agrin-22 and thus 
cannot discriminate betwen the distinct splice variants. 
Agrin-22 z+ transcripts are implemented in the accumulation of acetylcholine receptors (AChRs) 
at the neuromuscular junction, whereas the agrin z0 transcript did not show any activity 
(Ferns et al, 1992). Furthermore, the mRNA pattern of the four isoforms showed a regionally 
specific expression in the CNS. While neurons predominantly express various combinations 
of all transcripts, non-neuronal cells exclusively contain agrin z0 (O`Connor et al, 1994). The 
agrin z0 transcript comprises the highest percentage (> 40%) in the adult rat CNS followed 
by agrin z8 and 19 with 60%. Agrin z11 constitutes the lowest percentage (< 7%) of these 
transcripts. Differences in the expression in matters of brain region and amount of transcript, 
indicate a physiologically significant regulation of agrin`s activity. In contrast to the activity 
at the NMJ, all z-splice variants showed similar effects in rescuing the filopodial response in 
hippocampal neurons of neurotrypsin-deficient animals (Matsumoto-Miyai et al, 2009). Since 
there is no data available on the protein expression level of these isoforms, information which 
would be available after quantitative proteomics, could shed light on agrin`s role in the CNS. 
The identification of such low expressed proteins is still a challenge (Zhang, 2007) and this fact 
is even potentiated when it comes to quantification. Nonetheless, such low-abundant proteins 
are thought to be diagnostic markers. Hence, it was speculate that agrin-22 isoforms could 
serve as reporter for neurotrypsin-dependent proteolytic changes at synapses in the CNS. 
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4.3.1 Depletion and in-solution digestion are essential in sample preparation
Developing quantitative LC-MS methods is a complex task and involves many technical 
considerations: development time, number of samples, sample preparation, matrix 
composition, required sensitivity and accuracy, robustness and instrumentation. One way to 
enhance the availability and detection of the low-abundant agrin-22 isoforms is the creation 
of a depleted fraction before mass spectrometric analysis. On this purpose, I used techniques 
based on individual physico-chemical properties such as immuno-affinity, cation-exchange, 
ion-exchange and size-exclusion, trying to fractionate and deplete serum proteins and thereby 
enriching low-abundant proteins. Four commercialized depletion kits have been tested by 
applying either murine serum samples or recombinant agrin-22 according to the capacity of the 
column material. All depletion experiments were carried out at room temperature according 
to manufacturer`s instructions. The agrin-22 recovery was in all cases tested by SDS-PAGE and 
Western blot with antibody R139. However, it appeared that endogenous agrin-22 failed to 
elute in depleted serum fractions using four commercially available depletion kits. Agrin-22 
was predominantly present in the eluates containing the high-abundant proteins, which 
suggested non-specific binding to either the column resin or the depleted bound proteins on 
the resin. For instance, it is likely that agrin-22 is accumulated by albumin. The biological force 
underlying this phenomenon could simply be the transport function that albumin exhibits in 
serum. By adding recombinant agrin-22, an inhibiting effect on the non-specific interaction of 
the endogenous cleavage product with the column material or high abundant serum proteins 
like albumin was observed. Further, three fractionation methods e.g. Microcon centrifugal filter 
devices (MWCO 30 kDa and 50 kDa), precipitation with ammonium sulfate, and gel filtration 
have been evaluated. Promising results were achieved by precipitation and size exclusion 
chromatography while the centrifugal filter devices displayed non-specific binding of agrin-22 
to either the filter or proteins in the high-molecular weight fraction. Taken together, the test of 
seven different depletion methods suggested gel filtration as the most efficient technique to 
remove albumin as well as other high-molecular weight proteins from serum. In addition, the 
protein separation of murine serum by size exclusion chromatography enabled the isolation 
of agrin-22 in one of the low-molecular weight fractions. This was not possible with any other 
depletion techniques which were tested in this study. By removing high-abundant proteins, 
total protein load for further analysis can be increased, improving the likelihood of detecting 
and identifying low-abundant agrin-22.
The CSF has a low protein concentration (150–450 mg/ml) and a high salt concentration 
(4150 mmol/l). However, the concentration of albumin (60% of the total CSF protein) and 
immunoglobulin is extremely high in the CSF (Hammack et al, 2003). The preparation of human 
CSF samples required a different protocol. The test of the depletion methods from the previously 
described sample preparation of murine serum was not applicable because of the low sample 
volume (50-100 µl) provided by the clinics. Additionally, the high salt concentration in CSF 
requires an additional desalting step. Results from a study of Zhang suggested dialysis in order 
to assure optimal protein recovery (Zhang, 2007). Depletion was achieved by fractionation 
with graduated addition of acetonitrile (ACN). In order to test whether this protocol would 
be an appropriate method for serum, I similarly performed the preparation for both sample 
systems. The obtained pellets (P1 and P2) and the supernatant (S2) were analyzed by Western 
blot analysis. As expected, higher protein amounts were detected in murine serum samples 
compared to the human CSF. In human CSF, agrin-22 was isolated in the low-molecular 
weight fraction e.g. the second supernatant (S2). In contrast, agrin-22 was isolated in murine 
serum samples in the first pellet (P1) which represents the fraction of high-molecular weight 
proteins. Taken together, the result clearly indicates the strong influence on the isolation of the 
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protein of interest which is induced by the different protein composition in these two sample 
systems. Serum and CSF samples had to be differently prepared in order to deplete the protein 
composition and isolate agrin-22.
In mass spectrometry-based quantification, the protein amount is usually not directly 
measured, but is rather inferred from the experimentally determined amount of peptides 
rendered by in-solution or in-gel digestion of the target protein (Havlis & Shevchenko, 2004). 
Since chemical and physical properties of proteins are diverse, the recovery of peptides might 
vary considerably. It is documented that significantly more proteins can be identified in samples 
separated by SDS-PAGE (ten fractions) than those separated by organic precipitation (three 
fractions) (Xu et al, 2006). Nonetheless, digestion of proteins embedded into a polyacrylamide 
matrix affects the recovery of peptides, and therefore, the results may strongly depend on 
which peptides were selected as a reference for the quantification. The efficiency of an in-gel 
digestion is protein-dependent and comprises strong variations for different peptides that 
originate from the same protein. It is concluded that using in-gel digestion strongly affects the 
accuracy of the absolute quantification, and priority should be given to technologies that enable 
direct quantification in complex in-solution protein mixtures (Peng & Gygi, 2001). Particularly 
as digestion of proteins in-solution enabled their robust quantification. The reduction in 
sample processing however could interfere with the detection of low-abundant proteins 
such agrin-22 in some way that suppresses its signal intensity. However, intensive, multi-step 
sample preparation is problematic concerning the reproducibility of the analyses. As it was 
aimed at quantifying agrin-22 z-transcript levels, the most reproducible sample processing 
was preferred. Therefore, in-solution digestion was chosen, as it is an adequate tool for sample 
preparation in a quantization assay. The risk of high variations in peptide recovery is limited.
4.3.2 Targeted mass spectrometry - evaluating optimized parameters
Mass spectrometry-based targeted protein quantification provides a powerful tool to 
systematically assess quantitative differences in protein amounts of individual samples. The 
recent advance in biomedical and clinical research is highlighted by an emerging number 
of reports on proteomics in trauma patients, diagnosis of ovarian cancer, biomarkers in 
psychiatry, proteomics in cardiovascular surgery, and biomarker discovery in the CSF for 
neurodegenerative diseases (Alpantaki et al, 2007; Ardenaki et al, 2002; Hunnerkopf et al, 
2007; Matt et al, 2007; Zhang et al, 2005). After comparison of the proteome of a diseased 
sample versus normal, novel protein candidates have been associated with the pathogenesis 
of a disease. Further characterization and validation of these putative biomarkers is extremely 
sophisticated due to the huge complexity of biological systems and the heterogeneity of human 
samples (Pan et al, 2009). This is reflected by the remarkably small number of validated 
biomarkers (Aebersold et al, 2005; Anderson & Anderson, 2002). The major method used for 
targeted protein quantification has been the enzyme-linked immunosorbent assay (ELISA). 
Nonetheless, the ELISA approach is limited by the lack of antibodies with high specificity for 
most novel biomarker candidates. The development and implementation of mass spectrometry-
based targeted proteomics for clinical applications offers an alternative to circumvent these 
limitations. A robust and highly sensitive assay using mass spectrometry is provided by 
moving from full scan spectrum monitoring to single ion monitoring (SIM) or selected reaction 
monitoring (SRM). To gain maximum sensitivity, SRM allows for the selection of a single mass 
ion to quantify and further filter via a distinct fragment ion to discriminate it from other 
components that share the initial mass ion. It is particularly suited to the analysis of complex 
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matrices. Therefore, the confirmation of a protein in human CSF using an SRM approach should 
overcome the huge dynamic range of CSF. The SRM approach offers higher sensitivity when 
compared to normal proteomics profiling experiments. 
I was using in-solution digestion mixtures of the four recombinant agrin-22 z-transcripts and 
four synthetic specific tryptic peptides (proteotypic peptides, PTPs) to develop optimized 
parameter settings. Synthetic PTPs are of high need in SRM quantification assays when the PTPs 
are fixed like in this particular case to distinguish between splice variants of a single protein 
of interest. If these PTPs do not show up under standard conditions, which are automatically 
defined by the software, additional experiments with synthetic PTPs are indispensable in order 
to set up all parameters for satisfying performance and spectra. The performance is linked to 
reproducible spectra as well as to correct quantification values for targeted PTPs. After the 
first measurements with the in-solution digestion mixtures of the four recombinant agrin-22 
isoforms, a dramatic difference in the relative abundance between the PTPs was recognized. 
The following sections describe the systematic study which was performed to unravel the set 
of problems. 
The unit resolution setting enhances PTP detection
Each mass analyzer has some variation in its capabilities because of the individual design. The 
performance of a mass analyzer can be defined by the characteristics accuracy, resolution and 
mass range and scan speed. The ability of a mass analyzer to accurately measure m/z values 
is a direct funtion of the resoltuion of the instrument.  The reoslution (also termed resolving 
power) is the ability of the mass analyzer to distinguish between two m/z falues and can be 
determined by the measurement of m/z and the full with at half maixmum (FWHM). Higher 
resolution offers the separation of individual isotopes of an ion. Additionally, enhanced 
resolution is leading to more narrow peaks, thus allows a more accurate determination of the 
elution time. These factors directly influence the spetrum quality in the SRM approach. I wanted 
to test the performance of the instrument in relation to the resolution of the measurement. The 
impact of the resolution settings for the first quadrupole (Q1) was especially critical for the 
agrin-22 z19 variant. The detection failed for two fragment ions in the enhanced resolution 
mode (Q1 = 0.1) whereas unit resolution (Q1 = 0.7) enabled detection of all four fragment ions. 
Therefore, I preferred a lower setting for the resolution and accepted the loss in sensitivity 
which is associated therewith.
The in-solution digestion is sufficient for recombinant agrin-22 z-transcripts
I evaluated the efficiency of the in-solution trypsin digestion of the recombinant agrin-22 
isoforms and the ionization of the PTPs by SIM on the triple quadrupole instrument. The spectra 
were recorded manually during direct injection of the digestion mixtures. As ionization devices 
and experimental conditions influence the charge state, I chose a direct infusion method with 
50% acetonitrile (ACN) for sample introduction to mimic the amount of eluent needed for C18 
elution of the PTPs when using the LC-MS approach. Furthermore, all SIM experiments were 
performed on the triple quadrupole instrument where the SRM was carried out as well. This 
secures that no additional effect caused by a different ionization source influences the dominant 
charge state of the precursor. All PTPs could be detected with the same relative abundance, 
indicating that the digestion was sufficient. Main differences between the PTPs were observed 
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in the charge state. The charge distribution is based on the amino acid sequence and showed 
the expected pattern. The SIM spectra provided clear evidence that all PTPs are present in 
similar concentrations and ionize with comparable sufficiency. Therefore, the differences in 
relative abundance have to originate from other parameters in the workflow.
The poor fragmentation of agrin-22 z19 leads to signal loss
A limitation of current proteomics quantification approaches for SRM analyses is the 
theoretically selected precursor and product ions and corresponding collision energy (CE) 
used for the fragmentation. This process is fully automated by the software which is used 
for setting up the list of transitions. It leads to a theoretically ideal selection of transitions. In 
the case of the current study, this selection lead to false annotations of precursor ion charge 
states as only doubly charged ions are selected as usual species. Besides, the chosen CE used 
for the fragmentation process showed not to produce the amount of fragmentation required 
for satisfactory precursor ion spectrums. Targeting the dominant precursor charge state is 
essential for satisfying product ion spectra. Furthermore, the efficiency of fragmentation is 
linked to the quality of the observed product ion spectra. Therefore, I evaluated whether it is 
possible to assign any differences between the agrin isoforms. Fragmentation of agrin-22 z0, 8, 
and 11 was sufficient, but agrin-22 z19 showed a dramatic loss in the ability of fragmentation. 
I manually defined the ideal collision energy to optimize fragmentation, but the fragmentation 
pattern was still inadequate. This is one major reason for the pronounced decrease of relative 
abundance for the product ions of agrin-22 z19. Furthermore, one single peptide MS/MS 
measurement is used for protein quantification in the SRM approach, therefore this problem is 
exacerbated. As the ability of breaking peptide bonds is a matter of the amino acid composition, 
there is no possibility to compensate this effect.
Higher amount of acetonitrile enhance the elution of all PTPs
Flow injection experiments at different ACN concentrations (5, 20, and 50%) confirmed a high 
non-specific affinity of the z+ transcripts to tubings and fittings in the chromatographic system. 
While the non-specific interaction existed at 5 and 20% ACN, the interaction was conspicuously 
inhibited using a high ACN concentration of 50%. Additionally, the in silico calculated retention 
time index for all agrin-22 splice variants indicated that high ACN concentration is a precondition 
for the z+ transcripts. In addition, the Bull Breese index was in silico calculated for all four splice 
variants with the prospector program and suggests medium hydrophobicity due to the surface 
tension of the amino acid sequence. 
I wanted to implement these findings in order to optimize the analytical conditions for 
the C18 separation of the PTPs. There are two major possibilities to enhance polar/ionic 
interaction on RP-phases to enhance the peptide recovery: optimization of the gradient 
and the column temperature. Recently, it was suggested by several reports that elevated 
temperature is indispensable especially for hydrophobic proteins and peptides (Martosella et 
al, 2006; Blackler et al, 2008). I was using four individual gradients to evaluate the possibility 
of decreasing the retardation of the agrin-22 PTPs on the reversed-phase C18 resin and to 
prevent non-specific binding to the surface in the chromatographic system. Therefore, starting 
conditions of the gradient were increased from 5 to 10, 20 and 40% ACN, respectively. The 
recovery of all agrin-22 z-transcripts was clearly enhanced by the application of higher ACN 
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concentrations directly at the beginning of the gradient. The four transitions of the PTP for 
the agrin-22 transcript z0 showed improved detection using the 10% gradient compared 
to their relative abundance at the 5% gradient and only a slight enhancement was detected 
applying the 20% gradient. Therefore, recovery of agrin-22 z0 is suggested to be sufficient 
even at lower ACN concentrations. The transitions for the agrin-22 z8 transcript showed strong 
enhancement in their recovery only on the 20 % gradient and the same was true for the agrin-22 
z11 transcript. In contrast, the transitions of the agrin-22 z19 transcript were not detectable 
at any gradient below 20%. Two transitions were detected applying the 20 % gradient. Their 
relative abundance showed strong improvement at the 40% gradient. However, the analysis of 
the agrin-22 z19 transitions was not reproducible in three replicates. In parallel, application 
of the 40% gradient was leading to the loss of retardation for all other agrin-22 transcripts as 
they eluted with the solvent directly after the gradient developed. Therefore, the 20% gradient 
is suggested as ideal condition for the optimized elution of all PTPs. The results indicated that 
the selection of a higher ACN proportion at the beginning of the gradient was essential for the 
detection of the agrin-22 PTPs. In parallel, sample carry over between the measurements was 
inhibited by an 10% isopropanol wash step of the column between all samples. 
Elevated column temperature has no effect on PTP elution
Elevated temperature can be used to reduce the viscosity as it enhances solute diffusion which 
leads to highly narrow and symmetrical peaks (Boyes et al, 1993). I measured the effect on the 
retention time and peptide recovery using the standard gradient and heating the micro C18 
column to 40, 50, and 60°C, respectively. The measurements for a fetuin digest, which I chose as 
representative standard sample system, displayed irreducible retention times for 40 and 50°C, 
but no specific signal of any tryptic peptide of fetuin could be observed at 60°C. Furthermore, the 
synthetic PTPs of agrin-22 have been detected exclusively at 40°C. For both sample systems, a 
high number of unspecific signals with a high relative abundance were observed applying 60°C. 
The appearance of unspecific signals were ascribed either to the instability of the electrospray 
performance or to the column material. Poor spray performance was especially observed at 
50°C and with much higher impact at 60°C. As the flow rate was kept constant throughout 
all runs, a decrease in back pressure with increasing temperature was observed. I wanted to 
compare the retention times between the runs and therefore accepted the poor electrospray 
performance. All unspecific signals during the whole measurement could be assigned to one 
[M+H]+ species with a m/z-value of 512 which is by definition not a tryptic peptide. It could be 
possibly an indication for the degradation of the C18 column resin. 
The complex protein composition increases retention
Matrix effects cause a strong variation in the response from the analyte. In particular, ion 
suppression from interfering compounds and various cross talk effects can have a dramatic 
effect on the precision of the method. Hence, I wanted to elucidate the effect on the recovery of 
the agrin-22 PTPs based on the complex protein matrix in human CSF. The comparison of SRM 
spectra of the agrin-22 z0 PTP which was spiked into two differentially diluted CSF samples 
revealed a strong difference in the retention time between both solutions. The retention time 
of agrin-22 z0 transitions in the 1:10 diluted CSF sample was increased by about ten minutes 
compared to the retention in the 1:100 diluted CSF. Hence, it was claimed that there is indeed a 
strong matrix effect in human CSF samples. A sample dilution of 1:100 would possibly decrease 
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the detection of agrin-22 z-isoforms. On the purpose to indentify the minimal dilution needed 
to get rid of the matrix effect, I analyzed 1:10. 1:20. 1:30, and 1:40 dilutions of CSF. In addition, 
I included the detection of the highly abundant tryptic peptide TEATQGLVLWSGK which is 
located in agrin-22 and could provide quantitative information about the overall agrin-22 level. 
Based on the quantitative data from agrin-22 z0 and the TEATQGLVLWSGK peptide, it would 
be possible to calculate the amount of the less accessible agrin-22 z+ isoforms. Additionally, 
the analyses offered the alternative to evaluate the matrix effect for a standard tryptic peptide 
which showed a standard elution profile between 10-30% ACN on a reversed-phase C18 
material in previous experiments. Measurements for both tryptic peptides clearly indicated the 
strong influence of the CSF matrix on retention and relative abundance. In the case of agrin-22 
z0, the CSF dilution of 1:40 showed a shift back to the same retention time as observed for the 
pure digestion mixture of recombinant agrin-22 z0. Furthermore, I measured the 1:30 diluted 
human CSF sample with LC-ICR-FT-MS and analyzed the resulting spectra with the Mascot 
database search algorithm. The identification of agrin-22 z0 as well as the highly abundant 
tryptic peptide TEATQGLVLWSGK was found to be impossible.
Assuming that the method had all the analytical power which was needed, it was still not 
possible to run analyses with reproducible results. The absence of agrin-22 z0, 8, 11, and 19 
was found to be due to several parameters influencing the SRM efficiency: (i) non-specific 
binding of all PTPs to the chromatographic system and the reversed-phase C18 resin which 
increases referring to the molecular weight, (ii) poor fragmentation of agrin-22 z19, (iii) strong 
matrix effect from protein composition of human CSF. Taken together, the quantitative analyses 
of agrin-22 as well as of the z-transcripts have been found to be impossible with the established 
mass spectrometric method.
4.4 Neurotrypsin`s activity can be monitored 
       in human CSF
The emerging interest in extracellular proteolysis in the nervous system was originated by a 
huge number of reports implementing this process into the regulation of neurogenesis, cell 
migration, axonal growth, and synapse elimination. Hence, it is described to be important for 
adaptive changes in signal transmission. The expression pattern of neurotrypsin in the adult 
murine brain is claimed to be highly intriguing in a distinct subset of neurons (Gschwend et al, 
1997). In situ hybridization showed elevated labeling in the cerebral cortex, the hippocampus, 
and the amygdala, indicating that neurotrypsin may have a role in learning and memory 
processes during crucial stages of nervous system development. Agrin, the so far unique 
substrate for neurotrypsin, is expressed in neuronal tissues especially during development 
and throughout adulthood. Recent findings showed that the activity-dependent formation 
of dendritic filopodia was abolished in hippocampal neurons of neurotrypsin-deficient mice 
(Matsumoto-Miyai et al, 2009). The filopodial response could be fully rescued by exogenous 
application of agrin-22. It implicates the neurotrypsin-dependent cleavage of agrin as crucial 
step in activity-dependent reorganization of synaptic circuits in the brain. Physiologically, the 
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amount of agrin-22 in human CSF samples can provide insights into neurotrypsin`s activity and 
agrin`s role in the developing brain. I performed quantitative Western blots for agrin-22 using 
antibody R139 for three independent subject groups. To obtain inter-subject differences, all 
analyses were performed volume-adjusted. 
4.4.1 Neurotrypsin`s activity is modulated throughout development
First, I evaluated age-dependent changes of neurotrypsin`s proteolytic activity in a large 
sample set of 84 independent subjects at the age of 2 months until 35 years. As the CSF flow 
is initiated earliest in the first days after birth and accumulation of proteins is therefore not 
reliable, I excluded samples from subjects younger than 2 months from the study. Information 
about a possible status of disease was not provided by the clinic, thus the obtained amounts 
of the cleavage product agrin-22 were defined as age-associated. The results suggested high 
evidence that agrin-22 can be separated and quantified precisely by the applied method. The 
agrin-22 level was clearly elevated in samples from 2 months old subjects. The signal intensity 
follows a conspicuously decrease at the age of 6 months and therefore highly correlates with 
the neurotrypsin-dependent cleavage pattern in murine brain tissue during early development 
(Reif et al, 2007). The study demonstrates that agrin-22 levels decline with aging and ongoing 
development of the CNS. However, it is most likely that neurotrypsin`s proteolytic activity 
persists at a basal level throughout adulthood. The difference between samples from 10 
year-old until 35 year-old subjects was slight. In addition, the presence of several cases can 
be demostrated where agrin-22 gains high levels independent of the subject’s age. It is most 
likely that these specific cases represent the upregulation of either neurotrypsin`s activity or 
of the expression of both proteins due to individual changes in the nervous system. Whether 
these changes are caused upon physiological- or diseased-based processes is currently not 
understood. 
4.4.2 Neurotrypsin`s activity is moderately increased in Epilepsy
Short-term memory is defined as a process in which information is evaluated after a few 
seconds, whereas in long-term memory processes, the information is stored for more than 
a few minutes and can be exactly retrieved after the process of consolidation (Squire et al, 
1984). Furthermore, it is thought that this process is dependent on reorganizations at the 
neural systems level which last for weeks, months or even years (Squire and Alvarez, 1995). 
The standard memory tests are mainly based on information retention after a delay of 30 
minutes. Thus, little is known about long-term memory (Butler and Zeman, 2008). Patients 
with epilepsy report very often on memory dysfunctions, especially subjects with adult-onset 
temporal lobe epilepsy (TLE) where memory-related brain structures such as the hippocampus 
are affected by seizure activity (Hermann et al, 1997). It is documented that epileptic activity 
in temporal lobe and hippocampus is likely to disrupt simultaneous activity in neocortical cell 
assemblies (Blake et al, 2000). The process of consolidation in long-term memory is especially 
impaired in patients with TLE (Martin et al, 1991). These patients had problems to recall verbal 
memory after a delay of 24 hours. No differences could be observed after 30 minutes when 
compared to controls. Blake and colleagues could show that there is additional evidence of 
accelerated long-term forgetting in case of verbal material in patients with TLE after very long-
term retention intervals of 8 weeks (Blake et al, 2000). The short-term and episodic memory 
performance was indistinguishable from the same group of patients and controls after 30 
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minutes delay. These findings indicate defects in selective memory in subjects with TLE. Butler 
and Zeman hypothesize several contributory mechanisms to accelerated long-term forgetting 
(ALF) in some patients with epilepsy: (i) clinical or subclinical seizure activity, (ii) structural or 
other underlying brain pathology, (iii) an adverse effect of anticonvulsant medication, or (iv) 
psychological mechanisms and showed that (i) as well as (ii) are the most likely cases (Butler 
and Zeman, 2008). The expression of agrin and neurotrypsin is high in the CA1 region of the 
hippocampus and the interaction of both molecules is hypothesized to play an important role 
in the process of learning and memory. 
Recently it was shown in cultured hippocampal neurons that the release of neurotrypsin into 
the extracellular synaptic space is activity-dependent (Frischknecht et al, 2008). I speculated 
about following situation: elevated agrin-22 concentrations in the CSF of epilepsy patients 
may result during high neuronal activity and reflect one significant symptom of this disease. 
Another reason for selecting this neuronal disorder was due to reports confirming impairment 
of memory in epilepsy patients. To address these questions, I performed a comparative study 
of human CSF samples including 17 epilepsy patients, 19 healthy controls as well as an age-
associated correlation with the sample set from the previous study on age-dependent agrin-22 
regulation. Latter samples were particularly included since the provided healthy control 
samples were grouped towards higher age in comparison to the epilepsy cases. Concerning 
the age-dependent regulation of neurotrypsin’s activity, the correlation of signal intensities 
between the first two groups caused deceptive high levels of agrin-22 in subjects with 
epilepsy. However, the agrin-22 amount was slightly increased in an enhanced number of 
epilepsy patients compared to the age-matched samples. It was possible to directly compare 
a set of four independent epilepsy and age-related samples of exactly the same age. Statistical 
significancy could not be assessed due to the low number of samples matching the same age. 
However, preliminary results assume a tendency for enhanced neurotrypsin activity in subjects 
with epilepsy but do not allow for a significant distinction between the three groups in this 
study. A larger number of samples for detailed future analysis will therefore be needed. In 
addition, detailed information about the type of epilepsy and the onset of the disease will be 
an important means to obtain meaningful insights into neurotrypsin`s activity in the brain of 
epilepsy patients.
4.4.3 The agrin-22 amount is slightly decreased in Alzheimer`s disease
It was reported that heparan sulfate proteoglycans (HSPG) levels are increased in brains from 
Alzheimer’s disease (AD) patients (Snow & Wight, 1989). Highest agrin expression has been 
detected in severely affected brain regions such as hippocampus and amygdala (Boew & Fallon, 
1995; Braak& Braak, 1991). Furthermore, it was shown that agrin binds b-amyloid peptide Ab 
(1-40) in its fibrillar state via a mechanism involving the heparan sulfate glycosaminoglycan 
chains of agrin (Cotman et al, 2000). It is suggested that agrin is able to accelerate Ab fibril 
formation and to protect Ab(1-40) from proteolysis in vitro. Therefore, it was concluded that 
agrin may be an important factor in the progression of Ab peptide aggregation and in Ab 
persistence in the brain of AD patients. Additionally, there are emerging speculations about the 
idea that dementia may be a cause of epilepsy as seizures and dementia describe a concurrently 
manner (Abou-Khalil, 2010). Recently, it has been shown in a small number of patients with 
a progressive form of memory dysfunction that there is not necessarily a loss in brain volume 
which is typically provoked by AD (Hogh et al, 2002). Those patients recovered to normal 
memory performance after anti-epileptic medication. Several cases of memory impairment 
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occurred in patients with epilepsy and encourage the hypothesis of an epilepsy-derived form 
of AD (Ito et al, 2009). 
I performed quantitative Western blot analyses of CSF from 10 AD patients versus 10 healthy 
control subjects. A slight decrease of the agrin-22 level was shown in the AD parents compared 
to the healthy controls. This may reflect a lower proteolytic activity of neurotrypsin which 
could be a result of the perturbed neuronal activity in AD. In parallel, it may be a possible effect 
of the suggested aggregation of agrin with the Ab peptide. Therefore, agrin`s accessibility to be 
cleaved by neurotrypsin might be hindered. Statistical analysis could not confirm a significant 
difference between AD patients and healthy controls for agrin-22 levels. Taken together, the 
result render it difficult to conclude whether neurotrypsin`s activity is reduced in AD. In 
addition, the low number of samples and the missing information about the type of AD and the 
age of the patients does not allow for a clear statement. Hence, it will be a necessary requirement 
for detailed future analysis to obtain a larger number of grouped samples to obtain meaningful 
insights into neurotrypsin`s activity in the brain of AD patients.
4.5 Monitoring of calsyntenin-1 ectodomain shedding 
       in human CSF
The N-terminus of calsyntenin-1 is released into the extracellular space after x-cleavage by 
ADAM10 and ADAM17 (Hata et al, 2010). Thus it exhibits strikingly similar features as the 
prominent transmembrane, amyloid precursor protein (APP), whose misregulation in 
proteolytic processing is thought to contribute to Alzheimer`s disease. Calsyntenin-1 is mainly 
expressed in all CNS neurons, whereas expression levels of Calsyntenin-2 and -3 vary between 
neuronal subpopulations (Hintsch et al, 2002). The pyramidal neurons in the hippocampal CA1 
region reveal high expression of only Calsyntenin-1. In contrast, part of the Purkinje cells in 
the cerebellum express calsyntenin-2 and -3, but lack in calsyntenin-1. The distinct pattern for 
each of the members suggests specific functions in distinct neuronal areas.
4.5.1 The ectodomain of calsyntenin-1 is accumulated in human CSF
I wanted to shed light into the proteolytic processing of the calsyntenin family and identify 
the proteolytic fragments present in the human CSF. Therefore, I performed data-dependent 
FT-ICR analysis for all tryptic peptides of calsyntenin-1, -2, and -3 covering the m/z range 300 – 
1.600 and Mascot database search. Data analysis revealed highly reliable protein identification 
for calsyntenin-1. The identified eleven tryptic peptides are restricted to the proteolytically 
released N-terminal part of calsyntenin-1 and could be identified in three independent human 
CSF samples. The impossibility to identify calsyntenin-2 and -3 with FT-ICR was assumedly 
to their remarkably low expression level in the brain. Hence, the sensitivity of the mass 
spectrometric method used in this measure is not sufficient for their detection. The presence 
of calsyntenin-1 in human CSF was further confirmed by targeted mass spectrometry. For 
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this, a selected reaction monitoring (SRM) experiment was designed using the highly abundant 
proteotypic peptides and their respective fragments identified by Mascot data. I chose the 
PTPs IPDGVVSVSPK (549 m/z) and EGLDLQVLEDSGRGVQIQ (715 m/z) both representing the 
N-terminal ectodomain of calsyntenin-1. It was possible to detect all four transitions in four 
independent human CSF samples with considerable response. Concerning the significant result 
of the SRM measure, it is suggested that calsyntenin-1 is the predominant member present in 
human CSF. 
4.5.2 Proteolytic processing of calsyntenin-1 is consistent throughout aging
Furthermore, I wanted to firstly investigate whether there is an age-dependent regulation of 
the proteolytic processing of calsyntenin-1. Secondly, I wanted to evaluate whether it is possible 
to monitor the ectodomain shedding in human CSF by quantitative Western blot. 
The distribution of calsyntenin-1 underlies a basal level. Comparing the protein abundance 
between the ages of 2 months until 35 years, the differences are very subtle. Interestingly, there 
are several CSF samples which show a strong accumulation of calsyntenin-1 irrespective of 
the age. This finding is giving evidence of the possibility to monitor a potential misregulation 
of calsyntenin-1 processing, which is most likely a consequence of pathological changes in the 
nervous system in human CSF. 
4.5.3 Unaltered ectodomain shedding of calsyntenin-1 in Alzheimer`s disease
Calsyntenins and APP undergo a similar coordinated proteolytic processing (Araki et al, 2003). 
APP and the cytoplasmic X11L/Mint2 protein form a tripartite complex with calsyntenin-1. 
Therefore it was suggested that formation of this complex stabilizes intracellular APP 
metabolism and mediates suppression of the Ab generation. Cleavage of calsyntenin-1 
and APP at their primary cleavage sites (x and a or b, respectively) is enabled when X11L 
dissociates from the tripartite complex. Subsequent secondary intramembranous g-secretase-
mediated cleavage at the g/e-site results in the formation of intracellular fragments of APP 
(AICD) and calsyntenin-1 (CICD). The cytosolic AICD cleavage product is thought to bind the 
nucleo-cytoplasmic shuttling protein Fe65 and the histone acetyltransferase Tip60 and forms 
a transcriptionally active complex (Araki et al, 2004). Similarly, the intracellular fragment 
CICD can associate with Fe65, and it was suggested that this process suppresses the Fe65-
dependent gene transactivation activity of APP, probably because CICD competes with the AICD 
for binding to Fe65. In addition, deficiencies in the X11L-mediated interaction and imbalance in 
the metabolism of calsyntenin-1 and APP may be related to neuronal disorders like AD. 
Quantitative Western blots of human CSF samples from 10 AD versus 10 healthy control subjects 
(HCS) were performed. The average value of ectodomain shedding of calsyntenin-1 in AD patients 
was marginally increased compared to the HCS. Statistical analyses revealed no significant changes 
between both groups. Because of the low number of samples available for this study, it is not 
possible to give a definite conclusion on whether calsyntenin-1 processing in AD is diverging from 
HCS. The requirement for detailed future analysis is to obtain a larger number of grouped samples 
which would provide closer insights into calsyntenin-1 ectodomain shedding of AD patients.
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4.5.4 Calsyntenin-1 ectodomain shedding is stable in Epilepsy patients
Recently, it was shown in our group that proteolytic processing of calsyntenin-1 and APP is 
dependent on neuronal activity (unpublished results). The chemical LTP stimulation was 
performed in whole hippocampi of young mice. Both potassium-based TEA and non-potassium-
based PFR chemical LTP stimulation protocols increase ectodomain shedding of the two 
molecules, whereas TEA elicits a stronger LTP-inducing effect than PFR. It might well be, that 
there is a connection of neuronal activity and proteolytic processing which could contribute to 
a better understanding of pathological mechanisms leading to neuronal disorders.
CSF samples from 17 epilepsy patients and 19 healthy control subjects were analyzed by 
quantitative Western blot. In addition, I included age-associated samples from the previously 
described study. Ectodomain shedding was not changed by a conspicuous amount in epilepsy 
patients, neither compared to healthy control subjects nor to age-associated controls. The 
small-scale quantitative data obtained in this study gives useful information about tendencies 
of proteolytic product accumulation in the CSF as a cause of neuronal disorders. But it appears 
difficult to decisively answer the question whether neurotrypsin`s activity or calsyntenin-1 
ectodomain shedding are considerably involved into or a cause of the processes of AD and 
epilepsy. A large sample set would be required for future analyses to monitor the accumulation 
of these proteolytic fragments. In addition, detailed information about the type of epilepsy and 
the onset of the disease will be an important means to shed light on the proteolytic processing 
of calsyntenin-1.
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5.1 Cell biology
5.1.1 HEK Ebna cell cultivation
Optimal growth of HEK Ebna cells was achieved with a cell density between 2x 105 – 3x 106 
cells/ml in Ex-cell 293 medium. Usually, cells were splitted to a concentration of 2x 105 cells/
ml twice a week by diluting the cells with fresh media (dilution ~1:10). Cells were cultivated 
in Erlenmeyer flasks (optimal flask size ~5x of culture volume) and counted to determine 
accurate dilution.
5.1.2 Transient DNA transfection with polyethylenimin
The production of the recombinant proteins (agrin-22 z0, 8, 11, and 19) was performed 
using transient DNA transfection with non-viral gene delivery agent polyethylenimin (PEI) 
as DNA carrier (Baldi, 2005). PEI stock solution was prepared at 1 mg/ml, its pH adjusted 
to 7 with HCl and stored at -80°C. Cells were grown to a density of 1 x 106 – 3.5 x 106 cells/
ml at the day of transfection, sedimented at 500xg for 30 min and adjusted to 1x 106 cells/
ml in 500 ml RPMI buffered with 25 mM HEPES. Transfection mixture was prepared 10 
minutes prior to transfection by mixing solutions A and B (A: 1.25 mg DNA in 25 ml 150 
mM NaCl; B: 3.75 ml PEI stock solution in 25 ml 150 mM NaCl). Cells were diluted 1:1 with 
Ex-cell 293 medium 5 h after transfection, and incubated for three days at 37°C and 10% 
CO
2
 at a constant spinning rate of 75 rpm.
5.1.3 Protein Purification
HEK Ebna cell supernatant (2l) was dialyzed 12 hours at 4°C with 20 mM Tris-HCl (pH 
8.5) containing 400 mM NaCl. The buffer was exchanged three times to allow for complete 
replacement. The dialyzed supernatant was clarified and concentrated to a volume of 200 ml 
using a tangential flow filtration device using a Pellicon XL membrane (MWCO 10 kDa, Filtration 
area 50 cm2; Millipore, Switzerland)
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5.1.4 Immobilized metal-ion affinity chromatography
The concentrated cell supernatant (200 ml) with recombinant histidine-tagged protein was 
affinity-purified by HIS-Select HF nickel-affinity gel (Sigma), which enables the purification of 
histidine-tagged proteins due to hydrophilic nickel chelate-linkage. After wash, histidine-tagged 
proteins were eluted elution buffer (Tris buffered saline: 20 mM Tris-HCl, pH 8 containing 
400 mM NaCl, 250 mM imidazole) by a gradient from 8% to 100% in 10 column volumes. 
The presence of the protein was confirmed by silver-stained SDS PAGE and Western blot 
with antibody R139. Elution fractions were concentrated to 1 ml by centrifugal filter devices 
(Amicon Ultra-15, MWCO 5.000; Millipore, Switzerland) by centrifugation at 3.500 rpm for 30 
minutes. The concentrate was further desalted with a NAP-5 column (GE Healthcare, Zurich, 
Switzerland) by elution with 500 ml buffer (20 mM MOPS, 100 mM NaCl, pH 7.5). 
5.2 Generation of neurotrypsin-specific mouse lines
In this study, we were using a neurotrypsin transgenic mouse line overexpressing neurotrypsin 
(Muslik 533). Expression of neurotrypsin in this line is controlled by the brain-specific Thy-
1.2 expression cassette. It drives strong constitutive expression of the transgene specifically 
in neurons (Caroni, 1997). Transgenic expression starts around postnatal day 6 (P6) to P10, 
at a time when it can influence activity-dependent rearrangements of synaptic connections 
and neuron-glia interactions during the late phase of nervous system development. The Thy-
1.2 activity peaks at P12 and remains relatively low throughout adulthood (Radrizzani et al., 
1995). Furthermore, neurotrypsin knock-out (NT-KO) mice were used to demonstrate that 
proteolysis of agrin and thus the generation of its fragments is dependent on neurotrypsin. The 
animals were tested for the presence of the transgene or the deficiency of neurotrypsin by PCR 
genotyping using specific primers.
5.2.1 Polymerase Chain Reaction (PCR) - PCR genotyping
Genomic DNA was extracted with alkaline lysis from tail biopsies of offspring from hNT 
overexpressing mice crossed with wild-type Black/6 mice. 300 μl alkaline lysis reagent (25 mM 
NaOH; 0.2 mM EDTA, pH 12.0) were added to tail biopsies and lysed for 45 min at 96°C. To stop 
the reaction, 300 μl neutralizing reagent (400 mM Tris-HCl, pH 5.0) were added. 1 μl of cleared 
extraction mixture was used for 20 μl reaction mix. For all PCR reactions, the following reaction 
mix was prepared: 1x Buffer, 0.25 mM dNTPs, 1.5 mM MgCl
2
 and 0.1 μl Taq-Polymerase (5 U/μl; 
Applied Biosystems), 0.5 μM forward primer and 0.5 μM reverse primer. The primer sequences 
and the PCR program for each mouse line are indicated below (for all but NTKO TAG was used 
as a positive control for PCR amplification, PCR products of NTKOF01 and NTKOR02 indicated 
NTKO and of NTKOF01 and NTKOR03 indicated wild-type alleles):
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Muslik 533
hNTSIIfor 5’-GCAATGTGCCAGATTCAGCAG-3’
Thy1back 5’-CCCATGTTCTGAGATATTGGAAG-3’
TAG83for 5’-GGAGGAGAGAGACCCCGTGAAA-3’
TAG82back 5’-ACACGAAGTGACGCCCAATCCGT-3’
PCR program: 1x (3’, 95°C), 40x (45’’, 95°C; 45’’ 63°C; 60’’, 72°C), 1x (5’ 72°C)
NT-KO
NTKOF01 5’-CAGAGCTCCTGGCGCTCATC-3’
NTKOR02 5’-GGAAGACAATAGCAGGCATGCTG-3’
NTKOR03 5’-CTCGCAGCTCAGCCCAACTG-3’
PCR program: 1x (3’, 95°C), 40x (45’’, 95°C; 45’’ 61°C; 60’’, 72°C), 1x (5’ 72°C)
5.3 Body fluids for biomarker discovery
5.3.1 Murine serum
Blood samples were taken from transgenic neurotrypsin-deficient (NT-KO), neurotrypsin-
overexpressing mice (Muslik 533) and their wild-type littermates at different age from postnatal 
day 1 (P1) to P30. The reference sample for quantification was pooled from eight to twelve 
NMRI wild-type mice at embryonic day 18 (E18). All blood samples were transformed into 
micro-collection tubes (Microtainer, Becton Dickinson AG, Allschwil, Switzerland) with serum 
separator additive, left for 30 minutes at room temperature until coagulation was completed 
and centrifuged at 12.000x g for 15 minutes. The obtained serum includes all proteins not used 
in blood clotting, electrolytes, antibodies, antigens, hormones, and any exogenous substances 
(e.g., drugs and microorganisms). All serum samples were aliquoted and stored in Eppendorf 
tubes at –20°C until analysis, diluted 1:10 in PBS buffer and analyzed volume-adjusted. For 
the quantification by Western Blot analysis, always 1 µl serum was diluted 1:10 in PBS buffer. 
To determine the proteolytic neurotrypsin activity, the b-cleavage fragment agrin-22 was 
quantified in serum. Signal intensity for agrin-22 was observed to be strongest at the age E18, 
therefore the pooled serum serves as a reproducible and reliable reference. 
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5.3.2 Human CSF
For the screening of agrin-22 as a reporter for neurotrypsin activity in vivo, we obtained human 
cerebrospinal fluid (CSF) samples from several hospitals in Zürich, Switzerland. All CSF samples 
were isolated by lumbar puncture according to a standard procedure, transferred into low-
binding Eppendorf tubes and stored at –80°C until analysis. All samples were loaded volume-
adjusted (30 µl) onto a 4-12% SDS PAGE gel. The quantification by Western blot analysis was 
achieved by antibody R139 (4th boost) against agrin-22 and antibody R131 (3rd boost) against 
calsyntenin-1.
Age-related samples
81 CSF samples at different age from 2 months (2M) to 35 years (35Y) without further 
information about the status of any disease were obtained from the children’s hospital Zürich. 
Alzheimer`s disease samples
We received 10 CSF samples from Alzheimer`s disease (AD) patients and 10 CSF samples from 
healthy control subjects (HCS). The HCS subjects were negatively tested for AD according to the 
standard clinical procedure. The samples were provided by the clinic of geriatric psychiatry 
Zürich. 
Epilepsy samples
The children`s hospital Zürich provided 17 CSF samples from epilepsy patients at a defined age 
and CSF from control patients without clinical symptoms for epilepsy.
5.4 Serum Depletion
Depletion of high-abundant proteins from complex sample systems is essential for the analysis 
of low-abundant molecules by mass spectrometry. The expression of agrin and neurotrypsin 
in mouse tissues was shown to peak in the first postnatal days and declines to a low level 
in adulthood. Therefore, we wanted to enable the detection of neurotrypsin-dependent 
agrin-22 splice variants by separating murine serum to obtain a sample system with less 
protein complexity. Seven different depletion techniques based on various physico-chemical 
characteristics were tested in this study. All depletion experiments were carried out at room 
temperature according to manufacturer`s instructions. The agrin-22 recovery was always 
verified by SDS-PAGE and Western blot with antibody R139.
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5.4.1 ProteomeLab IgY-12 Kit
The ProteomeLab IgY-12 kit (Beckman Coulter Intl. SA, Nyon, Switzerland) allows the removal 
of twelve highly abundant proteins from biological fluids: albumin, IgG, a1-antitrypsin, IgA, 
IgM, transferrin, haptoglobin, a1-acid glycoprotein, a2-macroglobulin, HDL and fibrinogen in 
one single step. The kit is based on affinity columns using antigen affinity-purified polyclonal 
avian antibody (IgY)-antigen interactions. It has a capacity of 10 µl human serum per spin 
column cycle. On the purpose of depletion, 10 µl murine serum (wild-type, E18) were diluted 
1:50 in dilution buffer (Tris buffered saline: 100 mM Tris-HCl, pH 7.4, 1.5 M NaCl). The sample 
is incubated with the column material for 15 minutes on an end-to-end rotator at room 
temperature, centrifuged for 30 seconds at 400 x g and the flow-through sample is collected 
for further analysis. To remove non-specifically bound proteins, three wash steps with dilution 
buffer were applied. The bound proteins were eluted using stripping buffer (1 M Glycine-HCl, 
pH 2.5) a total of 2 times. Therefore, the beads were incubated at room temperature for 3 
minutes and centrifuged for 30 seconds at 400 x g to collect the eluant. All fractions were TCA-
precipitated and loaded on a 12.5% SDS-PAGE for silver staining and 4-12% NuPAGE gel for 
Ponceau-red staining and Western blot analysis with antibody R139.
5.4.2 ProteoPrep Immunoaffinity Albumin and IgG Depletion Kit
The ProteoPrep Immunoaffinity Albumin and IgG Depletion Kit (Sigma-Aldrich, Buchs, 
Switzerland) has been designed to specifically remove albumin and IgG from human and 
murine serum (25-50 μl). The ProteoPrep Immunoaffinity medium in the pre-packed spin 
columns is based on a mixture of two beaded media containing recombinant expressed, small 
single-chain antibody ligands. We were using 25 µl murine serum (wild-type, E18) and another 
25 µl from the same serum sample with addition of recombinant agrin-22 z19 (275 ng). The 
serum samples were both diluted to 100 µl with equilibration buffer, added on the column, 
incubated at room temperature for 10 minutes and centrifuged for 60 seconds at 8.000 x g. The 
eluat is reapplied on the column and incubated for 10 minutes at room temperature to ensure 
optimal depletion. The spin column is centrifuged for 60 seconds and the twice depleted serum 
is obtained. A wash step is applied to elute remaining unbound proteins from the spin column 
by adding 125 µl equilibration buffer and centrifuge for 60 seconds. The bound proteins are 
extracted two times by adding 150 µl of the Protein Extraction Reagent Type 4. All fractions 
were Wessel-Flügge precipitated, separated using 4-12% NuPAGE gels and analyzed by Western 
Blot with antibody R139. 
5.4.3 ProteoSpin Abundant Serum Protein Depletion Kit 
The ProteoSpin Abundant Serum Protein Depletion Kit (Norgen, BioCat GmbH, Heidelberg, 
Germany) provides a fast and simple procedure for the effective depletion of major serum 
proteins including albumin, a-antitrypsin, transferrin and haptoglobin from serum samples. It 
is based on an ion-exchange mechanism. The complexity of the sample is reduced, allowing for 
the detection of less abundant proteins. The eluted samples are ready for use in downstream 
applications including LC-MS. In a first step, the column is activated by adding 500 µl column 
activation buffer and wash buffer. Serum sample (10 µl, wild-type, P5) is diluted 1:50 in the 
same buffer, applied on the column and centrifuged for one minute at 6.700 x g. The flow-
through is kept for analysis of assessing albumin and high abundance protein depletion. After 
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a column wash with 500 µl of column activation and wash buffer, the depleted serum is eluted 
by applying two times 100 µl of elution buffer, centrifugation of one minute at 6.700 x g and 
addition of 5 µl neutralizer to the eluat. Depletion efficiency was analyzed by silver gel and 
Western blot with antibody R139. 
5.4.4 ProteoExtract Albumin/IgG Removal Kit
The ProteoExtract Albumin/IgG Removal Kit (Calbiochem) provides a fast, reproducible and 
highly specific method to simultaneously remove serum albumin and IgG from various body 
fluids like serum and CSF. It uses gravity-flow columns pre-packed with a novel albumin affinity 
resin and a unique immobilized protein A polymeric resin. For samples with high albumin 
content a volume of 20 µl serum is recommended. We were using 15 µl murine serum (wild-
type, P5) which was diluted to a volume of 350 µl with the provided binding buffer. The column 
is equilibrated with 850 µl binding buffer; the diluted sample is applied and passes through 
the column by gravity-flow. To wash the column, 600 µl binding buffer is applied two times. 
All fractions are pooled and consequently contain the depleted serum samples. The bound 
proteins (albumin and IgG) remain trapped on the column. The depleted serum was analyzed 
by silver gel and Western blot using antibody R139.
5.4.5 Microcon YM-30 and YM-50
On the purpose to separate serum by molecular weight, Microcon centrifugal filter devices 
(Millipore) were used according to manufacturer’s instructions. We wanted to test the efficiency 
of depletion by concentrating the high molecular weight fraction in serum in the supernatant 
and the separation of the low-molecular weight proteins in the flow-through. The experiments 
were performed with 30 mg/ml recombinant agrin-22 z19 and 200 µl rat CSF. The protein 
concentrations of the load, flow-through and supernatant were measured by UV-spectroscopy 
on a nano-Drop spectrophotometer (Thermo Scientific; Wohlen, Switzerland). Recovery of 
agrin-22 z19 was further confirmed by Western blot using antibody R139. 
5.4.6 Gel filtration
The chromatographically method is based on size-exclusion and molecules are mainly separated 
according to their molecular weight. Gel filtration was performed using a Superose12 (10/30) 
column, 100 µl murine serum (wild-type, P10) and 2x PBS as elution buffer. For chromatography, 
a flow rate of 0.3 ml/min for 1.5 column volumes was chosen and elution fractions of 300 
ml were sampled in a 96-well plate. All fractions were analyzed volume-adjusted (20 µl) by 
separation on 4-12% NuPAGE Bis-Tris gels, silver-staining and Western blot analysis with R139 
antibody.
5.4.7 Ammonium sulfate precipitation
We precipitated and fractionated serum proteins with regard to their solubility in a solvent. 
The solubility is defined by the interaction of the charged functional groups of the protein 
with the molecules of the solvent. A 4M stock solution of ammonium sulfate and 5 ml murine 
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serum (wild-type, E18) diluted 1:2 in PBS buffer were used. The ammonium sulfate solution 
was added stepwise to the serum starting at 10% (v/v) and increasing the amount in steps 
of 10% until 100% (v/v). In order to avoid high local concentrations of ammonium sulfate, 
addition of the stock solution was performed by continuous shaking. The precipitate and the 
supernatant were analyzed in parallel with 4-12% NuPAGE Bis-Tris gels, Ponceau-red staining 
of the membrane and Western blot using antibody R139.
5.5 SDS PAGE
Murine serum samples and human cerebrospinal fluid (CSF) with equal volumes were boiled 
in NuPAGE LDS sample buffer following manufacturer’s instructions and electrophoretically 
separated on 4-12% NuPAGE Bis-Tris gels (Invitrogen, Basel, Switzerland) using MOPS buffer 
and constant current of 30 mA per gel. These pre-cast gels were mainly used for optimized 
agrin-22 detection in murine serum samples and human CSF. Alternatively, samples with 
equal volumes were resolved by SDS-PAGE on conventional, discontinuous 12.5 % gels 
(Laemmli, 1970).
5.6 Immunoblotting
In order to detect agrin-22 isoforms, proteins separated via SDS PAGE were transferred onto 
Immobilon-P polyvinylidene difluoride (PVDF) membrane (45 mm, Millipore, Switzerland) in a 
semi-dry blotter Trans-Blot SD Transfer Cell (Bio Rad Laboryties, Inc., Hercules, CA, USA) using 
1 x blotting buffer (25 mM Tris, 192 mM glycine, 20 % methanol) at 24 Volts for 1 hour at room 
temperature. On the purpose to detect calsyntenin-1 ecto-domain, proteins were wet blotted 
in a Criterion blotter (Bio Rad Laboryties, Inc., Hercules, CA, USA) using 0.5x blotting buffer 
(12.5 mM Tris, 96 mM glycine, 10% methanol) at 60 Volts for 3 hours at 4°C. Membranes were 
washed in methanol and air-dried for 30 minutes. The membranes were stained with Ponceau 
red solution (2 % Ponceau-S, 30 % trichloric acid, 30 % sulfosalicylic acid) and destained in 
distilled water. Primary antibodies were diluted in PBS buffer containing 0.1% (v/v) Tween-20 
(PBS-T) and 5% (v/v) skim milk powder (Migros, Switzerland) and membranes were incubated 
overnight at 4°C. After wash with PBS-T, incubation with the peroxidase-conjugated secondary 
antibodies was performed for 1 hour at room temperature in PBS-T containing 5% skim milk 
powder. Immunoreactive bands were developed using chemiluminescent substrate ChemiGlow 
(Alpha Innotech GmbH, Kasendorf, Germany) and analyzed on a Fujifilm LAS-3000 Imager 
(Raytest AG, Wetzikon, Switzerland) with AIDA software (Raytest GmbH, Straubenhardt, 
Germany). 
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5.6.1 Antibodies
Polyclonal antibodies
Polyclonal rabbit antiserum R132 and goat antiserum G91 were raised against the C-terminal 
90-kDa fragment of agrin (agrin-90). Goat antiserum G92 and rabbit antiserum R139 were 
raised against the C-terminal 22-kDa fragment of agrin (agrin-22; Reif et al., 2007). Western 
blotting: To verify the presence of full-length agrin as well as neurotrypsin-dependent agrin 
fragments in murine serum and human CSF, both antibodies against agrin-90 and agrin-22 
were used. The antibodies anti-agrin-90 and anti-agrin-22 are able to detect both full-length 
agrin (data not shown). Co-expression of agrin and neurotrypsin in HeLa cells resulted in 
the release of agrin-22, agrin-90, and agrin-110 that originated from partial cleavage at the 
α-site (Reif et al., 2007). This pattern demonstrates that neurotrypsin-dependent cleavage 
at the β-site is not necessary for cleavage at the α-site. It is suggested that either agrin 
cleavage at the α-site precedes cleavage at the β-site, or that cleavage occurs at both sites in 
parallel. As analyses of murine serum and human CSF showed only the presence of agrin-22, 
Western blotting was performed with anti-agrin-22 antibodies to monitor neurotrypsin`s 
activity in vivo. The antibody R139 showed less background signals in the complex protein 
samples compared to G92 and was therefore used for quantification. 
The polyclonal antibody R131 (3rd boost) was generated against murine calsyntenin-1 
ectodomain.
Purchased antibodies
Purchased antibodies were from Chemicon (Lucerne, Switzerland; APP N-term [MAB348; 
clone 22C11; m; WB 1:3.000]), Santa Cruz Biotechnology (Nunningen, Switzerland; anti-myc 
[Sc-78]), Sigma Aldrich (Buchs, Switzerland; b-actin [A5316; m; WB 1:5.000]), Roche (Basel, 
Switzerland; anti-GFP [1814460; m; WB 1:2.000]), and Invitrogen (Basel, Switzerland; human 
IgG l-chain [HP6054; h; WB 1:2.000]).
Horseradish peroxidase (HRP)-conjugated secondary antibodies (WB 1:20.000) were from 
Kirkegaard & Perry Laboratories (Gaithersburg, MD, USA) and Chemicon (Lucerne, Switzerland). 
Affinity-purified antibodies
Polyclonal rabbit antibody R139 was generated against murine agrin-22. For the isolation of IgGs, 
rabbit serum (5ml, R139 3rd boost) was diluted 1:10 in coupling buffer (10 mM Na
2
HPO
4 
x 2H
2
O, 
10 mM NaCl, pH 7) and loaded onto a protein A column (GE, Healthcare, Zurich, Switzerland). 
Elution was performed with 100 mM Glycin-HCl (pH 2.7) and neutralized with 2M Tris-HCl 
(pH 11). The specific IgGs were isolated via CN-Br-Sepharose column (GE Helathcare, Zurich, 
Switzerland) with agrin-22 z19 as ligand, eluted using 100 mM Glycine, 0.05% Tween-20, 10% 
glycerol (pH 2.7) and neutralized with 2 M Tris-buffer (pH 11). 
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Antibody dilutions
Name/antigen    Type            Dilution for 
        Western blotting
G91 (agrin-90)   serum     1:10.000
R132 (agrin-90)   serum  (2nd  boost)    1:3.000
G92 (agrin-22)   serum     1:10.000
R139 (agrin-22)   serum (4th  boost)    1:1.000
R139 (agrin-22)  affinity-purified   1 µg/ml
R131 (calsyntenin-1)  IgG fraction (3rd boost)   1:2.000
anti-APP N-term       1:3.000
anti-GFP        1:2.000
IgGl chain         1:2.000
anti-ß-actin   ascites fluid    1:10.000
HRP-conjugated
anti-rabbit   IgG     1:20.000
HRP-conjugated
anti-mouse   IgG     1:20.000
HRP-conjugated
anti-goat   IgG     1:30.000
5.6.2 Quantification and statistical analysis
Densitometric analyses of the protein bands were performed using AIDA software. Signals 
of two independent blots per genotype were quantified and used for statistical analyses. For 
analyses of agrin-22 in murine serum and human CSF, agrin-22 signals were normalized to 
the reference signal from murine serum of wild type E18. For the analyses of calsyntenin-1 
ectodomain, signals were normalized to the reference signal for calsyntenin-1 ectodomain in 
a CSF sample pool. Then, adjusted values obtained from transgenic or neurotrypsin-deficient 
samples of each experiment were compared to the corresponding adjusted signals from the 
samples of wild-type littermates, whereby the control signal of the reference (wild type, E18) 
was set to 100 percent. Data are presented as mean ± S.E.M. Statistical analyses were performed 
using unpaired Student’s t-test (Sigmaplot, Systat Software, Inc., San Jose, CA, USA).
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5.7 Sample preparation for Mass spectrometry
All mass spectrometric measurements were performed at the Functional Genomics Center 
Zurich (FGCZ), either in the service (Protein Analysis Group) or in the User Lab.
On the purpose to analyze agrin-22 isoforms by mass spectrometry (MS), several sample 
preparation protocols were tested. As a high non-specific binding of agrin-22 isoforms to all kind 
of surfaces was suggested and approved by MS, it was essential to reduce sample manipulation 
as much as possible. In addition, particular care has to be taken in the selection of tubes for 
sample preparation. We were using low-binding tubes and washed them three times with 
methanol prior usage to remove sanitizers which were leading to signal suppression during 
MS analyses. They showed no/low non-specific binding of agrin-22 which was confirmed by 
MS analysis with synthetic agrin-22 peptides (data not shown). When handling larger sample 
volumes of several ml, glass test tubes were used to avoid non-specific binding. 
5.7.1 In-gel digestion
Proteins were separated by 4-12% NuPAGE Bis-Tris gels and visualized by Coomassie Brilliant 
Blue (Invitrogen) staining. Protein bands at the molecular weight of interest were excised, 
cut into 1 mm3 cubes and put into low-binding tubes. The bands were destained with 50% 
acetonitrile and dehydrated in a vacuum centrifuge for 20 minutes until gel pieces show an 
opaque color. Destained, washed, and dehydrated gel pieces were rehydrated in digestion 
buffer (25mM NH
4
HCO
3
, pH 8) containing 50 ng trypsin for 5 minutes on ice and then covered 
with digestion buffer. The digestion mixture was incubated over night at 37°C and stopped by 
the addition of 10% formic acid. To extract the proteolytic peptides from the gel matrix, gel 
pieces were incubated three times with extraction solution (50% acetonitrile / 5% TFA). The 
recovered extracts were pooled together and dried down in a vacuum centrifuge. The dried 
extracts were stored at -20°C until mass spectrometric analysis. For the analysis, peptides were 
redissolved in equilibration buffer (5% acetonitrile / 1% TFA) used as starting condition for 
LC-separation.
5.7.2 In-solution digestion
Digest (1)
After acetonitrile fractionation and evaporation of the liquid phase, proteins were dissolved 
in digestion buffer (25mM NH
4
HCO
3
 pH 8) containing 10% acetonitrile (v/v). Protein 
concentration was measured using the Q-Bit system to evaluate the required amount of trypsin 
(2%, w/w). To increase the solubility of the proteins and therefore the efficiency of digestion, 
10% RapiGest (v/v) was used as detergent. The digestion mixture was incubated over night at 
37°C followed by evaporation of the solvent in a speed-vac. The samples were stored at -20°C 
until mass spectrometric analysis. For the analysis, peptides were resuspended in equilibration 
buffer (5% acetonitrile / 1% TFA) used as starting condition for LC-separation.
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Digest (2) 
Proteins were dissolved in digestion buffer (25mM NH
4
HCO
3
 pH 8) containing 50% methanol 
(v/v). Protein concentration was measured using the Q-Bit system, to evaluate the amount of 
trypsin (2%, w/w) needed. To increase the solubility of the proteins and therefore the efficiency of 
digestion, 10% RapiGest (v/v) was used as detergent. The digestion mixture was incubated three 
hours at room temperature followed by evaporation of the solvent in a speed-vac. The samples were 
stored at -20°C until mass spectrometric analysis. For the analysis, peptides were resuspended 
in equilibration buffer (5% acetonitrile / 1% TFA) used as starting condition for LC-separation.
5.8 Protein identification with nano-LC-ESI-MS/MS
5.8.1 Protein Analysis Group 
Murine serum samples were pooled and agrin-22 was isolated by immunoaffinity 
chromatography using immobilized affinity-purified R129 antibody. As column material NHS-
activated sepharose was used to covalently link affinity-purified polyclonal rabbit antibody 
(R139). Column material was prepared following manufacturer’s instructions. The appearance 
of agrin-22 in the elution fractions was confirmed with Western blot and corresponding 
elution fractions were pooled. Samples were separated on 4-12% NuPAGE gels as previously 
described. Separated proteins were visualized using the Colloidal Coomassie blue staining 
kit (Invitrogen AG, Basel, Switzerland). Bands in the 25-20 kDa region corresponding to the 
22kDa fragment of agrin were cut out, trypsin-digested and analyzed via nanoflow-LC-ESI-MS/
MS using a nanoAquity UPLC/Q-TOF Ultima API (Waters, Baden, Switzerland). Peptides were 
separated on a BEH C18 column (75 µm x 15 cm) at a flow rate of 350 nl/min using a gradient 
formed between solvent A (0.1% formic acid) and B (0.1% fromic acid in actetonitrile). Protein 
identification was carried out with Mascot.
5.8.2 User Lab
In-house columns
The production of the fused silica capillary columns (75 µm x 8 cm) was performed with a 
LASER puller. Reversed phase material (Magic C18 AQ beads 5 μm, 100 Å (Michrom)) was 
added in a minimal amount to a glass micro-vial with a small magnetic stirring rod and 1ml of 
methanol to make a slurry. A high-pressure vessel was used for packing the column. Packing was 
performed on a magnetic stir plate using a Helium pressure of up to 30 bars and stopped when 
the bed volume reached 8 cm. The capillary was washed with methanol for 30 minutes and two 
chromatographic separations with a standard peptide (e.g. 50 fmol/ml Glufib) were performed 
to evaluate and optimize the LC-MS system and to block active sites in the column material. On 
the purpose to wash and equilibrate the in-house fused silica capillary columns used for LC-MS 
analysis, we injected 20% ACN using the gradient which was chosen for the sample analysis. 
After the equilibration, the C18 resin was additionally primed for the analysis by injection of 
the standard Glufib. This step was performed three to five times until the retention time and 
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peptide recovery was reproducible which was calculated by integrated peak area of Glufib in 
an extracted ion chromatogram. The gradient used for this measure is listed in the section LC-
gradients as Standard gradient. 
Data-dependent mass spectrometry
RP-nano-LC-ESI-MS was performed on an Agilent 1100 LC-System (Agilent Technologies AG, 
Basel, Switzerland) coupled to an LTQ-TOF mass spectrometer (Waters, Baden, Switzerland), 
operating in split flow to reduce the flow rate. Samples were automatically injected into a 10-
µl loop and loaded onto an analytical column (75 µm x 8 cm column packed in-house) prior to 
ionization. Peptide mixtures were delivered to the analytical column at a flow rate of 300 nl/
min using various gradients formed between solvent A (various % ACN, 0.2% formic acid) and 
solvent B (0.2% formic acid), in 80% ACN). The gradients used for analysis are listed below in 
the section LC-gradients. 
Alternatively, nano-LC MS/MS was performed on a nano-LC Eksigent system (Eksigent, Axel 
Semrau, Sprockhövel, Germany) in-line to a 7-Tesla LTQ-FT mass spectrometer (Thermo Fisher 
Scientific AG, Reinach, Switzerland). With a flow rate of 150 nl/min, peptides were transferred to 
the analytical column (75 µm x 8 cm column packed in-house) and eluted with various gradients 
fromed between solvent A (0.1% fromic acid) and solvent B (0.1% formic acid in 80% ACN, see 
section LC-gradients). Survey scans were recorded in the ICR cell with a target value of 106 and 
a resolution of 100.000 at 400 m/z. MS/MS spectra were recorded in a data-dependent manner 
using an inclusion list of tryptic peptides for either agrin-22 or the calsyntenin members at the 
ion trap from the three most intense signals. Charge state screening was enabled and singly, 
quadruply and not-assigned charge states were rejected. Precursor masses already selected for 
MS/MS were excluded for further selection for 60 seconds and the exclusion window was set 
to 20 parts per million (ppm). The size of the exclusion list was set to maximum (500 entries).
Targeted mass spectrometry
Targeted nanoflow-LC MS/MS was performed on a nano-LC (Eksigent, Axel Semrau, Sprockhövel, 
Germany) in-line to the triple quadrupole mass spectrometer (TSQ Vantage and TSQ Quantum; 
Thermo Fisher Scientific AG, Reinach, Switzerland). The flow rate for peptide elution was of 150 
nl/min and peptides were transferred to the analytical column (75 µm x 8 cm column packed 
in-house) and eluted in a gradient of acetonitrile in 0.1 M acetic acid. The different gradients 
used for the measure are listed below in the section LC-gradients. The mass peak width for Q1 
full width half maximum (FWHM) was set to Q1 = 0.7 Th for unit resolution and to 0.1 Th for 
enhanced resolution. The Q3 FWHM was in all cases set to 0.7 Th, scan width to 0.002 m/z and 
scan time to 0.05 sec (16 transitions = 0.8 sec/cycle). The selected reaction monitoring (SRM) 
MS spectra were acquired in targeted mode using a transition list of proteotypic peptides for 
either agrin-22 or the calsyntenin-1 ectodomain. The list of agrin-22 PTPs for each z-transcript, 
their product ions and the collision energy for fragmentation is described in Table 5.2. To avoid 
sample carry-over, wash cycles with 10% isopropanol were applied after each run.
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Description Proteotypic peptide         m/z             Fragment      CE [V]
Agrin-22 z0   TFVEYLNAVTESEK    815.404 4    492.229       31
             593.277
             692.346
            763.383
            877.426
            990.510     
          1153.573
          1282.616  
Agrin-22 z8     TFVEYLNAVTESELANEIPVEK    1248.131   427.276       45
            585.360
            714.403     
            899.483
          1141.609 
          1357.648
          1458.732 
          1628.837
Agrin-22 z11   TFVEYLNAVTESPETLDSGALHSEK     913.112              943.447      43
              1383.675
              1470.707
              1599.749
                 1201.596 
          1383.675      56
              1597.796
              1821.922
                                     1935.965
Agrin-22 z19    TFVEYLNAVTESELANEIPVPETLDSGALHSEK 1369.164   943.447      50
          1383.675
          1470.707 
          1599.749
          1801.891
          1383.675      65
          1579.796
          1821.922
          1935.965
Table 5-2. Agrin-22 PTPs for each z-transcript , fragment ions and CE for the first test of targeted mass 
spectrometry. 
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Instrument maintenance on the TSQ Vantage and Quantum
The TSQ Vantage and Quantum were calibrated monthly with polytyrosine-1,3,6 (Thermo 
Electron) that comprised Tyr, (Tyr)
3
, and (Tyr)
6
, by following the instructions of the instrument 
manual.
To test the instrument performance before analyzing the samples, we measured a dilution 
series of the standard peptide Glu-1 fibrinopeptide (Glufib) from 800 amol, 8 fmol to 80 fmol 
using the Standard gradient for LC-MS (see section LC-Gradients). We calculated the regression 
coefficient of a calibration curve based on the integrated peak areas of the tryptic peptide 
EGVNDNEEGFFSAR with the m/z 785.842.
For optimized, reproducible MS analyses, the calibration and inter-day mass axis stability of 
the instruments was regularly tested and monitored after a set of five samples. Therefore we 
performed selected reaction monitoring of the standard peptide Glufib. We chose the highly 
abundant proteotypic peptide (PTP) EGVNDNEEGFFSAR with the m/z 785.842 and the 
retention time of 29.4 minutes (standard gradient). For SRM analysis, the fragments with m/z 
627,324; 684,346; 813,388, and 887,377 were selected to monitor the transitions. 
LC-Gradients
Standard Gradient 1: start at 5% ACN, in 1 minute to 10%, in 7 minutes to 35%, in 4 minutes
                                          to 80% (for 12 minutes).
Gradient 2: start at 20%, in 25 minutes to 60%, in 12 minutes to 80% (for 10 minutes).
Gradient 3: start at 40%, in 25 minutes to 60%, in 12 minutes to 80% (for 10 minutes).
MALDI
The digestion solutions were spotted on the MALDI target plate using recrystallized a-cyano-
4-hydroxycinnamic acid matrix solution with a 1:1 ratio. The spotted samples were analyzed 
by a MALDI-TOF/TOF mass spectrometer (ABI 4700 Proteomics Analyzer, Applied Biosystems, 
Rotkreuz, Switzerland). 
5.8.3 Database search and protein identification
The raw files from the mass spectrometer were converted into Mascot generic files (mgf) with 
Mascot Distiller and searched against a Swissprot-d database using Mascot Server (version 2.2; 
Matrix Science, London, UK) (Perkins et al., 1999). The parameters for precursor tolerance and 
fragment ion tolerance were set to ±5 ppm and ±0.8 Da, respectively. 
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